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Abstract 
 
Recently, the widely accepted theory that TB disease resulted from one infecting M. 
tuberculosis strain leading to heightened immune protection against subsequent infections, 
has been revised. Epidemiological studies and the advances in molecular genotyping 
techniques have highlighted the rapidly frequent isolation of several different M. tuberculosis 
strain lineages in single disease episodes, often with differing drug susceptibilities. This has 
important implications on drug susceptibility testing and the treatment of patients. It has also 
highlighted the relative contributions of exogenous reinfection and endogenous reactivation in 
TB disease progression. However, our understanding of the nature and frequency of mixed 
infections is lacking. This study investigated the frequency and detection of mixed TB 
infections in the Delft region of the Western Cape, as part of a larger clinical trial on the effects 
of multi-nutrient supplementation and standard treatment on the TB bacteriological response. 
 
Newly diagnosed, adult TB patients (n=154) produced a single weekly sputum sample over an 
8-week period. Genomic DNA was extracted from colonies grown from MGIT cultures on LJ 
slopes. Spoligotyping was used as an initial screen to detect mixed infections as well as to 
assess the epidemiology of M. tuberculosis in these serial isolates (n=686). In addition, clonal 
relatedness of the isolates was assessed by MIRU-VNTR analysis. Thereafter PCR assays to 
detect infections of W-Beijing and non-W-Beijing isolates, as well as to differentiate mixed 
non-W-Beijing isolates were carried out. Phenotypic and genotypic drug susceptibility was 
carried out.  
 
Spoligotyping indicated that W-Beijing isolates constituted a large proportion (47.8%) of 
circulating     M. tuberculosis in this region, with other strains detected including LAM (17.1%), 
T (14.7%), X (6.4%), H (7.9%), S (4.3%), and F33 (2.1%) strains. Using both spoligotyping 
and PCR assays, mixed infections were detected 21 (16.3%) of 129 patients screened. 
Phenotypic and genotypic DST confirmed that all isolates identified in patients as harbouring 
mixed strains by spoligotyping were fully susceptible to both RIF and INH. MIRU-VNTR 
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analysis for genetic relatedness identified 1 clonal cluster in the mixed samples identified by 
spoligotyping, consisting of the T1, T4, W-Beijing and W-Beijing + X3 isolates.  
The frequency of mixed infections, particularly in high disease burdened areas, is high, and 
warrants further attention. This finding has great implications with regards to the interpretation 
of epidemiological and DST data, and the subsequent treatment of patients.  
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1.1. Introduction 
1.1.1. Historical Context 
Mycobacterium tuberculosis (M. tuberculosis), the causative agent of human tuberculosis (TB) 
(Koch, 1882), is mankind’s oldest and most successful pathogens (Gutierrez et al, 2005).  So 
great is its antiquity that M. tuberculosis DNA has been found in mummified remains in the 
Andes Mountains, dating between 140 – 1200 A.D. (Konomi et al, 2002); in pre-Columbian 
Peru, dating between 1000 – 1300 A.D. (Salo et al, 1994); and in Egypt, dating between 2050 
– 1650 B.C. (Zink et al, 2003). Other references date findings in Egypt as early as 3000 and 
5000 B.C. (Zimmerman et al, 1979; Morse et al, 1964 respectively). These findings suggest 
that TB has been infecting man, certainly in Egypt, since the pre-Dynastic period (Zimmerman 
et al, 1979).  
 
The study of the evolutionary history of M. tuberculosis has been difficult and often 
controversial, due to the relatively static nature of the M. tuberculosis complex genomes; M. 
tuberculosis complex bacterial nucleotide sequences are 99.9% identical (Vultos et al, 2008). 
It is believed that the members of the M. tuberculosis complex are the clonal progeny of a 
successful ancestor resulting from a bottleneck event 20000 – 35000 years ago (Gutierrez et 
al, 2005). For decades, scientists have hypothesised that Mycobacterium bovis (M. bovis) is 
that ancestor (Brosch, 2002), and started infecting humans around the time when humans 
began domesticating cattle around the same time as the bottleneck (Smith, 2003).  However, 
recent molecular advances have allowed further analyses into this field and have shown that 
Mycobacterium canettii (M. canettii), a tubercule bacillus of rare occurrence and a smooth 
colony morphology (Gutierrez et al, 2005), could represent modern progenies of an ancestral 
species termed Mycobacterium prototuberculosis (M. prototuberculosis), from which M. 
tuberculosis may have evolved (Ernst et al, 2007) 
 
TB was described clinically in 400 B.C. by Hippocrates in Of the Epidemics, detailing patients 
with bloody sputum and a “wasting disease”, with associated chest pain and chronic cough, 
suggesting that TB was already then well established (Mathema, 2006; Smith, 2003). TB 
continued to spread across the globe, due mostly to immigration, while scientists debated 
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what the cause of this disease was (Smith, 2003). Some scientists doubted that it was a single 
disease, as there were so many varied symptoms among patients, while others denied the 
infectivity of the disease (Daniel et al, 1994). Some of TB’s former titles, such as lupis vulgaris, 
consumption, King’s Evil and White Plague (Mathema et al, 2006), have been pandemic in 
Europe and North America for the last 500 years (Iseman, 1994). During the 17th and 18th 
centuries, at the height of the White Plague, 20% of all adults died of tuberculosis, while an 
estimated 1 billion people died of tuberculosis between 1850 and 1950 (Iseman, 1994). It 
wasn’t until Robert Koch, in 1882, published his landmark paper, “Die Atiologie der 
Tuberkulose”, that the causative agent was identified. He described the TB bacillus and 
named the pathogen Mycobacterium tuberculosis by carrying out staining techniques, which 
Koch developed to better see microorganisms for characterisation (Koch, 1882).  
 
Following on from Edward Jenner’s studies on vaccination, many scientists placed their hope 
in M. bovis, which causes disease in cattle, as a possible vaccine candidate; however, M. 
bovis was equally as contagious in humans (Palomino, 2007). Albert Calmette and Camille 
Guérin, from 1908 – 1919 attenuated a strain of M. bovis by serial passage 230 times, 
resulting in an avirulent strain termed BCG (Bacille Calmette-Guérin). BCG was later 
administered into the first human subjects in 1921 and has remained, ever since, the most 
widely distributed vaccine in the world (Palomino, 2007). 
 
In 1945, Selman Waksman, a soil biologist, discovered the antibiotic streptomycin (STR) and 
showed that it had a high activity against M. tuberculosis (Iseman, 1994). This landmark 
discovery launched the TB chemotherapeutic era. However, shortly after this discovery, 
reports of resistance to streptomycin emerged. It was found that streptomycin alone was not 
sufficient to effectively eradicate the pathogen from patients, but rather selected out, from the 
numerous numbers of bacilli, those that had a natural resistance to streptomycin (Iseman, 
1994). Fortunately, not long after the discovery by Waksman, other antibiotics were 
discovered or manufactured. The drugs p-aminosalicylic (PAS) and isonicotinic acid hydrazide 
(isoniazid; INH) were found to have a higher efficacy than streptomycin, and when used in 
combination, it was found that no resistance emerged (Gillespie, 2002). Combination therapy 
has since then been the backbone of the treatment of TB. Since the establishment of 
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combination chemotherapy, a host of antibiotics have been included in what is today’s 
standard treatment regime, including INH, ethambutol (ETH), rifampicin (RIF), pyrizinamide 
(PZN) and STR (Plorde, 1994).  
 
1.1.2. Current Burden of Disease 
Today, TB remains one of the most important unresolved diseases around the world, 
particularly in developing countries such as India, Brazil and South Africa (Iseman, 1994; 
Iseman and Heifets, 2006). In 2006, 9.2 million new cases of TB were reported as well as 1.7 
million deaths (WHO, 2008). It is estimated that 2 billion people, roughly a third of the global 
population, is infected with M. tuberculosis, of which 10% will develop active TB in their 
lifetime, with HIV sufferers being most vulnerable (WHO, 2007). Africa has the highest per 
capita rates of TB infections with 28% of the world’s TB cases being found in Africa (WHO, 
2007). It was estimated in 2006 that there were 500 000 cases of MDR-TB in the world (WHO, 
2008). TB is also a disease of poverty, with the majority of cases occurring in developing 
nations (WHO, 2007). 
 
1.1.3. Antibiotic Resistance in M. tuberculosis 
Despite an effective therapy regime for TB that has been in place for many years, today we 
see TB prevalences and incidences that have exceeded those since before the discovery of 
streptomycin (Gillespie, 2002; Zager and McNerney, 2008). Patient non-compliance as well as 
inadequate dosing by health practitioners has been blamed for the emergence of multi-drug 
resistant (MDR) M. tuberculosis (MDR-TB) and extensively-drug resistant (XDR) M. 
tuberculosis (XDR-TB), which makes the current treatment programs for TB highly ineffective 
(Drobniewski and Yates, 1997; Zager and McNerney, 2008). MDR-TB is defined as being 
resistant to the two first-line drugs INH and RIF (WHO, 2000), while XDR is MDR-TB that is 
also resistant to a second-line injectable drug, such as capreomycin, and a fluoroquinolone 
(Zager and McNerney, 2008). Resistance to antibiotics is achieved through various 
mechanisms such as a mutation in the drug target, which decreases the binding of the drug; 
reduced uptake of the drug; active efflux of the drug, once inside the cell; the presence of an 
enzyme that deactivates the drug; over-production of the drug target, resulting in titration of 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
7 
 
the antimicrobial agent; or the presence of an alternative enzyme to compensate for the loss 
of another enzyme inhibited by the drug (Fluit et al, 2001). Molecularly, resistance to 
antibiotics in M. tuberculosis develops due to spontaneous chromosomal mutations 
(Ramaswamy and Musser, 1998). Mathematical models estimate that the rate of spontaneous 
mutations occur at a frequency of (in mutations per bacterium per cell division) 3.32 X 10-9 for 
RIF, 2.56 X 10-8 for INH, 2.29 X 10-8 for STR and 1.0 X 10-7 for ETH (Gillespie, 2002).  
There are many molecular tools available to scientists today that allow them to detect 
chromosomally encoded determinants of resistance, such as polymerase chain reaction 
(PCR), and hybridisation studies (Fluit et al, 2001). 
 
1.1.4. M. tuberculosis Strain Diversity 
For many centuries M. tuberculosis has been infecting man and thus has been coevolving with 
man. As man has a diverse migratory history, M. tuberculosis has had to face many different 
geographical pressures placed on it and has in response to this, evolved clonally (Brudey et 
al, 2006). The various clonal lineages of M. tuberculosis have distinct phylogeographical 
characteristics that separate them from one another (Brudey et al, 2006).  The hypothesis is 
that the M. tuberculosis complex originated in East-Africa and expanded to the rest of the 
world with human migration out of and back into Africa (Brudey et al, 2006, Gagneux et al, 
2006).  Currently, the six major M. tuberculosis lineages recognised circulating around the 
world include Indo-Oceanic, East-Asian (including the Beijing family), East-African-Indian, 
Euro-American and West-African lineages 1 and 2 (Gagneux et al, 2006). Each have adapted 
to the various human populations that inhabit the regions of origin of the strain lineages; for 
example, a person of Chinese decent living in San Francisco is more at risk of acquiring an 
East-Asian M. tuberculosis infection (OR 19.8, 95% CI: 4.6 – 84.2; P<0.001) than their 
American counterparts (Gagneux et al, 2006).  In South Africa, particularly in the Western 
Cape, the Beijing and Haarlem strain families are overrepresented among children (Marais et 
al, 2006), while the Beijing and LAM3/F22 families predominate in adults (Nicol et al, 2005). It 
is of importance to scientists, particularly in South Africa where the prevalence of TB is so 
high, to genotype M. tuberculosis strains, as it gives an indication of the circulating lineages, 
as well as to discern whether or not there is an association between genotype and drug 
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resistance (Marais et al, 2006), or the ability of that lineage to cause extrapulmonary disease 
(Nicol et al, 2005).  
 
1.2. Antibiotic Resistance in M. tuberculosis 
1.2.1. Anti-tuberculosis Chemotherapy 
The current standard treatment regime for TB is known as directly observed therapy short 
(DOTS) course treatment, and involves the supervised administration of multiple drugs for a 
minimum of 6 months (Warner and Mizrahi, 2006). There are currently two courses of 
antibiotics in the treatment of TB, namely the first line and second line antibiotics. Traditionally 
the first line antibiotics include INH, RIF, PZA, ETH, and STR while the second line of 
treatment includes the aminoglycosides kanamycin and amikacin, the polypeptide 
capreomycin, PAS, cycloserine, the thioamides ethionamide and prothionamide and several 
fluoroquinolones such as moxifloxacin, levofloxacin and gatifloxacin (Palomino, 2007). DOTS 
treatment follows a two phase plan with the first phase using three or more drugs, normally 
INH, RIF and PZA, for 2 months to allow the fast killing of dividing bacilli. The second phase is 
4 months of 2 drugs, usually INH and RIF, to kill off any remaining bacilli and prevent 
reoccurrence (Palomino, 2007). Resistance to any of the first line drugs requires the 
introduction of second line drugs into the regiment (Palomino, 2007). 
 
As it can be seen from the above treatment strategies, INH and RIF are the two most 
important antibiotics. INH, upon entering the cell through diffusion, is metabolically activated 
and binds to InhA, an enoyl-acyl carrier protein, involved in mycolic acid elongation (Marrakchi 
et al, 2000). Bacilli death is the result of an accumulation of mycolic acid intermediates in the 
cytoplasm of M. tuberculosis (Vilcheze and Jacobs, 2007). RIF, upon entering the bacillus, 
binds to the DNA-dependant RNA polymerase and prevents transcription in M. tuberculosis 
(Prescott et al, 2005). Resistance to these drugs results in MDR-TB (WHO, 2000).  
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1.2.2. Emergence of Resistance 
In M. tuberculosis, resistance to any of the antibiotics is primarily achieved via spontaneous 
chromosomal mutations in genes responsible for the metabolism of the antibiotic or in one or 
more of the drug’s targets (Ramaswamy and Musser, 1998). A number of different genes are 
known to be associated with drug resistance in M. tuberculosis (Table 1.1). 
 
Table 1.1. Summary of the molecular determinants of antituberculosis drug resistance 
Antibiotic Associated mutated gene or mutation 
Rifampicin rpoB 
Isoniazid katG 
 inhA 
 ndh 
 oxyR-ahpC 
Streptomycin rrs 
 rpsL 
Pyrazinamide pncA 
 IS6110 Insertion 
Ethambutol embB 
Fluoroquinolones gyrA 
 gyrB 
(Adapted from Gillespie et al,  2002) 
 
With RIF resistance, 95% of the mutations that confer resistance occur in an 81-bp region in 
the rpoB gene, encoding the β subunit of the DNA-dependant RNA polymerase, known as the 
RIF resistance-determining region (RRDR), with the most common mutations occurring at 
codons 516, 526 and 531 (Huitric et al, 2006).  
 
In INH resistance, many genes have been associated with conferring resistance, making 
describing INH resistance complex (Mokrousov et al, 2002 (2)). However, the katG gene, 
encoding a bi-functional catalase-peroxidase enzyme, and the inhA gene, encoding an enoyl-
acyl carrier protein, are the most frequently associated genes in conferring INH resistance 
(Ramaswamy et al, 2003). In katG the most common mutation (95%) associated with INH 
resistance is the Serine-Threonine transition at codon 315 (S315T) (Hazbon, et al, 2006), 
while in inhA, the most common mutation (8-20%) is a C-T single nucleotide polymorphism 
(SNP) at position 15 upstream of the mabA-inhA operon in the promoter (C-15T) 
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(Ramaswamy et al, 2003; Hazbon et al, 2006). Other genes associated with INH resistance 
include ndh, encoding an NADH dehydrogenase (Cardoso et al, 2007), and the oxyR-ahpC 
intergenic region, involved in oxidative stress (Ramaswamy et al, 2003). In a study by 
Ramaswamy and colleagues, 20 different genes associated with INH resistance were studied 
and some 10% of INH resistant M. tuberculosis isolates in their study showed no mutation in 
any of the genes studied, concluding that there are unknown mechanisms and determinants of 
INH resistance still to be discovered (Ramaswamy et al, 2003). 
 
In STR resistance the two most frequently reported genes involved in resistance are rrs, which 
encodes 16S rRNA, and rpsL, which encodes ribosomal protein S12. Both are involved in 
protein synthesis (Sekiguchi et al, 2007).The most frequently reported rpsL mutation is K43R, 
while in the rrs gene, mutations are clustered in the highly conserved 530 loop (van Rie et al, 
2001). 
 
PZA resistance is associated with the gene pncA, which encodes pyrazinamidase, an enzyme 
necessary for the activation of PZA (Sekiguchi et al, 2007). Many mutations have been shown 
to be associated with PZA resistance, with the mutations dispersed throughout the gene; 
including A3E, D53N, P54L, C72W and M175V (Sekiguchi et al, 2007). 
 
ETH resistance is achieved through mutations emerging in the embABC gene cluster, with the 
most common site of mutation occurring within the embB gene (Shen et al, 2007). The most 
frequent mutation seen is at codon 306 in the embB gene, with estimates of 60% of ETH 
resistant isolates containing a mutation in this region (Plinke et al, 2006). However, recently 
there has been some controversy over the codon 306 region as a predictor of ETH resistance, 
with Hazbon and colleagues suggesting that this codon region is associated with broad drug 
resistance rather than specifically ETH resistance (Hazbon et al, 2005). Several authors 
disagree and maintain the significance of the embB codon 306 mutations in the emergence of 
ETH resistance (Plinke, et al, 2006; Shen et al, 2007; van Rie et al, 2001). 
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Resistance to the second line fluoroquinolones is achieved through mutations arising in the 
DNA gyrases A and B encoded by gyrA and gyrB, respectively (Aubry et al, 2006). The 
gyrases affect the supercoiling of the DNA and are the targets of the fluoroquinolones (Fluit et 
al, 2001). The most common mutations reported occur at codons 90, 91 and 94 in the A 
subunit, and at codon 510 in the B subunit (Matrat et al, 2006; Aubry et al, 2006). 
 
The need for so many antibiotics in the effective treatment of TB and the resultant magnitude 
of molecular determinants of resistance has necessitated the need for accurate methods of 
determining drug susceptibility. Additionally, given that rapid diagnosis of drug resistance in 
patients has positive outcomes within the communities, in that the spread of TB from infected 
contacts is reduced, the need for molecular assays that allow for the rapid and accurate 
diagnosis of drug resistance is of paramount importance. Several molecular tests are available 
today to aid clinicians in detecting drug resistance and to determine DST of the many 
antibiotics used in the treatment of TB (Fluit et al, 2001). 
 
1.2.3. Drug susceptibility testing of M. tuberculosis 
The outcome of a patient suffering from TB is related to the efficiency and turnaround time of 
the DST performed (Angeby et al, 2002). The more rapid an accurate diagnosis of drug 
resistance is made, the more time a patient has on an adequate regime of medication 
resulting in less time in the communities shedding bacilli and remaining infectious (Angeby et 
al, 2002). Thus rapid and inexpensive molecular tests are needed for the effective 
management of TB.   
Traditionally, DST has been performed directly and indirectly on solid-based media such as 
Lowenstein-Jensen (LJ) slopes or Middlebrook 7H10/7H11 plates (Palomino et al, 2007). The 
three routine DST methods that use these media are the proportion method, the resistance 
ratio method and the absolute concentration method. All three methods require a 
decontaminated sample (direct) or a culture (indirect) that is inoculated onto the solid media 
with or without antibiotics (Palomino et al, 2007). However, due to the slow nature of M. 
tuberculosis growth, the turnaround time for this DST is anywhere from 4 to often more than 6 
weeks (Goloubeva et al, 2001). To solve the problem of long turnaround times, several 
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automated methods using liquid broth have been developed, to greatly reduce the time taken 
to achieve results (Palomino et al, 2007). 
 
The non-radiometric automated BACTEC Mycobacteria Growth Indicator Tube (MGIT) 960 
DST system (Becton Dickinson Microbiology) has been favoured over the radiometric 
BACTEC 460 as the standard automated DST system (Rusch-Gerdes et al, 2006). The MGIT 
960 is a system that allows for the detection and DST of M. tuberculosis from an isolated 
culture and has been validated to provide DST results for the antibiotics STR, INH, RIF, ETH 
(SIRE) as well as PZA (Piersimoni et al, 2006). The MGITs use a modified Middlebrook 7H9 
liquid broth supplemented with antibiotic, as well as a silicon disk containing a fluorescent 
compound (Becton Co, 2005). The fluorescence is quenched by the available oxygen, but as 
the M. tuberculosis isolate grows and uses up the free oxygen, the fluorescence is released 
and measured by the automated BACTEC system (Piersimoni et al, 2006). Results are 
obtained in 4 to 19 days for positive results and tubes not registering a result after 42 days are 
considered negative (Becton Co, 2005). Several authors have evaluated the BACTEC MGIT 
960 system for DST and M. tuberculosis detection (Kruuner et al, 2006; Rusch-Gerdes et al, 
2006; Somoskovi et al, 2003), as well as to determine critical concentrations for the second-
line antibiotics (Kruuner et al, 2006; Rusch-Gerdes et al, 2006). The BACTEC MGIT 960 
system has shown to have sensitivities and specificities of 1.00 and 1.00 for STR, 0.98 and 
1.00 for INH, 1.00 and 1.00 for RIF, and 0.96 and 1.00 for ETH, respectively (Ardito et al, 
2001). In another study the sensitivities and specificities were 0.97 and 1.00 for STR, 0.95 and 
1.00 for INH, 1.00 and 0.97 for RIF, 0.99 and 1.00 for ETH, and 0.96 and 0.87 for PZA, 
respectively (Scarparo et al, 2004). This shows that the MGIT 960 automated system is an 
excellent method for reliable and relatively fast DST for M. tuberculosis. However, this system 
has a few drawbacks such as the need for heavy and very expensive machinery as well as 
highly trained personnel and thus is not suited to a poor resource setting (Shiferaw et al, 
2007).  
 
Another DST tool that has been developed to facilitate a more rapid turnaround time and is 
inexpensive is known as the microscopic observation drug susceptibility (MODS) assay. This 
method is based on the characteristic formation of M. tuberculosis in liquid media, the so 
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called “serpentine cord formation” as viewed through an inverted light microscope (Palomino 
et al, 2007). M. tuberculosis sputum isolates are inoculated into a standard 24-well plate 
containing Middlebrook 7H9 liquid broth, with each row containing a standard concentration of 
test antibiotic, as well as a broth-only control row. Each column represents a sample and 4 to 
5 samples can be tested per plate. A non-inoculated and an H37Rv control column are also 
included in the experiment (Iseman and Heifets, 2006). In a study evaluating the MODS 
assay, Shiferaw and colleagues reported that of the 262 smear-positive isolates, MODS had a 
significantly higher detection rate (96.9%) than the culture on LJ (94.3%) (P=0.016), had a 
sensitivity, specificity and accuracy of 92.0, 99.5 and 98.8%, respectively, using the proportion 
method as a reference (concordance: 98.8%), and their median turnaround time for the MODS 
assay was 9 days with 95.7% of all isolates being positive in 14 days (Shiferaw et al, 2007). 
This shows that the MODS assay is highly suited to resource poor settings. Draw backs of the 
assay is that an expensive inverted light microscope is needed as well as training of personnel 
is required to familiarize oneself with the different growth formations as viewed through the 
microscope (Palomino et al, 2007). 
 
Other DST assays that are currently being used, albeit less frequently, include the Etest (AB 
BIODISK), which showed a high level of agreement with the proportion method on LJ medium 
with all first-line antibiotics tested (Hazbon et al, 2000); the nitrate reductase assay, also 
known as the Griess method, an inexpensive and rapid DST assay, based on the ability of M. 
tuberculosis to reduce nitrate to nitrite (Angeby et al, 2002); and a rapid high-throughput 
absolute concentration method, an automated version of the MODS assay (Palomino et al, 
2007). 
 
1.2.4. Detection of Resistance Determinants 
Molecular assays that utilize the fact that resistance to an antibiotic is achieved through 
spontaneous chromosomal mutations (Ramaswamy and Musser, 1998), and that in most of 
the cases the mutation and the gene wherein the mutation lies is more often than not known 
(Ramaswamy et al, 2003), are far more likely to be more rapid and sensitive than the 
phenotypical and biochemical assays used for DST (Hillemann et al, 2007). The most 
common and widely used methods are PCR and hybridization (Fluit et al, 2001). 
Un
ive
rsi
ty 
of 
Ca
pe
 To
w
14 
 
PCR is used to amplify in vitro a specific region of DNA (Atlas and Bej et al, 1994). The 
reaction consists of repetitive three stage cycles; one cycle consisting of a high temperature 
DNA denaturation followed by cooling to allow oligonucleotide primers to anneal to the defined 
target region (Atlas and Bej et al, 1994). Finally the temperature is raised to allow a thermal 
stable DNA polymerase (often Taq polymerase from Thermus aquaticus) to extend the newly 
synthesised DNA strand by the incorporation of free deoxynucleoside triphosphates (dNTPs) 
(Atlas and Bej et al, 1994). Multiplex Allele-Specific (MAS) PCR utilises different pairs of 
primers that allows simultaneous amplification of several DNA fragments at the same time 
(Atlas and Bej et al, 1994, Mokrousov et al, 2002 (1)). The different annealing temperatures 
(Ta) of the primers result in differential amplification of one or more of the fragments and often 
no visible detection of some fragments can occur (Atlas and Bej et al, 1994). Large differences 
in the fragment lengths will also favour the amplification of the smaller fragment instead of the 
larger fragment (Atlas and Bej et al, 1994). MAS PCR can thus be used to target commonly 
reported mutations in genes known to confer resistance to certain antibiotics, and allow one to 
distinguish between wild-type (WT) sequences and sequences harbouring a mutation 
(Mokrousov et al, 2002 (1)). This is aided by the sequencing of the PCR products and 
comparing it to published WT sequences, such as H37Rv (Kiepiela et al, 2000). 
 
In the sequencing reaction dideoxinucleotide triphosphates (ddNTPs) are incorporated into the 
growing 3’ end of newly synthesised DNA, chain elongation terminates due to the lack of the 
3’-hydroxyl group usually present in dNTPs but absent in ddNTPs (Sanger et al, 1977; 
Zimmermann et al, 1988). The chance incorporation of ddNTPs instead of dNTPs terminates 
elongation at all possible sites along the template, in oligonucleotides of varying length, all 
with the same 5’ end but each with a 3’ end corresponding to one of four ddNTPs in the 
template (Sanger et al, 1977; Zimmermann et al, 1988). The four ddNTPs are fluorescently 
labelled with a different colour, and upon gel electrophoresis the products migrate towards the 
positive electrode and each product passes through a laser that reads the different fluorescent 
labels and computer software converts that signal into a DNA sequence that can later be 
analysed (Zimmermann et al, 1988). 
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Mokrousov and colleagues developed the MAS PCR assay to originally detect embB codon 
306 mutations and ETH resistance (Mokrousov et al, 2002 (1)) and later modified the assay to 
detect katG codon 315 variations and INH resistance (Mokrousov et al, 2002 (3)). Thus the 
assay can be modified to detect all other resistance determinants provided the sequence of 
the gene and mutation is known. As PCR and electrophoresis can be completed in a day, this 
assay could potentially be used as an alternative DST method that provides fast and reliable 
results as compared to the others mentioned previously.  
 
Hybridization is one of the world’s oldest and well used molecular techniques (Fluit et al, 
2001). Hybridization is the process whereby a segment of single-stranded DNA, known as a 
probe, covalently binds to another homologous single–stranded segment of DNA, usually 
immobilized on a support matrix, such as a nitrocellulose membrane or a magnet bead, with a 
relative stringency (Fluit et al, 2001). Probes can be labeled with many enzymatic compounds 
that allow for the biochemical detection of a hybridization event (Fluit et al, 2001). 
 
A commercially available reverse-hybridization assay, known as the GenoType MTBDRplus 
assay (Hain Lifescience GmbH, Nehren, Germany), was recently evaluated by Hillemann and 
colleagues (Hillemann et al, 2007).  This assay tests for INH and RIF resistance by a 
combination of multiplex PCR and reverse-line hybridization onto strips containing 
oligonucleotides of the common resistance determinants in the katG, rpoB and inhA genes 
(Palomino et al, 2007). Either the omission of a wild-type band or the presence of one or more 
bands corresponding to the common mutations indicates a resistant strain (Hillemann et al, 
2007). In the evaluation 125 clinical isolates and 72 smear-positive sputum samples, made up 
of 106 RIFR/INHR, 10 RIFS/INHR, and 80 RIFS/INHS, were tested with the MTBDRplus assay 
for its ability to detect RIF and INH resistance (Hillemann et al, 2007). The results showed that 
71/72 sputum samples and all 125 clinical samples produced discernable results. In addition 
with the MTBDR assay, which does not detect the inhA mutations, both assays, compared to 
conventional DST methods, were able to identify RIF resistance in 74/75 isolates (98.7%) and 
30/31 sputum samples (96.8%), as well as INH resistance in 69/75 isolates (92.0%) and 37/41 
sputum samples (90.2%) (Hillemann et al, 2007). They concluded that this improved assay is 
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a reliable method for detecting INH and RIF resistance directly from sputa (Hillemann et al, 
2007). 
Studies have shown a correlation between drug resistance profiles and specific M. 
tuberculosis strain lineages (Gagneux et al, 2006 (2); Hillemann et al, 2006). Additionally, 
correlations between strain lineage and relative fitness and virulence have also been 
postulated (Gagneux et al, 2006 (1)). As such, understanding and knowing as much about the 
evolutionary heritage of the various strains circulating around the world is of great importance. 
 
 
1.3. M. tuberculosis Strain Diversity 
 
1.3.1. Worldwide Prevalence of M. tuberculosis Lineages 
As mentioned previously, through the co-evolution of mankind and M. tuberculosis, several 
strain lineages have emerged, specific to certain geographical regions around the globe 
(Gagneux et al, 2006 (2)).  
 
In Sweden, from a study by Brudey and colleagues, 23.2% of isolates belonged to the 
Haarlem family, followed by the W-Beijing (9.8%), Latin American and Mediterranean (LAM; 
8%), and the East-Asian-Indian (EAI; 6.2%) families (Brudey et al, 2004). However, overall in 
Scandinavian countries, the ill-defined T family represents 33%, followed by the EAI (22%), 
Haarlem (20%), LAM (11%), Central Asian (CAS; 5%), X (5%) and W-Beijing (4%) families 
(Brudey et al, 2004). 
 
Since the discovery of the W-Beijing family, this group of strains have predominated in the 
Asian countries (van Soolingen et al, 1995), with Gagneux reporting a prevalence of 33.8% in 
Far-East Asia, 24.3% in the Middle East and Central Asia, and 22.9% in the Oceana regions 
(Gagneux et al, 2006 (2)). 
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Recently, in Rio de Janeiro, Brazil, a novel lineage, related to the LAM family of strains, was 
described and found to be a major cause of TB in that region (Lazzarini et al, 2007). The strain 
was designated RDRIO due to a novel large sequence polymorphism (LSP) that characterizes 
this strain (Lazzarini et al, 2007). 
 
In Pakistan it was reported that the prevalent strain families were the CAS1 (39%) and the W-
Beijing (6%) lineages (Hasan et al, 2006), while in the Archangel Oblast region of Russia the 
W-Beijing family represented 44.5% of the strains collected, of which 43.4% were MDR and 
92.5% clustered (Toungoussova et al, 2002). 
 
Of the 103 MDR isolates collected in Germany (Hillemann et al, 2005), 60.2% were of the W-
Beijing lineage, and interestingly displayed different resistance determinants than the non-W-
Beijing MDR isolates (Hillemann et al, 2005). 
 
In South Africa it was found that the F11 strain, which is part of the LAM family, represented 
21.4% of isolates collected and was as successful as the W-Beijing family (16.5%) in causing 
TB in the Western Cape (Victor et al, 2004). The Haarlem family is also overrepresented 
amongst children with drug-resistant TB in the Western Cape (Marais et al, 2006).  
 
Still in South Africa, a very recent study carried out was the first to describe the frequency and 
distribution of M. tuberculosis genotypes across most of the provinces (Stavrum et al, 2009). 
Of the 252 collected isolates from eight of the nine provinces, spoligotyping and MIRU-VNTR 
analysis detected that the ill-defined T lineage was the most prevalent strain family (25.8%) 
followed by the W-Beijing lineage (10.3%) (Stavrum et al, 2009). 
 
1.3.2. The M. tuberculosis W-Beijing Family 
As seen from the worldwide prevalence above, the W-Beijing family constitutes a major 
proportion of strains circulating the globe, and is responsible for much morbidity and mortality 
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(Bifani et al, 2002) in part, due to its association with MDR. The W-Beijing family originates 
from the Beijing province of Eastern Asia and was first described in 1995 (van Soolingen et al, 
1995). The mechanisms for how this group of strains has managed to spread globally and 
maintain a high virulence despite its association with MDR, is still not entirely known (Bifani et 
al, 2002). 
 
However, what is known is that the W-Beijing family belongs to the East-Asian lineage 
(Gagneux et al, 2006 (2)) and is a member of the phylogentically termed Principle Genetic 
Group 1 set of strains (Palomino et al, 2007). These strains are characterized by the presence 
of an inverted IS6110 copy within the DR region, an IS6110 element within the origin of 
replication and one or two IS6110 copies in a DNA region called NTF. A characteristic W-
Beijing lineage-defining small nucleotide polymorphism (SNP) is the G81A in Rv3815c as well 
as LSPs RD105, RD142, RD150 and RD181 (Palomino et al, 2007). The standard 
spoligotyping pattern was described in 1995, which shows that all W-Beijing strains have 9 
spacer regions; namely 35 to 43 (van Soolingen et al, 1995). W-Beijing strains are significantly 
associated with drug resistance; OR 1.8 (95% CI: 1.2 – 2.7) for any drug, 1.7 (95% CI: 0.95 – 
2.9) for INH, 4.0 (95% CI: 1.4 – 11.9) for RIF, 2.3 (95% CI: 1.4 – 3.7) for STR, 3.0 (95% CI: 
0.38 – 23.2) for ETH, and 4.2 (95% CI: 1.2 – 14.7) for MDR (Glynn et al, 2006), and as such, 
represent a group of strains that necessitate a large amount of attention and research. 
 
It has been hypothesized that the widespread nature of the W-Beijing family could be due to 
the resistance of the lineage to the BCG vaccination, where in areas such as South Africa, is 
routinely and widely used (van Soolingen et al, 1995). The vaccine primes the immune system 
to mount a specific and rapid immune response towards an infecting strain of M. tuberculosis 
(Kremer et al, 2009). Studies showing an association between BCG vaccination (determined 
by the presence of a BCG scar) and an increased risk of acquiring TB from a W-Beijing strain 
(van Soolingen et al, 1995) have been reported. This implies that although BCG may offer 
protection from other strains of M. tuberculosis, protection against W-Beijing strains is not 
offered, and that W-Beijing strains represent ‘escape variants’ of M. bovis  BCG (Kremer et al, 
2009). W-Beijing strains are also associated with extrapulmonary TB disease as well as 
treatment failure and relapse (Reed et al, 2007). Recently it was discovered that certain 
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groups within the W-Beijing family produce a unique phenolic glycolipid, PGL-tb, which is 
hypervirulent in mouse models, as well as having the dormancy regulon, controlled by the 
DosR transcription factor, constitutively expressed (Reed et al, 2007). The expression of this 
regulon in times of oxygen deprivation and nitric oxide production, as encountered within the 
granuloma during M. tuberculosis latency, may contribute significantly to the virulence of the 
W-Beijing family (Reed et al, 2007). 
 
1.3.3. Genotyping M. tuberculosis 
The molecular tools available to researchers today, that allow them to differentiate strain 
families from clinical samples, are based on differences between strains, such as IS6110 copy 
number, spacer sequences present in the direct repeat (DR) or the variable number of tandem 
repeats (VNTRs) in mycobacterial interspersed repetitive units (MIRUs) (Mathema et al, 
2006). Each tool has its advantages and disadvantages and most importantly each offer a 
different level of discriminatory power. 
 
The gold standard in genotyping M. tuberculosis has long been IS6110 restriction fragment 
length polymorphism (RFLP) typing (Mathema et al, 2006). This method is based on the 
restriction of genomic DNA by PvuII, which cuts IS6110 once, followed by Southern Blot 
hybridization and probing for the element (van Embden et al, 1993). The resultant banding 
pattern is descriptive of a specific strain, and can be compared to other strains manually, 
either with the naked eye, or using computer software (Mathema et al, 2006) to determine 
whether strains are related or not. This typing method has a high level of discrimination for 
strains with higher copy numbers of IS6110, but is not suitable for typing strains with few 
copies of the element, or in rare circumstances, where a strain contains no element at all 
(Mathema et al, 2006). Another limitation is that this technique is very labour intensive, 
requiring subculturing and DNA isolation of the strains tested and has a slow turnaround time, 
of approximately 30 to 40 days (Mathema et al, 2006). 
 
Spoligotyping is a PCR-hybridisation technique that simultaneously detects and types M. 
tuberculosis complex bacteria. These organisms contain a unique locus known as the DR 
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region which consists of directly repeated sequences interspersed with spacer regions of 
between 35 to 41bp (Kamerbeek et al, 1997). The order of the spacer regions remains the 
same when comparing many different strains, however between the strains, deletions or 
insertions of spacers often occur. Thus it is possible to compare the presence or absence of 
the spacer regions to determine whether strains are related (Kamerbeek et al, 1997). 
Spoligotyping involves PCR amplification of the DR region using primers that anneal to the 
DRs, resulting in the amplification of the spacer regions. The reverse primer is biotin-labelled 
and therefore all PCR products are biotin-labelled (Kamerbeek et al, 1997). The PCR products 
are then hybridized to a membrane containing parallel lines of covalently linked 
oligonucleotides from known spacers. The membrane is then incubated in streptavidine-
peroxidase and detected using the enhanced chemiluminescence (ECL) Direct Nucleic Acid 
Labeling and Detection System (Amersham Biosciences) on a light sensitive film. The biotin-
labeled probes anneal to regions of homology on the membrane and streptavidine anneals to 
biotin. A signal is produced when the streptavidine-peroxidase, bound to the biotin-labeled 
primers, catalyses a light reaction using the ECL detection reagents as a substrate, which is 
then captured on light sensitive film. The film, after exposure to the membrane, is then 
developed and fixed and the resulting profile is compared to a database and the strains are 
genotyped accordingly (Kamerbeek et al, 1997). 
 
Mycobacterial interspersed repetitive unit variable number tandem repeat (MIRU-VNTR) 
typing, is an automated amplification and electrophoresis technique that differentiates strains 
on the basis of the number of MIRUs in 12 VNTR loci (Supply et al, 2000; 2001). The results 
are reported as a 12-number numerical code representing the number of MIRUs at each locus 
(Supply et al, 2000; 2001). The standard 12 loci studied include locus 2, 4, 10, 16, 20, 23, 24, 
26, 27, 31, 39, and 40 (Ali et al, 2007). The discriminatory power of MIRU-VNTR analysis is 
dependent on the number of loci evaluated, but generally when 12 loci are evaluated and 
combined with spoligotyping, the discriminatory power is greater than or equal to IS6110-
RFLP (Mathema et al, 2006). The advantages of this technique is that it is a rapid, high-
throughput technique and has a better resolution than spoligotyping, and along with the 
digitized output, means than intra-laboratory comparisons are made simpler (Mathema et al, 
2006). The introduction of fluorescently-labeled primers allows for the automated analysis 
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when used in conjunction with a capillary sequencer (Mathema et al, 2006). The disadvantage 
is that it is less discriminatory than IS6110-RFLP typing (Supply et al, 2000; 2001). 
In a study by Savine and colleagues, the stability of the VNTRs of MIRUs from 12 loci was 
assessed over time (Savine et al, 2002). They assessed the temporal stability of 123 serial 
isolates from 56 smear-positive patients. These isolates were separated by up to 6 years and 
belonged to a variety of distinct IS6110-RFLP patterns (Savine et al, 2002). They showed that 
the MIRU-VNTRs are stable over time and are therefore very reliable in the follow-up of 
patients chronically infected with TB, and that this technique is a highly powerful tool for 
genotyping M. tuberculosis (Savine et al, 2002). 
 
In another study, Filliol and colleagues assessed MIRU-VNTR analysis against spoligotyping, 
IS6110-RFLP and double-repetitive-element (DRE) PCR (Filliol et al, 2000). The results 
showed that in 6/12 cases (50%), VNTR-defined clusters were further subdivided by 
spoligotyping; in comparison to 7/18 (39%) cases where spoligotyping defined clusters were 
further subdivided by VNTR. When used alone, the least discriminant technique was VNTR 
analysis, but significantly improved when in association with spoligotyping, however 
spoligotyping and DRE-PCR had the highest discriminatory power (Filliol et al, 2000). They 
concluded that although the discriminatory power of VNTR was lower than the other tests, this 
technique may offer additional phylogenetic information that may be helpful to trace the 
molecular evolution of M. tuberculosis (Filliol et al, 2000). 
 
Using this typing technique, the CAS1 strain family of M. tuberculosis, which is the most 
prevalent strain in Pakistan, was characterized (Ali et al, 2007). A total of 178 CAS1 and 189 
‘unique’ M. tuberculosis strains were analyzed and the discriminatory index was calculated 
using the Hunter Gaston Discriminatory Index (HGDI). The 349 MIRU patterns obtained from 
the 367 strains tested indicated that MIRU loci 10, 16, 26, 27, 31, 39 and 40 were ‘most 
discriminatory’ (DI: ≥0.6), with loci 26 and 31 being ‘highly discriminatory’. Loci 4, 20, 23 and 
24 were found to be ‘moderately discriminatory’ (DI: 0.3 – 0.59), and loci 2 was found to be 
‘poorly discriminatory’ (DI<0.3) for typing CAS1 strains specifically (Ali et al, 2007).   The 
authors concluded that MIRU typing is an excellent way to estimate the phylogenetic 
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relatedness amongst CAS1 strains (Ali et al, 2007). Interestingly, the association between 
CAS1 strains and MDR was not significant (P = 0.21). 
 
1.4. Mixed M. tuberculosis Infections 
In the past, TB was thought to have occurred due to a single infection with a single strain of M. 
tuberculosis, resulting in immunity to further infections (Shamputa et al, 2004). However, 
recent studies, with the advent of improved molecular genotyping tools, have highlighted the 
relevant proportion of TB cases caused by multiple infections of two or more different strains 
of M. tuberculosis (de Viedma et al, 2004; Shamputa et al, 2004; Shamputa et al, 2006; 
Palomino et al, 2007). Despite this knowledge, the study of mixed infections is poorly 
understood (Shamputa et al, 2004, 2006). A mixed infection, or clonal heterogeneity, is the 
result of a superinfection in a previous TB case by a new M. tuberculosis strain, leading to the 
simultaneous or sequential presence of two or more different strains in the same patient (de 
Viedma et al, 2004), often referred to as exogenous reinfection. This is highly prevalent in 
high-incidence settings such as South Africa (Shamputa et al, 2006). Another class of mixed 
infections is the presence of multiple populations of M. tuberculosis derived from a single 
ancestral strain, each displaying genetic drift (Palomino et al, 2007). Due to the very lobus 
nature of the lungs, compartmentalization can occur, whereby “pockets” of different clones of 
the infecting M. tuberculosis strain may occur (de Viedma et al, 2004), making interpretation of 
DST and genotyping data difficult and problematic (Shamputa et al, 2004). 
 
An epidemiological study carried out in Cape Town revealed that 19% of patients harboured 
simultaneous infections with both Beijing and non-Beijing lineages of M. tuberculosis (Warren 
et al, 2004). Furthermore, it was noted that 57% of all patients infected with a Beijing strain 
were additionally infected with a non-Beijing strain (Warren et al, 2004). The researchers also 
noted that the occurrence of mixed infections was more frequently detected in retreatment 
cases (23%) compared to new cases (17%) (Warren et al, 2004). This was done using a novel 
PCR that detected strains in sputum belonging to Beijing and non-Beijing lineages. Utilising 
four primer sets, designed to anneal to regions of the chromosome specific to the Beijing and 
non-Beijing strains, Warren and colleagues concluded that the PCR improved the estimate of 
Un
ive
rsi
ty 
of 
C
pe
 To
wn
23 
 
mixed infections in the Western Cape (19%) compared to the 4.8% that spoligotyping alone 
detected, and that this relatively high rate of mixed infections has great implications in the 
interpretation of DST and other molecular data (Warren et al, 2004).  
 
Very recently, an inter-provincial genotyping study was carried out in South Africa, using 
spoligotyping and MIRU-VNTR typing (Stavrum et al, 2009). It showed that 54% of the 
collected T strains analysed by MIRU-VNTR typing were of mixed M. tuberculosis 
subpopulations (Stavrum et al, 2009). MIRU-VNTR can aid in detecting mixed infections; a 
sample containing different strains will display several alleles for one locus. However, this is 
based on the assumption that those strains differ in alleles at that specific locus, but even 
different strains could have the same MIRU-VNTR profile and would not be detected as being 
mixed (Stavrum et al, 2009). 
 
In one study, 10 colonies from each primary M. tuberculosis isolate of 97 HIV negative TB 
patients were screened for heterogeneity and detectable mixed infections by spoligotyping, 
IS6110-RFLP and MIRU-VNTR (Shamputa et al, 2004). Infections from heterogeneous 
bacterial subpopulations were detected in samples from 8 patients (8.2%), with the frequency 
of detectable mixed infections in the study population being 2.1% (Shamputa et al, 2004). 
Although the researchers allude to the possibility of introducing a bias in the selection criteria 
of the study population, they conclude that the findings have implications on the interpretation 
of molecular epidemiological results for patient follow-ups as well as transmission studies 
(Shamputa et al, 2004). 
 
In another study, several pre-treatment isolates from 199 smear-positive male adult inmates 
were screened using IS6110-RFLP as well as MIRU-VNTR analysis (Shamputa et al, 2006). 
Mixed infections were found in 26 cases (13.1%). Using either IS6110-RFLP or MIRU-VNTR 
alone would have missed mixed infections in 26/26 (100%) or 14/26 (54%) cases, respectively 
(Shamputa et al, 2006). They conclude that the current methods to genotype M. tuberculosis 
greatly underestimate the actual heterogeneity of the bacilliary population in TB patients, 
particularly in high-incidence settings (Shamputa et al, 2006). 
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In a study screening for heterogeneity using IS6110-RFLP and spoligotyping, 30 colonies from 
each primary M. tuberculosis isolate from 12 children with TB were collected (de Viedma et al, 
2004). All cultures from 11 of the 12 children were homogenous, while in 1 child (8.3%), a 2-
year old in whom microevolution events were unlikely and who had no risk of overexposure, 
clonal heterogeneity was found (de Viedma et al, 2004). This led to the conclusion that clonal 
heterogeneity should be expected in primary cases (de Viedma et al, 2004).  
 
 
1.5. Conclusion 
Despite its antiquity and vast history, M. tuberculosis is described as an emerging pathogen 
(Hopewell, 1996) and remains the leading cause of death due to an infectious disease 
worldwide (Plorde, 1994). M. tuberculosis is considered an emerging pathogen, not because 
the bacillus has recently emerged but because scientists, health practitioners and 
professionals, along with governments have only recently begun working together to formulate 
treatment regimes in order to stop the spread of this devastating disease (Hopewell, 1996). 
There is an urgent need for newer and more effective chemotherapies as well as standardized 
methods of detection, DST as well as strain typing. The fact that TB infection can be the result 
of several infecting M. tuberculosis strains simultaneously requires scientists and clinicians to 
revaluate the way we analyse and interpret epidemiological and DST data. Furthermore, the 
fact that the presence of several different strains of M. tuberculosis has great consequences 
on the way that patients are treated, it is imperative that more reliable and sensitive 
techniques are developed that will differentiate out the mixed strains.  In order to reach the 
2015 STOP TB Partnership goals of halting and reversing international incidences of TB, and 
halving prevalence and deaths, in comparison to 1999 (WHO, 2007), we all need to be 
working together in order to curb TB. By doing this we may see the 2050 goal of eliminating 
TB as a public health problem (WHO, 2007). 
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1.6. Project Aims and Objectives 
 
This project aims: 
1. To determine the strain lineage of all isolates collected and included in this study by 
spoligotyping, as a means of assessing the epidemiology of the circulating strains, as well as 
to screen for mixed infections; 
2. To test for Rifampicin and Isoniazid resistance in those isolates determined to be mixed, 
using the GenoType MTBDRplus assay, to identify if there is a corresponding change in drug 
susceptibility to change in spoligotyping pattern; 
3. To assess the genetic relatedness of the mixed isolates by MIRU-VNTR analysis; 
4. To screen all isolates, including those identified by spoligotyping to be mixed, for (i) 
additional mixed isolates, and (ii) to confirm the results obtained by spoligotyping, by carrying 
out PCR assays that detect mixed isolates belonging to the W-Beijing and non-W-Beijing 
lineages; 
5. To develop a PCR-based assay to differentiate between infecting non-W-Beijing strains, 
and to screen all isolates, including those identified by spoligotyping to be mixed, for (i) 
additional mixed isolates, and (ii) to confirm the results obtained by spoligotyping. 
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Chapter 2 
Materials and Methods 
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2.1. Bacterial isolates, drug susceptibility testing, and growth conditions 
In a larger study conducted by the University of the Western Cape (UWC) in South Africa, the 
affects of vitamin A and zinc supplementation on time to sputum conversion in newly 
diagnosed smear-positive tuberculosis (TB) patients, living in the Delft region of the Western 
Cape, was addressed (M. Visser; personal communication). This trial, a double-blinded, 
randomized, placebo-controlled trial, investigated whether or not micronutrient 
supplementation with vitamin A versus placebo, and zinc versus placebo, in addition to anti-
TB medication, would reduce the time to sputum conversion over an 8 week period.  Adults, 
aged between 18 and 65 years of age, with newly diagnosed pulmonary TB and living in the 
Delft community, were enrolled into the trial. Early-morning baseline sputum samples were 
collected from 154 patients, at the community clinic in Delft, under the supervision of the 
research nurse. The subsequent weekly samples were brought into the clinic by the patients 
themselves, unsupervised, over the 8 week study period, from 2005 to 2008. Patients with 
negative sputum samples were excluded, as were samples contaminated during storage. 
Contamination from fungi was most common. In addition several samples from patients were 
misplaced during the study and were thus lost for analysis. Hence, some patients, at the end 
of the study period, had less than 8 samples for analysis. From the initial 154 patients enrolled 
in the study a total of 686 isolates were obtained and included in this study. 
 
Collected sputum samples were decontaminated by the NALC/NaOH 
decontamination/digestion method in the Medical Microbiology Diagnostic laboratory at Groote 
Schuur Hospital (GSH), Cape Town. These were then inoculated into Mycobacteria Growth 
Indicator Tubes (MGITs) containing OADC-enriched Middlebrook liquid media supplemented 
with MGIT PANTA antibiotics and placed into an automated BACTEC MGIT 960 system (BD) 
for the monitoring of growth. Each tube has imbedded an oxygen-sensitive fluorescent disk 
that aids in the detection of growth. Oxygen present in the tube quenches the fluorescence 
and the BACTEC 960 will detect no growth. Active growth uses up the available oxygen in the 
tubes and the fluorescence is released and captured by the BACTEC 960. The samples were 
incubated until growth was observed or until the end of the testing protocol (56 days). After the 
results were recorded, the MGITs were stored in boxes at room temperature in the Biosafety 
Level III (BSL3) facility in the Division of Medical Microbiology, University of Cape Town. 
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The strains were inoculated from the MGITs onto Lowenstein-Jenson (LJ) slopes (Bio-Rad) 
and left to grow at 37°C for 4 – 6 weeks in the BSL3 facility, until growth was observed. 
Colonies were picked from the slopes and inoculated into 1.25ml ADC-supplemented 
Middlebrook 7H9 broth (Appendix A) in 2ml screw-cap tubes. These cultures were incubated 
at 37°C for a week, after which 500µl of 50% glycerol was added to each tube, mixed 
thoroughly by inverting the tubes several times, and then stored at -80°C.  
 
Phenotypic drug susceptibility DST for rifampicin (RIF) and isoniazid (INH) was performed 
using the automated BACTEC MGIT 960 system as part of routine diagnostics at the Medical 
Microbiology diagnostic laboratory at GSH. Genotypic DST was also carried out using the 
Genotype MTBDRplus assay (Hain Lifescience, Germany), on the samples suspected of 
harboring mixed M. tuberculosis isolates. This PCR and reverse hybridization assay detects 
the most frequently observed chromosomal determinants associated with multi-drug 
resistance (MDR) M. tuberculosis, including resistance to both RIF and INH (WHO, 2000). The 
membrane used is a strip containing covalently bound DNA probes corresponding to the 
various resistance determinants. High-level resistance to isoniazid is tested by detecting the 
S315T mutation of katG, while low-level resistance to isoniazid is tested by detecting the C-
15T promoter mutation of inhA. Resistance to rifampicin is tested by detecting the common 
rifampicin resistance determining region (RRDR) mutations in rpoB, namely the D516V, 
H526Y, H526D and S531L mutations (Hain Lifesciences). The 50µl amplification mix 
contained the following components: 35µl of the primer/nucleotide mix (PNM) in the kit, 1X 
HotStartTaq polymerase buffer, 0.5mM MgCl2, 1X Q-solution and 1U of HotStartTaq DNA 
polymerase. To each reaction, 5µl of DNA extracted from MGIT cultures (2.2.2) was added. 
Amplification proceeded with an initial denaturation and polymerase activation at 95°C for 
15min followed by 10 cycles of 95°C for 30sec and 58°C for 2min, and a further 20 cycles of 
95°C for 25sec, 53°C for 40sec and 70°C for 40sec. Lastly, an elongation at 70°C for 8min 
completed the amplification. 
 
Hybridization of the amplicons was performed using a TwinCubator®, an automated incubator 
and shaker specifically designed for the demand of the molecular diagnostics of Hain 
Lifesciences. The TwinCubator® contains wells for 12 oligonucleotide strips, and is fully 
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programmable for the timed stages of the protocol. Briefly, the TwinCubator® was pre-warmed 
to 45°C along with solutions HYB (green) and STR (red) to 45°C. The other reagents, except 
CON-C (orange) and SUB-C (yellow), were warmed to room temperature. CON-C and SUB-C 
remained at 4°C (according to manufacturer’s instructions). CON-C and SUB-C were diluted 
1:100 with CON-D and SUB-D, respectively. In the corner of each well, 20µl of DEN (blue) 
was applied to which 20µl of the amplified product was added, and mixed by brief aspiration 
followed by 5min incubation at room temperature. Each DNA strip was marked with a pencil 
beneath the coloured marker at the end of the strip, for ease of identification. Carefully, 
avoiding contamination in neighboring wells, 1ml of HYB solution was added to each well and 
gently homogenized to ensure adequate mixing. A DNA strip was then placed in each well, 
with the coated surface facing upwards. The tray was then placed onto the TwinCubator® and 
incubated with shaking at 45°C for 30min. Buffer HYB was then completely aspirated and 1ml 
of STR buffer was added to each well and incubated at 45°C for 15min. Buffer STR was then 
carefully poured off and the tray gently tapped to remove any residual buffer in the wells. The 
strips were then washed once, with 1ml of RIN buffer for 1min in the TwinCubator®. The rinse 
buffer was then poured off as before and 1ml diluted CON-C was added to each well and 
incubated on the TwinCubator® at 45°C for 30min. CON-C was then discarded and the strips 
washed twice in RIN for 1min each, and then once with distilled water, on the TwinCubator® 
platform. To each strip, 1ml of diluted SUB-C was then added and incubated in the dark, 
without shaking for 3-20min. The reaction was stopped by rinsing twice with distilled water. 
The strips were removed with forceps and gently blot dried between two sheets of absorbent 
paper. 
 
Hybridization signals must be present for all three of the controls, namely the conjugate 
control, which controls for hybridization-specific anomalies; the amplification control, which 
ensures that the PCR conditions were optimal; and the M. tuberculosis control, which ensures 
that the sample being tested is in fact from the M. tuberculosis complex (Figure 2.1). 
Hybridization signals for any of the wild-type (WT) probes indicate that no mutation in that 
region was detected, and that the isolate be considered susceptible to either RIF or INH. The 
absence of a signal in the WT probes and the presence of a specific mutation probe, indicates 
that a particular resistance determinant is present in that strain, and that the isolate be 
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considered resistant to either RIF or INH. A diagrammatic representation of a strip, depicting 
the bound probes, is featured in Figure 2.1. 
 
Figure 2.1. Diagrammatic representation of hybridized GenoType MTBDRplus assay strips. All probes appear 
labelled on both the left and right of the strips. Hybridization signals are represented by dark horizontal bands. 
Strip 1: Signals for all wild-type (WT) probes and the absence of any signals for the mutation probes indicates 
that this isolate is fully susceptible to both RIF and INH. Strip 2: Signals for both the rpoB mutation probe 2A and 
the katG mutation probe 1 indicate that this isolate is resistant to both RIF and INH. Strip 3: The absence of a 
signal for any rpoB mutation probes indicate that this isolate is susceptible to RIF while the presence of a signal 
for the inhA mutation probe 1 indicate that this isolate has a low level of resistance to INH. Strip 4: Signals for the 
rpoB mutation probe 3, katG mutation probe 2 and inhA mutation probe 3A indicate that this isolate is resistant to 
both RIF and highly resistant to INH. Strip 5: The absence of a WT probe as well as a mutation probe indicates 
that a mutation is present but one that isn’t covered by the mutation probes, and is considered resistant. Here 
both the absence of rpoB WT probe7 and the katG WT probe, as well as the absence of any signals in the 
mutation probes, indicate resistance to both RIF and INH. Adapted from the GenoType MTDRplus Assay online 
brochure (http://www.hain-lifescience.de/uploadfiles/file/produkte/mikrobiologie/mykobakterien/MTBDR-plus-
sl_eng.pdf). 
 
2.2. Extraction of genomic DNA  
2.2.1. Extraction of genomic DNA from colonies grown on LJ Slopes 
M. tuberculosis colonies were picked from the LJ slopes and inoculated into 500μl of distilled 
water in 2ml screw-cap tubes and heat killed in a water bath (Memmert) at 80°C for one hour 
in the BSL3 facility. After one hour of heat killing, 70μl of 10% SDS (BDH, Ltd) and 50μl 
(10mg/ml) proteinase K (Novagen) was added to each sample and placed in an Eppendorf 
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thermomixer at 60°C set at 400 rpm for an hour. After shaking, a 100μl aliquot of pre-heated 
(60°C) 5M NaCl (Saarchem, Merck) and 100μl pre-heated (60°C) 10% CTAB (Sigma) 
(Appendix A) was added to each sample and mixed thoroughly by inverting several times by 
hand. Shaking was resumed at 400rpm at 60°C for 15 minutes. The samples were then 
placed in the -70°C freezer for 15min, thawed and then reincubated in the 60°C Eppendorf 
thermomixer at 400rpm for 15min. The samples were removed and cooled at room 
temperature. After cooling, 700μl of chloroform/isoamyl alcohol (24:1) (Saarchem, Merck) 
(Appendix A) was added to each tube and inverted by hand for 20 – 25 times ensuring that the 
two phases formed a homogenous suspension. The tubes were centrifuged (Eppendorf 
5417C) for 10min at 13000rpm. The aqueous upper phase was then transferred to a fresh 
1.5ml Eppendorf tube with 1 volume of cold isopropanol (Saarchem, Merck) and mixed by 
inverting the tube by hand several times until a DNA precipitate was seen. The samples were 
incubated at -20°C for 30min, followed by centrifugation for 10min at 13000rpm. The 
supernatant was removed and the pellet washed with 80% ethanol and centrifuged for a 
further 10min at 13000rpm. The supernatant was removed and the pellet was air-dried before 
resuspending in 55μl of distilled water. The DNA was then quantified by electrophoresing 5μl 
of the purified DNA on a 1% agarose (Whitehead Scientific) (Appendix A) gel and comparing 
the intensity of the bands with Hyperladder I (Appendix B) and λ DNA. The extracted DNA was 
stored at 4°C to prevent the shearing effect caused by repetitive freeze-thawing. 
 
2.2.2. Extraction of genomic DNA from MGIT cultures 
Genomic DNA was extracted from MGIT cultures for use in PCR assays and for spoligotyping. 
From the MGIT cultures, 1.8ml was transferred to 2ml screw-cap tubes and centrifuged for 
10min at 13000rpm. The supernatant was removed and the cells were resuspended in 500μl 
of distilled water. The cells were then heat killed in a water bath at 80°C for an hour. After this, 
the samples were microwaved (LG Multiwave) on high (900 watts) for 1 – 2 minutes to release 
the DNA from the cells. An aliquot (4μl) was used as template in PCR assays and 
spoligotyping. 
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2.3. Agarose gel electrophoresis and DNA visualisation 
Gel electrophoresis is a useful technique to separate nucleic acids on the basis of size. When 
agarose polymerises it forms pores, the size of which is dependent on the percentage of 
agarose; a higher percentage equates to more agarose being polymerised and thus smaller 
pores. Usually the larger the nucleic acids in a sample the lower the agarose percentage must 
be in order for the pore sizes to be large enough to allow the nucleic acids to migrate through 
the gel. Electrophoresis is performed in a gel tank containing 1X Tris-acetate EDTA (TAE) 
buffer (Appendix A). A current is passed through the buffer from the negative electrode to the 
positive electrode, which causes the negatively charged nucleic acids to migrate through the 
gel towards the positive electrode. The concentrations used ranged from 1% to 2% weight per 
volume (w/v) agarose dissolved in 1X TAE by heating in a microwave on high for 2 – 3min. 
Ethidium bromide (EtBr) is then added to a final concentration of 10ng/μl to visualise the 
migrated nucleic acid band(s). This is achieved because EtBr intercalates between DNA and 
fluoresces in the presence of UV light. The GoTaq reaction buffer contains a loading dye that 
allows one to monitor the migration of the nucleic acids as well as keeping the sample heavy 
in the wells. Depending on the size of the DNA fragments either HyperLadder I or 
HyperLadder IV (Bioline) (Appendix B), for larger to smaller fragments, respectively, was 
loaded alongside to determine the size and concentrations of DNA fragments. After 
electrophoresis the gel was placed onto a UV box (Fotodyne Inc.) for visualisation and the 
image captured using a digital camera (Kodak EDAS 290). 
 
2.4. DNA purification 
In order for PCR amplified DNA products to be sequenced they must be of a high quality and 
thus the need for purification. To purify DNA fragments from agarose gels, a MinElute Gel 
Extraction kit (Qiagen) was used. Gel bands containing DNA fragments of interest were 
visualised on a UV box wearing the appropriate face guard and excised using a scalpel 
removing as much surplus agarose as possible. The gel bands were placed into separate 
Eppendorf tubes and weighed. After the tubes were weighed, 3 gel volumes of buffer QG was 
added to each tube and incubated at 50°C for 10min until all the agarose had melted. An 
equal volume of isopropanol was added to each tube to precipitate the DNA. Each sample 
was then transferred to a MinElute spin column and centrifuged for 1 minute at 13000rpm to 
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allow the DNA to bind to the column matrix. The flow-through was discarded and 500μl of 
buffer QG was added to each spin column and centrifuged for a further minute at 13000rpm. 
Once again the flow-through was discarded and 750μl of buffer PE was added to wash the 
DNA, and was centrifuged for 1min at 13000rpm. The flow-through was discarded and the 
tubes were centrifuged for 1min at 13000rpm to remove residual ethanol from the DNA. The 
spin columns were placed in 1.5ml Eppendorf tubes and 10μl of distilled water was applied to 
each column. The DNA was then eluted by centrifugation for 1 minute at 13000rpm and stored 
at 4°C until needed. 
 
2.5. DNA Sequencing and analysis 
Sequencing reactions were carried out according to the protocol by Zimmerman and 
colleagues (Zimmermann et al, 1988). Essentially, when ddNTPs are incorporated into the 
growing 3’ end of newly synthesised DNA, chain elongation terminates due to the lack of the 
3’-hydroxyl group usually present in dNTPs but absent in ddNTPs. The chance incorporation 
of ddNTPs instead of dNTPs terminates elongation at all possible sites along the template, in 
oligonucleotides of varying length, all with the same 5’ end but each with a 3’ end 
corresponding to one of four ddNTPs in the template. The four ddNTPs are fluorescently 
labelled with a different colour, and upon gel electrophoresis the products migrate towards the 
positive electrode and each product passes through a laser that reads the different fluorescent 
labels and computer software converts that signal into a DNA sequence that can later be 
analysed. One microliter of purified DNA was quantified on a 2% agarose gel (Appendix A) 
alongside 5μl of the DNA marker HyperLadder IV (Bioline) (Appendix B).  The intensity of the 
purified DNA band was compared to that of the HyperLadder bands to determine the 
concentration of DNA in ng/μl. Based on the size of the DNA template approximately 5 – 10ng 
of DNA was used if the template size was 400 – 450bp, or 50 – 100ng of DNA was used if the 
template size was 2000 – 3000bp. In addition to the DNA template, the 20μl sequencing 
reaction volume contained 1X reaction buffer, 4μl of Sequencing Mix (Applied Biosystems) 
and 3.2pmol/μl of primer. The cycle conditions were as follows: an initial denaturation at 96°C 
for 30 seconds followed by 25 cycles of 96°C for 30sec, 50°C for 15sec and 60°C for 4min. 
The reactions were sent to the DNA Sequencing facility at the University of Stellenbosch 
where an ABI Prism 3100 Genetic Analyser (Applied Biosystems) was used to determine the 
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sequence of the samples. The chromatogram was analysed using the ChromasPro Version 
1.34 (Technelysium Pty Ltd) software package. Alignments and sequence modifications were 
done using the DNAMAN Version 4.0 (Lynnon BioSoft) software package.  
 
2.6. Spoligotyping 
Genetic relatedness between the different strains was determined using spoligotyping. This 
PCR-hybridisation technique simultaneously detects and types M. tuberculosis complex 
bacteria. These organisms contain a unique locus known as the Direct Repeat (DR) region 
which consists of directly repeated sequences interspersed with spacer regions of between 35 
to 41bp. The order of the spacer regions remains the same when comparing many different 
strains, however between the strains, deletions or insertions of spacers often occur. Thus it is 
possible to compare the presence or absence of the spacer regions to determine whether 
strains are related.  
Spoligotyping involves PCR amplification of the DR region using primers that anneal to the 
DRs, resulting in the amplification of the spacer regions. The reverse primer is biotin-labelled 
(Isogen) and therefore all PCR products are biotin-labelled (Figure 2.2). 
 
Figure 2.2. Schematic representation of the spoligotyping technique. (A) A depiction of the DR locus containing 
IS6110. (B) PCR primers anneal to the DR region and amplify the intervening spacer regions. The reverse primer 
DRa is biotin-labelled. (C) After developing the film following incubation with the ECL detection reagents, black 
square signals represent the spacer sequences that are present in each strain. (Adapted from Kamerbeek et al, 
1997) 
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The PCR products are then hybridised to a membrane (Isogen) containing parallel lines of 
covalently linked oligonucleotides from known spacers. The membrane is then incubated in 
streptavidine-peroxidase (Sigma) and detected using the enhanced chemiluminescence (ECL) 
Direct Nucleic Acid Labelling and Detection System (Amersham Biosciences) on a light 
sensitive film. The biotin-labelled probes anneal to regions of homology on the membrane and 
streptavidine anneals to biotin. A signal is produced when the streptavidine-peroxidase, bound 
to the biotin-labelled primers, catalyses a light reaction using the ECL detection reagents as a 
substrate, which is then caught on the light sensitive film. The film, after exposure to the 
membrane, is then developed and fixed and the resulting profile is compared to a database 
and typed accordingly. 
 
2.6.1. Amplification of the DR spacer regions 
The spoligotyping PCR was performed using reagents from Isogen – Lifescience. The 25μl 
reaction contains 1X Reaction Buffer, 1mM MgCl2, 200μl of each dNTP, 1X Reagent Q, 10μM 
each of biotin-labelled primer DRa, and primer DRb, 1U GoTaq (Promega). If genomic DNA is 
being used then 100 – 200ng is added as template otherwise a 4μl aliquot from a MGIT 
preparation is used as template. Included in the kit from Isogen were the M. tuberculosis 
H37Rv and the M. bovis BCG P3 controls which, along with the negative water control, were 
included in the reaction using 1μl each. H37Rv contains spacer sequences 1 – 19, 22 – 32, 
and 37 – 43, while BCG contains spacer sequences 20 – 21 and 33 – 36. Therefore by 
including both strains as positive controls, ensures that all spacer sequences are amplified 
equally from all strains (Kamerbeek et al, 1997). The negative water control is included to 
ensure that none of the reagents used are contaminated. The cycling conditions in the 
thermalcycler were an initial denaturation at 96°C for 15min, followed by 25 cycles of 96°C for 
1min, 55°C for 1min and 72°C for 30sec. A final elongation at 72°C for 5min completed the 
reaction. Amplified products were then stored at 4°C until needed.  
 
2.6.2. Hybridisation 
The reagents used for hybridisation were pre-warmed as follows: 2X SSPE/0.1% SDS at 
60°C, 2X SSPE/0.5% SDS at 60°C, 2X SSPE/0.5% SDS at 42°C and 2X SSPE at room 
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temperature (Appendix A). The amplified DR spacer PCR products were added to 150μl of 2X 
SSPE/0.1% SDS and heat denatured in the thermalcycler for 10 minutes at 99°C and 
immediately cooled on ice. The membrane (Biodyne C negatively charged nylon) was washed 
in 250ml of 2X SSPE/0.1% SDS in a 60°C oven with gentle shaking for 5min. The membrane 
was then placed inside the miniblotter apparatus (Isogen) (Figure 2.3) on a support cushion in 
such a way as to ensure the wells are perpendicular to the oligonucleotide probes. 
 
 
 
          Figure 2.3. Miniblotter apparatus supplied with the Spoligotyping kit (Isogen) (www.blossombio.com.tw)  
 
The blotter has 45 wells that connect to parallel grooves running the length of the apparatus. 
When the membrane is placed inside the blotter these grooves run perpendicular to the 
oligonucleotides on the membrane, and thus after hybridisation the spacers can be visualised 
on the film as black squares.  The fasteners were then tightened and residual fluid was 
aspirated out of the wells. The diluted PCR products were then transferred to the wells 
ensuring that no air bubbles were introduced and that no cross-well contamination occurred. 
The entire apparatus was placed in a 60°C oven and left to hybridise for 1 hour without 
shaking. After the 1 hour incubation the PCR products were removed from the blotter by 
aspiration. The membrane was then removed from the blotter with forceps and washed twice 
in 250ml 2X SSPE/0.5% SDS in a 60°C oven for 10min with gentle shaking.  The membrane 
was then placed inside a rolling bottle to cool down to room temperature before the addition of 
the 5μl of 5U/ml streptavidine-peroxidase in 10ml of 2X SSPE/0.5% SDS and incubated in the 
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rolling bottle in a 42°C oven with gentle rolling for 1 hour.  The membrane was then washed 
twice in 250ml 2X SSPE/0.5% SDS for 10min in a 42°C oven with gentle shaking and then 
rinsed twice in 250ml 2X SSPE at room temperature for 5min.  
 
2.6.3. Detection 
The ECL Direct Nucleic Acid Labelling and Detection System (G.E. Healthcare, Amersham) 
was used to detect the spacer regions. In a dark room, 5ml of detection reagent 1 and 5ml 
detection reagent 2 was mixed together and poured over the membrane. The membrane was 
then wrapped in a sheet of Saran-wrap and incubated for 1min. A piece of light sensitive film 
(Agfa) was then placed over the membrane in a film cassette and tightly closed to prevent light 
from entering. The film was then exposed to the membrane for 10min and developed. The film 
was placed in developer for 3min, rinsed in water for 1min and then placed in fixer for 1min 
before hanging out to dry. The pattern of spacers obtained for each strain, represented by 
black squares in rows, was then compared to known profiles in order to determine the strain 
family to which the strain belongs. The membrane can be reused after it has been stripped by 
incubating the membrane in 1% SDS (Appendix A) at 80°C for 30min twice, then in 20mM 
EDTA at pH 8 for 15min at room temperature. The membrane is then covered in Saran-wrap, 
to avoid dehydration, and stored at 4°C till reused. 
 
2.7. Mycobacterial interspersed repetitive units (MIRU) – variable number 
of tandem repeats (VNTR) typing 
MIRU-VNTR utilises regions in the chromosome of M. tuberculosis known as mycobacterial 
interspersed repetitive units (MIRU). There are 41 MIRU loci, spaced throughout the              
M. tuberculosis complex genome, 12 of which display variable number tandem repeats 
(VNTR) that differ in copy number within the MIRU loci (Supply et al, 2000, 2001). These 
regions are exploited in this assay to further characterize relatedness between strain lineages, 
by the formation of a numerical code that corresponds to the numbers of VNTRs in the 12 
MIRU loci. This is achievable due to the high discriminatory power that these loci have in 
differentiating related and unrelated strains. The results from this assay, the numerical codes, 
are fully reproducible and allow for inter-laboratory comparison of strains (Supply et al, 2001). 
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MIRU-VNTR has been enhanced by the use of fluorescently labelled primers, the products of 
which can be detected using an automated sequencer. MIRU-VNTR was used to determine 
the relatedness of the sequential isolates collected from each patient indicated as harbouring 
mixed isolates. The assay consists of a multiplex PCR assay that utilises four groups of three 
labelled primer sets each, to detect the 12 MIRU loci (Table 2.1) 
Table 2.1. MIRU-VNTR primer mixes and the corresponding amplified MIRU loci 
Multiplex PCR Mixture MIRU Locus aPrimer Sequence 5’à3’ (Label) 
A 4 GCGCGAGCCCGAACTGC (FAM) 
  GCGCAGCAGAAACGTCAGC 
 26 TAGGTCTACCGTCGAAATCTGTGAC 
  CATAGGCGACCAGGCGAATAG (HEX) 
 40 GGGTTGCTGGATGACAACGTGT (NED) 
  GGGTGATCTCGGCGAAATCAGATA 
   
B 10 GTTCTTGACCAACTGCAGTCGTCC 
  GCCACCTTGGTGATCAGCTACCT (FAM) 
 16 TCGGTGATCGGGTCCAGTCCAAGTA 
  CCCGTCGTGCAGCCCTGGTAC (HEX) 
 31 ACTGATTGGCTTCATACGGCTTTA 
  GTGCCGACGTGGTCTTGAT (NED) 
   
C 2 TGGACTTGCAGCAATGGACCAACT 
  TACTCGGACGCCGGCTCAAAAT (FAM) 
 23 CTGTCGATGGCCGCAACAAAACG (HEX) 
  AGCTCAACGGGTTCGCCCTTTTGTC 
 39 CGCATCGACAAACTGGAGCCAAAC 
  CGGAAACGTCTACGCCCCACACAT (NED) 
   
D 20 TCGGAGAGATGCCCTTCGAGTTAG (FAM) 
  GGAGACCGCGACCAGGTACTTGTA 
 24 CGACCAAGATGTGCAGGAATACAT 
  GGGCGAGTTGAGCTCACAGAA (HEX) 
 27 TCGAAAGCCTCGCGTGCCAGTAA 
  GCGATGTGAGCGTGCCACTCAA (NED) 
a Forward primer sequences are listed above the reverse primer sequence in each case, with the fluorescent dye 
indicated in each mixture. 
 
The 50µl reaction volume was made up in 96-well reaction plates and consisted of the 
following components: 1U HotStartTaq DNA polymerase (Qiagen, Germany), 1X HotStartTaq 
buffer (Qiagen, Germany), 1X Q-solution (Qiagen, Germany), 0.2mM each of dNTPs 
(Fermentas, Inqaba Biotech), 0.4µM of each of the primers, and 3.0, 2.0, 2.5 and 1.5mM 
MgCl2 (Qiagen, Germany) for mixtures A to D, respectively. To this 3µl of DNA extracted from 
MGIT cultures (2.2.2) was added to each mixture. All four mixes had the same amplification 
protocol, performed in an ABI Thermocycler, which consisted of an initial denaturation at 95°C 
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for 15min, followed by 40 cycles of 1min 30sec at 94°C, 1min 30sec at 58°C and 2min at 
72°C. A final elongation at 72°C for 10min completed amplification. After amplification the 
products were diluted 1:20 using distilled water into a fresh 96-well reaction plate, in order to 
reduce the signal from primer-dimers. Into a third reaction plate, 2µl of the diluted amplicons 
were added to 8µl of HiDi formamide (Applied Biosystems) and 0.2µl of MapMarker. 
MapMarker is used by the sequencing software to standardize the size of the signal peaks 
during analysis. The samples were then run on an automated sequencer (ABI 3100 Analyser; 
Applied Biosystems) in the Division of Human Genetics, University of Cape Town. The 
fluorescently labelled products are detected and an image of the peaks based on the size of 
the products generated. The product size corresponds to the number of VNTRs in that MIRU 
locus (Appendix D). The number of VNTRs in each MIRU locus forms a 12-digit numerical 
code, which is then used to compare the relatedness of each strain. Using the MIRU-
VNTRplus algorithm (www.miru-vntrplus.org) with a maximum allele difference between 
clusters set at 2, the 12-digit numerical codes are compared and analysed. Thus isolates with 
differences in two or less alleles are considered related and form part of a clonal complex, 
while isolates with more than two allele differences are considered unrelated. Isolates with 
identical alleles are considered the same strain. 
 
 
2.8. Detection of mixed Mycobacterium tuberculosis infections by PCR 
assay based on the direct repeat region polymorphism 
The Polymerase Chain Reaction (PCR) is used to amplify in vitro a specific region of DNA. 
The reaction consists of repetitive three stage cycles; one cycle consisting of a high 
temperature DNA denaturation followed by cooling to allow oligonucleotide primers to anneal 
to the defined target region. Finally the temperature is raised to allow a thermal stable DNA 
polymerase, often Taq polymerase from Thermus aquaticus, to extend the newly synthesised 
DNA strand by the incorporation of free deoxynucleoside triphosphates (Atlas and Bej, 2004) 
(Figure 2.4). 
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Figure 2.4. Schematic representation of the Polymerase Chain Reaction (PCR). A: Denaturing. B: Annealing. C: 
Elongation (P=Polymerase). D. The first cycle is complete. The two resulting DNA strands make up the template 
DNA for the next cycle, thus doubling the amount of DNA duplicated for each new cycle. (Taken from 
www.biologydaily.com/biology/PCR).  
 
 
A PCR assay to detect a mixed infection from W-Beijing and non-W-Beijing M. tuberculosis 
isolates in sputum (Warren et al, 2004), was used in this study.  The assay differentiates 
isolates based on the presence or absence of chromosomal markers unique to the defined 
evolutionary lineages of M. tuberculosis (Warren et al, 2004). A useful region in the 
chromosome of M. tuberculosis that is often used in genotyping studies, such as 
spoligotyping, is the direct repeat region (DR), which contains highly conserved direct repeats 
interspersed with highly variable spacer sequences (Kamberbeek et al, 1997). The 
polymorphism present in this region that makes it suited for delineating strains is that the 
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spacer sequences across the lineages may be deleted. Thus it is possible to genotype strains 
of M. tuberculosis based on the presence or absence of the spacer regions, as is done in 
spoligotyping (2.8.). Unique to the Beijing lineages is the absence of the majority of the direct 
repeats and spacer sequences, except for spacer sequences 35 to 43, as well as the 
presence of the insertion sequence (IS) IS6110 in region Rv2820 of the M. tuberculosis 
chromosome. 
 
This PCR assay (Warren et al, 2004) utilizes four separate sets of overlapping primers; primer 
sets 1 and 2 detect Beijing isolates, while primer sets 3 and 4 detect non-Beijing isolates 
(Figure 2.5). 
 
Figure 2.5. Schematic depicting the relative positions of primer sets 1 – 4 in the DR in all non-W-Beijing and W-
Beijing strains. Large arrows: direction of open reading frames. Square boxes: insertion of IS6110 in the DR (in 
Beijing isolates IS6110 is inverted). Dotted lines: region deleted in all Beijing strains. Small arrows: position of 
primer sets 1 – 4. (Adapted from Warren et al, 2004).  
 
Primer sets 1 and 2 (Table 2.1) are complimentary to a portion of IS6110 and Rv2820 (Figure 
2.5) and following PCR amplification results in an amplicon of 393bp and 239bp, respectively 
(Figure 2.6). Primer sets 3 and 4 (Table 2.2) are complimentary to Rv2819, which is deleted in 
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all W-Beijing strains, and upon amplification and electrophoresis, results in an amplicon of 
569bp and 308bp, respectively (Figure 2.6). Correctly amplified products visualized from all for 
primer sets indicates a mixed infection consisting of a W-Beijing and a non-W-Beijing isolate. 
 
Table 2.2. Primer sets and their sequences used in the PCR assay to detect mixed infections of M. tuberculosis. 
Primer Name Primer Sequence (5’ à 3’)a Region of Amplification 
PS1F TTC AAC CAT CGC CGC CTC TAC 5’ portion of IS6110 
PS1R CAC CCT CTA CTC TGC GCT TTG Rv2820 
PS2F ACC GAG CTG ATC AAA CCC G 5’ portion of IS6110 
PS2R ATG GCA CGG CCG ACC TGA ATG AAC  C Rv2820 
PS3F GAT CGC TTG TTC TCA GTG CAG Rv2819 
PS3R CGA AGG AGT ACC ACG TGG AG Rv2819 
PS4F GGT GCG AGA TTG AGG TTC CC Rv2819 
PS4R TCT ACC TGC AGT CGC TTG TGC Rv2819 
a Sequences as described by Warren et al, 2004. PS: Primer Set; F: Forward primer; R: Reverse primer. 
 
Figure 2.6. Schematic representation of the expected products following amplification from assays PS1, PS2, 
PS3 and PS4. The molecular weight marker (MWM) is represented as thin parallel lines, while amplicons are 
represented as thick horizontal lines. The appropriate MWM is labelled above each specific amplicon. 
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The PCR assay consisted of four separate reactions made up to a final volume of 25µl with 
1X HotStarTaq enzyme buffer (Qiagen), 3.5mM MgCl2 (Qiagen), 4mM dNTPs (Fermentas), 
25pmol of each primer, 0.5U of HotStarTaq DNA Polymerase (Qiagen) and 1µl of MGIT DNA 
template (2.2.2). Amplification was performed in ABI2720 Thermocycler (Applied Biosystems) 
under the following conditions: initial denaturation and enzyme activation at 95°C for 15min 
followed by 45 cycles of 94°C for 1min, 62°C for 1min and 72°C for 1min. Finally, an 
elongation at 72°C for 10min completed the amplification. The amplified products were 
electrophoresed with 5µl loading buffer on a 1.5% agarose gel at 100 volts for 1 hour and 
visualized (2.3).  
 
2.9. Differentiation of non-W-Beijing Mycobacterium tuberculosis 
infections by a 3-stage PCR algorithm 
The PCR assay (Warren et al, 2004), as described previously (2.4), allows for a modest 
approximation of mixed infections of M. tuberculosis in a high-burdened setting. However, as 
stated, a mixed population of infecting non-W-Beijing strains would go undetected if the assay 
was used in isolation. Thus there exists a need for an additional assay to separate out the 
various prevalent non-W-Beijing strains circulating in the Western Cape.  
 
According to several South African researchers (Nicol et al, 2005; Marais et al, 2006), there 
are four circulating non-W-Beijing strain lineages that are prevalent in the Western Cape 
(Table 2.3.). 
 
                                              Table 2.3. Prevalence of major circulating M. tuberculosis  
lineages in the Western Cape 
Strain Lineage Prevalence 
 (% of total study 
population) 
Study 1† Study 2‡ 
All LAM 33 28.6 
LAM3 30 NR 
X 10.5 6.3 
T 7 NR 
Haarlem 4 3 
                                             †Nicol et al, 2005 
                                             ‡Marais et al, 2006.  NR: Not Reported 
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The DR was used to differentiate each lineage based on the presence or absence of spacer 
sequences of each prevalent lineage (Figure 2.7.) 
 
 
Figure 2.7. Schematic depicting the consensus spacer sequences of each prevalent non-W-Beijing lineage.  The 
lineages are labeled on the right. Each spacer is numbered at the top from 1 through to 43 and is depicted as a 
black square. Spacer sequences that are absent in that lineage appear as a blank space. Arrows depict the 
forward and reverse primers of each PCR in the algorithm. Blue: RoD1 PCR; Green: RoD2 PCR; Red: RoD3 
PCR. (Adapted from the SpolD4 database; Brudey et al, 2006)    
 
 
As it can be seen in Figure 2.7, each lineage is characterized by a different arrangement of 
spacer sequences.  Based on these regions of difference (RoD), three separate PCR assays 
(RoD1 – 3) were designed in an algorithm format; starting from RoD1 one would work down 
toward RoD3 based on the results obtained from the previous PCR (Figure 2.8). 
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Figure 2.8. A 3-Step RoD PCR algorithm for the detection and differentiation of mixed non-Beijing M. 
tuberculosis isolates. Gels depicted as large rectangles. Molecular weight marker (MWM) depicted as 3 paralle l 
thin lines. Amplicons represented as bold horizontal lines. Molecular weights of amplicons labeled above each 
band. An amplicon of 1529bp after RoD1 indicates a LAM or S strain while the larger 1890bp amplicon indicates 
either T, X or H strains. An amplicon of 240bp after RoD2 indicates either a T or S strain (or an S strain, if in 
RoD1 the same sample yielded a 1529bp product) while the absence of a product indicates an X strain (or a LAM 
strain, but this would have been determined at RoD1). An amplicon of 395bp after RoD3 indicates a T strain (or 
LAM, X, or S strains but these would have been determined after RoD1 and RoD2), while the absence of an 
amplicon is indicative of an H strain.  
 
2.9.1. Differentiation using RoD1 PCR assay 
The first step in the PCR algorithm, RoD1 differentiates LAM strains from non-LAM strains 
based on the size of the amplicon. LAM strains are characterized by the absence of spacer 
sequences 21 – 24, whereas they are present in H, T and X lineages. RoD1F is designed to 
anneal to spacer sequence 20 while RoD1R is designed to anneal to spacer sequence 25 
(Table 2.4; Figure 2.7). In non-LAM strains a larger product of 1890bp is amplified while in 
LAM strains a smaller product of 1529bp is amplified (Figure 2.8), due to the absence of the 
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intervening spacer sequences. The insertion of IS6110 in spacer 25 accounts for the apparent 
large size of both products.  
 
Table 2.4. Primers and primer sequences used in RoD1 to differentiate non-Beijing M. tuberculosis isolates. 
Primer Name Primer Sequence (5’à3’) Amplified Region 
RoD1F ATT GCG CTA ACT GGC TTG Spacer sequences 21 - 24 
RoD1R TGC GGT GGT CGC TGA TC Spacer sequences 21 - 24 
F: Forward primer; R: Reverse primer. 
 
The master PCR mix, with a final volume of 50µl, contains 1X GoTaq Flexi enzyme buffer, 
3.5mM MgCl2, 4mM dNTPs, 25pmol of each primer, 1U GoTaq DNA polymerase and 2µl of 
MGIT DNA template (2.2.2). Amplification took place in a thermocycler under the following 
conditions: an initial denaturation at 95°C for 5min, followed by 35 cycles of 95°C for 1min, 
56°C for 1min and 72°C for 2min. Finally an elongation at 72°C for 5min completed the 
amplification. The products were electrophoresed on a 1% agarose gel and visualized (2.3). 
 
2.9.2. Differentiation using RoD2 PCR assay 
Further differentiation is needed after RoD1 if a product of 1831bp is amplified, which is 
indicative of either a T, X or H lineage. RoD2 separates strains of the X lineage from the T and 
H lineage based on the presence or absence of a 240bp amplicon. Strains from the X lineage 
are characterized by the absence of spacer sequence 18 (Figure 2.7). RoD2F (Table 2.5.) is 
designed to anneal to spacer sequence 18 and along with RoD2R (Table 2.5), which anneals 
to spacer sequence 21, will amplify a product of 240bp in strains H and T, in whom spacer 21 
is present. An absence of a product will indicate and X strain, but will also indicate strains of 
LAM lineage due to the absence of spacer 21 in these strains. However, all LAM strains will 
be separated out in RoD1 and thus RoD2 should serve as a confirmation (Figure 2.8). 
 
Table 2.5. Primers and primer sequences used in RoD2 to differentiate non-Beijing M. tuberculosis isolates 
Primer Name Primer Sequence (5’à3’)  Amplified Region 
RoD2F AGC TGC AGA TGG TCC GGG A Spacer sequences 18 – 21 
RoD2R ATT GGG ACA TCG ACA TCG AC Spacer sequences 18 - 21 
F: Forward primer; R: Reverse primer 
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The master PCR mix, with a final volume of 50µl, contains 1X GoTaq Flexi enzyme buffer, 
3.5mM MgCl2, 4mM dNTPs, 25pmol of each primer, 1U GoTaq DNA polymerase and 2µl of 
MGIT DNA template (2.2.2). Amplification took place in a thermocycler under the following 
conditions: an initial denaturation at 95°C for 5min, followed by 35 cycles of 95°C for 1min, 
62°C for 1min and 72°C for 30sec. Finally an elongation at 72°C for 5min completed the 
amplification. The products were electrophoresed on a 1.5% agarose gel and visualized (2.3). 
 
2.9.3. Differentiation using RoD3 PCR assay 
The last differentiation step in the algorithm, RoD3 will separate out the H and T strains based 
on the presence or absence of a 395bp amplicon (Figure 2.8). H strains are characterized by 
the absence of spacer sequence 31, which is present in the other strains (Figure 2.7). RoD3F 
(Table 2.6) is designed to anneal to spacer 26 while RoD3R is designed to anneal to spacer 
31, which, in T strains, will result in the amplification of a 395bp product. It could also indicate 
X and LAM strains, due to the presence of both spacer sequences 26 and 31, but as these 
would have been detected in the previous PCRs, this serves as a confirmation of those 
results. Thus the absence of this product will indicate an H strain, due to the absence of 
spacer 26 (Figure 2.8). 
 
Table 2.6. Primers and primer sequences used in RoD3 to differentiate non-Beijing M. tuberculosis isolates 
Primer Name Primer Sequence (5’à3’)  Amplified Region 
RoD3F TTC AGC ACC ACC ATC ATC C Spacer sequences 26 – 31 
RoD3R TGA TCG ACG CGA ACC TGT C Spacer sequences 26 – 31 
F: Forward primer; R: Reverse primer 
 
The master PCR mix, with a final volume of 50µl, contains 1X GoTaq Flexi enzyme buffer, 
3.5mM MgCl2, 4mM dNTPs, 25pmol of each primer, 1U GoTaq DNA polymerase and 2µl of 
MGIT DNA template (2.2.2). Amplification took place in a thermocycler under the following 
conditions: an initial denaturation at 95°C for 5min, followed by 35 cycles of 95°C for 1min, 
58°C for 1min and 72°C for 1min. Finally an elongation at 72°C for 5min completed the 
amplification. The products were electrophoresed on a 1% agarose gel and visualized (2.3). 
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3.1. Mycobacterium tuberculosis isolates included in this study 
By the end of the study period, 154 adult patients with newly diagnosed TB were enrolled and 
included in this study. Of the 154 patients, 8 were excluded on the basis that no positive 
sputum samples were obtained during the 8 week study. An additional 6 patients were 
excluded due to samples being lost during the course of the study. An initial sputum sample 
was collected prior to the start of treatment and is referred to as a baseline sample. Follow up 
samples were taken weekly for 8 weeks thereafter resulting in a collection of 9 samples from 
each patient. However, a number of samples had to be excluded due to the contamination of 
the samples, mainly due to fungal spores that may have been transferred into the MGIT 
cultures during subculturing from the original sputum sample. As a result, a total of 686 
samples from 140 patients were included in this study (Appendix D).  
 
                         
Genomic DNA was extracted from M. tuberculosis colonies grown on LJ slopes at 37°C 
(2.2.1) and electrophoresed along with a Lamda (λ) DNA titration and Hyperladder I (Appendix 
A) in order to quantify the DNA (Figure 3.1). A selection of strains comprising LAM, X, H and T 
strains were included as controls. 
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Fig 3.1. Agarose electrophoresis of genomic DNA from M. tuberculosis strains used as controls.  M:  Hyperladder 
I; Lane1: λ DNA (35ng); Lane 2: λ DNA (3.5ng); Lane 3:  Void; Lane 4: LAM  1; Lane 5: LAM  2; Lane 6: LAM  3; 
Lane 7: T  1; Lane 8: T  2; Lane 9: T  3; Lane 10: X  1; Lane 11: X  2; Lane 12: X  3; Lane 13: H  1; Lane 14: H  2; 
Lane 15: H  3 
 
Based on the intensity of the genomic DNA bands relative to the λ DNA (Figure 3.1) the 
concentration of DNA following extraction (2.2.1) is 30ng/µl for LAM 1 is (Lane 4; Figure 3.1), 
50ng/µl for LAM 2 (Figure 3.1; Lane 5) and 100ng/µl for the remaining control strains (Figure 
3.1; Lanes 6 – 15). In subsequent PCR assays, 2µl of 1:10 dilution of all strains other than 
LAM 1 and 2, equating to 20ng of DNA, was added as template. LAM 1 was diluted 1:3 and 
LAM 2 was diluted 1:5; 2µl of each, equating to 20ng of DNA, was added as template. 
 
3.2. Spoligotyping of isolates collected from patients 
To investigate the epidemiology of the isolates obtained from the patients enrolled in this study 
as well as to screen for potential mixed samples, spoligotyping (2.8) was performed on DNA 
prepared from MGIT cultures (2.2.2). Following amplification of the spacer regions in the DR 
locus, the products were hybridised in a miniblotter to a membrane containing the known 
spacer oligonucleotides and later visualised using the ECL method on a light-sensitive film. 
The profiles were compared to published lineages (Brudey et al, 2006) to determine the strain 
family to which the isolates belonged (Figure 3.2).  
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Figure 3.2. Autoradiographs of spoligotyping, of a selection of M. tuberculosis isolates from patients included in 
the study. Black squares represent spacer sequences present in the DR of each M. tuberculosis isolate, and are 
indicated above each autoradiograph. H37Rv and BCG controls are included to represent all spacer sequences. 
The negative water control is to rule out the possibility of contamination. Patient names are indicated to the right 
of each autoradiograph with isolates from each patient grouped together by a square bracket. Profiles 
representing all genotype families detected in the study are indicated in bold font after each patient name. H: 
Haarlem; WB: W-Beijing; L: LAM; T: T Family; X: Low-copy Clade X.  
 
The positive controls H37Rv and M. bovis BCG are included to ensure that the PCR amplifies 
all spacer sequences in the DR region. Strain H37Rv contains spacer sequences 1 – 19, 22 – 
32, and 37 – 43 (Figure 3.2). Spacer sequences 20, 21, 33 – 36 are present in M. bovis BCG 
(Figure 3.2). The negative water control is included to ensure no contamination is present in 
the assay. 
 
Analysis of the spoligotyping profiles obtained from isolates from 123 patients (88%) indicated 
that these patients were infected with a single genotype (Figure 3.2; Table 3.1). Only 1 viable 
culture was obtained from 11 patients; these could not be analysed with regards to mixed 
infections.  
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Table 3.1. Spoligotypes of sequential isolates obtained from 140 patients included in the study 
 
Patient 
Number 
Patient 
Name Number of Samples Genotyped 
†Genotype (n) 
2 FA 1 WB 
4 UO 3 L3 
5 GS 1 WB 
6 RB 1 L3 
7 XT 2 WB 
8 RJ 2 WB 
9 OA 4 WB 
10 MO 2 L3 
11 DP 6 WB 
12 TM 3 WB 
13 BB 6 WB 
14 MM 4 WB 
15 JS 5 WB 
16 DM 5 WB 
17 MM 1 T1 
18 WJ 6 WB 
19 BB 5 L3 
20 TM 7 WB 
21 CJ 4 WB 
22 JE 9 L5 
23 FM 5 WB 
24 NC 7 *T4 (6); S (1) 
25 ZD 3 X3 
26 YK 2 L3 
28 JJ 2 WB 
29 FJ 6 L3 
30 AV 2 WB 
32 WC 2 S 
33 WH 4 X3 
34 CI 3 WB 
35 NN 3 WB 
36 BQ 2 L3 
37 KM 1 WB 
38 TP 3 X2 
39 JD 4 T1 
40 SD 6 WB 
41 SM 2 X1 
42 MM 4 T1 
43 XM 6 WB 
44 DL 3 T1 
45 LG 7 T1 
46 JP 6 *T1 (4); S(2) 
47 ZM 6 L3 
48 ML 8 H1 
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49 DN 5 X1 
50 SD 8 WB 
51 SM 5 L3 
52 SM 9 L9 
53 TN 3 L3 
54 ER 5 WB 
55 BM 7 H1 
56 TZ 2 L3 
57 SM 8 WB 
58 NM 8 L3 
59 AM 8 WB 
60 JS 6 F33 
61 WM 8 WB 
62 CG 1 WB 
63 MC 4 T1 
64 BV 4 L9 
65 RR 5 L3 
66 RP 7 X1 
67 CE 5 T1 
68 NM 5 S 
69 BD 3 WB 
70 JB 2 T4 
71 NV 5 F33 
72 VF 2 WB 
73 NC 10 *WB (9); T4 (1) 
74 SE 4 WB 
75 CK 3 F33 
76 BD 2 T1 
78 NM 4 WB 
79 RC 7 WB 
80 GI 7 WB 
81 SM 3 *WB (2); WB + X3 (1) 
85 SA 4 WB 
86 AF 8 WB 
87 GK 9 WB 
88 NG 8 T1 
89 ZB 6 WB 
90 CD 3 L3 
91 IF 6 H1 
92 DS 1 T1 
93 SB 8 S 
94 CJ 7 H3 
95 AM 9 WB 
96 PJ 6 T1 
98 HV 4 S 
99 TN 6 X1 
100 CW 4 S 
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101 GP 8 WB 
103 RP 7 L3 
104 MM 7 WB 
105 AD 9 WB 
107 MD 6 *WB (4); WB + X3 (2) 
108 NM 1 WB 
109 NB 8 L3 
111 AL 7 WB 
112 AP 7 WB 
113 DM 1 L3 
114 VJ 2 WB 
115 JM 4 H1 
116 NS 4 L3 
117 TS 8 WB 
118 AG 3 *L3 (2); T4 (1) 
119 FK 9 H1 
120 IB 6 WB 
121 VS 3 WB 
122 HC 3 T1 
123 EJ 5 WB 
124 TJ 3 T1 
126 NS 4 WB 
127 ZC 2 WB 
128 SK 6 WB 
129 MN 5 WB 
130 MJ 4 H1 
131 DD 5 H1 
133 SM 5 WB 
134 
135 
DG 
SS 
3 
2 
T1 
L3 
  136 JI 5   WB 
  137 BJ 4   X3 
  138 PD 6   WB 
  139 DG 5   T1 
  140 PW 5   WB 
  141 NE 7   T1 
  142 WV 5   H1 
  143 JB 1   WB 
  144 EJ 8   WB 
  145 NN 8   WB 
  146 GM 8   T1 
  147 SD 7   S 
  148 DJ 8   WB 
  149 WM 7   H1 
  150 ME 7   X3 
  151 BH 1   L3 
  152 CB 7   WB 
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  153 WI 6   WB 
  154 MM 9   H1 
†WB: W-Beijing; X: Low Copy Number Clade X; T: Strain Family T; H: Haarlem; F33: Family 33; S: Strain Family 
S; L: LAM. (*Where 2 strain lineages are indicated sequentially in the same patient, that patient is considered to 
harbour a mixed infection). 
 
 
The remaining 6 patients (4.3%) displayed colonization with mixed isolates, as indicated by 
the heterogeneous patterns observed following spoligotyping (Figure 3.3).  
 
Figure 3.3. Mixed samples as detected by spoligotyping. Spacer sequences are represented by black squares 
and are arranged in order from 1 through to 43, as labelled at the top of the figure. Patient names as well as 
sample numbers and genotypes for each sample are indicated to the right of the figure. T: T Family strains; S: S 
Family strains; WB: W-Beijing; X: Low-copy clade X; L: LAM.  
 
Therefore, of the 129 patients with more than 2 viable cultures that were typed, 6 (4.7%) 
harboured isolates of different genotypes; 4 of these patients (24NC, 46JP, 73NC, and 
118AG) showed evidence of reinfection with a different strain, while 2 patients (81SM, and 
107MD) harboured mixed isolates (Figure 3.3; Table 3.1).  
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Of  the 140 patients included, 67 (47.8%) were colonised with W-Beijing isolates, 24 (17.1%) 
with isolates from the LAM family, 20 (14.3%) with isolates from the T family, 9 (6.4%) with 
isolates from the low-copy number clade X, 11 (7.9%) with isolates from the Haarlem family, 6 
(4.3%) with isolates from the S family and 3 (2.1%) patients were colonised with isolates from 
Family 33 (Figure 3.4).  
  
 
Figure 3.4. Distribution of circulating Mycobacterium tuberculosis strains in the Delft region of the Western Cape. 
The percentages of the total of 140 patients is indicated above each bar. 
 
Of the patients initially colonized with either T4 (24NC) or T1 (46JP) strains, both were found 
to harbour an additional S strain at the end of the study period (Figure 3.3). The first 3 isolates 
obtained from patient 73NC were of the W-Beijing lineage (Figure 3.3). The 4th isolate 
emerged as a T4 strain, thereafter the remaining 5 isolates were of the W-Beijing lineage. Two 
patients (SM81 and MD107) harbouring W-Beijing had a dual infection with X3 strains. In both 
patients, the X3 strain emerged after the initial isolation of the W-Beijing strains. Two LAM3 
strains were initially isolated from patient AG118, with a T4 isolated 4 weeks later. Due to 
missing or contaminated samples, it is unclear as to what the bacillary population 
encompasses during those 4 weeks, but would be of great interest. 
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3.3. Mycobacterial interspersed repetitive units (MIRU) – variable  
       number of tandem repeats (VNTR) typing of sequential isolates of 
       patients with mixed isolates 
 
To ascertain the genetic relatedness of the sequential isolates obtained from each of the 
patients colonized with mixed isolates, and to determine the relatedness of the infecting 
isolates between patients, 12-locus MIRU-VNTR was carried out. Following amplification of 
the MIRU loci using the grouped multiplex primers, the labelled products were detected in an 
ABI 3100 Analyser (Applied Biosystems) in the Division of Human Genetics, University of 
Cape Town. The sizes of the products were compared to published alleles (Supply et al, 2000) 
rendering the number of VNTRs in each isolate to a numerical code (Appendix D), and the 
genetic relatedness of the isolates was analysed using the MIRU-VNTRplus algorithm 
(http://www.miru-vntrplus.org/miru). Isolates differing from one another at 2 alleles or less 
were defined as being part of the same clonal complex, whilst those that differed at 3 or more 
loci were considered outliers. 
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Figure 3.5. Minimum spanning tree indicating the genetic relatedness of M. tuberculosis isolates obtained from 
patients with mixed infections. Genotypes are represented by circles and are labelled accordingly. Solid lines 
indicate a difference of ≤2 alleles between genotypes, indicating a clonal c omplex. Dotted lines indicate 
differences of 3 or more alleles between genotpyes and represent outliers. Numbers above the joining lines 
indicate the allelic difference between joining genotypes.  Isolates from the T1, T4, W-Beijing and X3 lineages 
formed a clonal complex, as demarcated by the square. WB: W-Beijing. 
 
Analysis of the MIRU loci revealed sequential isolates obtained from each individual patient 
are clonal and display the same number of VNTR alleles per locus; that is all T4 isolates 
(patients 24NC, 73NC and 118AC) were identical as were the T1 isolates (patient 46JP), S 
isolates (patients 24NC and 46JP), W-Beijing + X3 isolates (patients 81SM and 107MD) and 
LAM 3 isolates (patient 118AG) (Figure 3.5).  Although the W-Beijing isolates from patients 
73NC and 107MD were identical, they differed from the W-Beijing isolates from patient 81SM 
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by 2 alleles (Figure 3.5). The T4 isolates (patients 24NC, 73NC and 118AG), the T1 isolates 
(patient 46JP), and the W-Beijing isolates (patients 73NC, SM81, and 107MD) differed from 
one another by 2 or less alleles and form part of the same clonal complex (Figure 3.5). The S 
isolates (patients 24NC and 46JP) and the LAM 3 isolates (patient 118AG) had more than 2 
alleles different from the clonal complex genotypes and are therefore represented as outliers 
(Figure 3.5), and are thus considered unrelated. 
 
Interpretation of the electrophorerogram data of the W-Beijing + X3 mixed sample was 
difficult, as the expected separate peaks; one for each isolate, at each locus, was not present. 
Instead, one signal was obtained at each locus, and represented an amalgamation of alleles 
for each isolate, as the alleles neither represent a W-Beijing isolate, nor an X3 isolate 
(Appendix D). However the profile was related to the W-Beijing profiles of patients 73NC and 
107MD, as there was only a difference of 2 alleles between them (Figure 3.5). Interestingly, 
the W-Beijing + X3 mixed samples of patient 81SM and 107MD were identical (Appendix D; 
Figure 3.5). 
 
3.4. Drug Susceptibility Testing of mixed isolates using the  
       GenoType MTBDRplus assay 
 
Drug susceptibility testing (DST) was performed routinely in the diagnostic microbiology 
laboratory in GSH using the BACTEC MGIT 960 system (2.1) on the baseline and final 
samples collected from each patient enrolled in the study. Additional DST was performed on 
all samples from patients with mixed isolates using the GenoType MTBDRplus assay (2.2), to 
observe determine whether the DST profiles changes with corresponding changes in 
genotype profiles. Following PCR amplification of the regions on the chromosome known to 
contain determinants associated with resistance to RIF and INH, amplicons were hybridized to 
a membrane strip containing the corresponding oligonucleotides. No signal was detected for 
any of the probes corresponding to either RIF or INH resistance, indicating that all strains 
assayed are susceptible to both RIF and INH (Table 3.2). These results correspond with the 
DST results obtained using the BACTEC MGIT 960 system (Table 3.2). 
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Table 3.2. Resistance to RIF and INH of the M. tuberculosis isolates from patients harbouring mixed infections  
Patient 
Number 
Patient 
Name 
Sample 
Number Week Genotype 
MGIT MTBDRplus 
RIF INH RIF INH 
24 NC 1371553 0 T4 s s s s 
  1383366 1 T4 nd nd s s 
  1395436 2 T4 nd nd s s 
  1408416 3 T4 nd nd s s 
  1420396 4 T4 nd nd s s 
  1432832 5 T4 nd nd s s 
  1470151 8 S s s s s 
46 JP 1641320 0 T1 s s s s 
  1653908 1 T1 nd nd s s 
  1678107 2 T1 nd nd s s 
  1690893 3 T1 nd nd s s 
  1702165 4 S nd nd s s 
  1715024 5 S s s s s 
73 NC 1993545 0 WB s s s s 
  2006928 1 WB nd nd s s 
  2025035 2 WB nd nd s s 
  2031330 3 WB nd nd s s 
  2031350 4 T4 nd nd s s 
  2044964 5 WB nd nd s s 
  2057353 6 WB nd nd s s 
  2072165 7 WB nd nd s s 
  2084284 8 WB nd nd s s 
  2096927 9 WB s s s s 
81 SM 2049397 0 WB s s s s 
  2077185 1 WB nd nd s s 
  2101397 2 WB + X3 s s s s 
107 MD 2420713 0 WB s s s s 
  2450525 1 WB nd nd s s 
  2463471 2 WB nd nd s s 
  2475803 3 WB nd nd s s 
  2499983 4 WB + X3 nd nd s s 
  2522521 5 WB + X3 s s s s 
118 AG 2621209 0 L3 s s s s 
  2630475 1 L3 nd nd s s 
  2672229 2 T4 s s s s 
RIF: Rifampicin; INH: Isoniazid; s: susceptible; nd: not determined, 0: Baseline isolate. 
 
All isolates tested were indicated as being fully susceptible to both RIF and INH (Table 3.2). 
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3.5. Detection of mixed infections harbouring W-Beijing and non-W-       
        Beijing M. tuberculosis isolates 
 
A PCR assay was designed to screen for the presence of W-Beijing isolates and non-W-
Beijing isolates in samples obtained from patients (Warren et al, 2004). The assay, comprising 
four reactions, PS1, PS2, PS3 and PS4, is designed to differentiate W-Beijing isolates from 
non-W-Beijing isolates. PS1 and PS2 contain primers that specifically amplify unique W-
Beijing associated sequences and will therefore detect isolates belonging to the W-Beijing 
lineage. Similarly, PS3 and PS4 specifically amplify unique non-W-Beijing sequences and 
therefore will detect isolates belonging to non-W-Beijing lineages. Following amplification 
using PS1 and PS2, a product of 393bp and 239bp, respectively, is expected. Products of 
570bp and 309bp are obtained following amplification using PS3 and PS4, respectively. 
Positive amplification of all expected products for all four of the primer sets would indicate a 
mixed infection consisting of W-Beijing and non-W-Beijing isolates (Warren et al, 2004).  
 
Isolates, known to be W-Beijing strains following spoligotyping and MIRU-VNTR (Evans et al, 
2009) termed W-Beijing 1 and W-Beijing 2, were used as W-Beijing control strains. The 
laboratory reference strain H37Rv was used as a non-W-Beijing control. Genomic DNA was 
extracted from these control strains (2.2.1) and used as template for optimization of the PCR 
assays. 
 
The assay conditions were as described (Warren et al, 2004) with the exception that GoTaq 
DNA polymerase (Promega) was used instead of HotStartTaq DNA polymerase and Q-
Solution (Qiagen). Following amplification, the PCR products were separated by agarose gel 
electrophoresis (Figure 3.5). 
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Figure 3.6. Agarose gel electrophoresis of PCR products obtained using PS1, PS2, PS3 and PS4 for the 
detection of mixed W-Beijing and non-W-Beijing infections. Lane 1: PS1 negative water control; Lane 2: PS2 
negative water control; Lane 3: Hyperladder IV; Lane 4: PS1 W-Beijing control; Lane 5: PS1 non-W-Beijing 
control; Lane 6: PS2 W-Beijing control; Lane 7: PS2 non-W-Beijing; Lane 8: Void; Lane 9: PS3 negative water 
control; Lane 10: PS4 negative water control; Lane 11: Hyperladder IV; Lane 12: PS3 W-Beijing control; Lane 13: 
PS3 non-W-Beijing control; Lane 14: PS4 W-Beijing control; Lane 15: PS4 non-W-Beijing control. 
 
No signal was detected in the negative water controls ensuring no contamination of the 
reagents used (Figure 3.6; Lanes 1, 2, 9, 10). Products of expected size of 393bp and 239bp 
were obtained using PS1 and PS2, respectively (Figure 3.6; Lanes 4 and 5, and 6 and 7). 
Though PS1 and PS2 are designed to amplify W-Beijing only, products were obtained from 
the non-W-Beijing control in both PS1 and PS2. PCR products of 570bp and 309bp were 
observed using PS3 and PS4, respectively, when using non-W-Beijing as template. 
Additionally, amplification occurred in the W-Beijing control using PS3 and PS4, respectively 
(Figure 3.6; Lanes 12 and 14). The detection of non-W-Beijing using W-Beijing-specific 
primers, and vice versa, indicated that the PCR assay conditions were not fully optimized.  
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As products of equal intensity were obtained from both the W-Beijing and non-W-Beijing 
controls using PS2, optimizations were carried out on the non-W-Beijing control so as to 
detect conditions that would prevent non specific amplification from H37Rv. Optimizations 
included primer, MgCl2 and dNTP titrations, as well as adjusting the annealing temperature. 
 
The concentration of primers is a crucial parameter that must be carefully controlled in PCR 
(Atlas and Bej, 1994). If the primers are prone to dimerisation, too high a concentration will 
lead to the formation of more primer-dimers. Additionally, if the primer concentration is too 
high, and the primers are not prone to dimerisation, then the risk of non-specific amplification 
of spurious products, resulting from mispriming, increases (Atlas and Bej, 1994). A primer 
titration was performed on H37Rv to determine the optimum primer concentration. Following 
amplification, the products were separated by agarose gel electrophoresis (Figure 3.7).  
 
 
 
Figure 3.7.  Agarose gel electrophoresis of PS2 primer titration. Lane 1: PS2 negative water control; Lane 2: 
Hyperladder IV; Lane 3: PS2 15pmol; Lane 4: PS2 20pmol; Lane 5: PS2 25pmol. 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
w
65 
 
No signal was observed in the negative water controls, indicating that the reagents used were 
not contaminated (Figure 3.7; Lane 2). A product, corresponding to 239bp, was obtained from 
H37Rv genomic DNA using 15pmol, 20pmol and 25pmol of each primer in assay PS2 (Figure 
3.7; Lanes 3 – 5) 
 
Since dNTPs, the DNA polymerase and primers all require Mg for optimum binding, MgCl2 is 
essential for DNA:DNA interactions and binding (Atlas and Bej, 1994). The dNTPs compete 
for magnesium more than any of the other components, and as such, requires an MgCl2 
concentration higher than that of the dNTPs (Atlas and Bej, 1994). However, higher 
concentrations of MgCl2 can increase the presence of non-specific products, as mismatching 
of the primers to the template is tolerated better at higher concentrations of MgCl2. Too little 
Mg2+ and little to no products are formed (Atlas and Bej 1994). The concentration of dNTPs is 
also a crucial parameter to control. The higher the concentration of dNTPs the more Mg2+ is 
sequestered in the reaction resulting in less free Mg2+ resulting in poor polymerase activity 
(Atlas and Bej, 1994). Thus the interrelationship between dNTPs and MgCl2 is very important 
in optimizing PCR conditions. A MgCl2 titration as well as a dNTP titration were carried out for 
assay PS2. Following amplification, the products were separated using agarose gel 
electrophoresis (Figure 3.8). 
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Figure 3.8. Agarose gel electrophoresis of assay PS2 following MgCl2 and dNTP titrations. H37Rv genomic DNA 
was used as template.  Lane 1: negative water control; Lane 2: Hyperladder IV; Lane 3 1mM MgCl2 and 0.1mM 
dNTP; Lane 4: 1mM MgCl2 and 0.2mM dNTP; Lane 5: 1mM MgCl2 and 0.3mM dNTP; Lane 6: 1mM MgCl2 and 
0.4mM dNTP; Lane 7: 2mM MgCl2 and 0.1mM dNTP; Lane 8: 2mM MgCl2 and 0.2mM dNTP; Lane 9: 2mM 
MgCl2 and 0.3mM dNTP; Lane 10: 2mM MgCl2 and 0.4mM dNTP; Lane 11: 3mM MgCl2 and 0.1mM dNTP; Lane 
12: 3mM MgCl2 and 0.2mM dNTP; Lane 13: 3mM MgCl2 and 0.3mM dNTP; Lane 14: 3mM MgCl2 and 0.4mM 
dNTP. 
 
No signal was observed in the negative water control indicating the reagents were not 
contaminated (Figure 3.8). Products corresponding to 239bp were obtained in all reactions 
using H37Rv genomic DNA. Reaction conditions using MgCl2 at 1mM and dNTPs at 0.4mM 
yielded product with the lowest intensity (Figure 3.8; Lane 6). Subsequent optimizations of 
dNTPs using 1mM MgCl2, were carried out using H37Rv genomic DNA and DNA from W-
Beijing 1 and W-Beijing 2 control strains. Following amplification, the products were separated 
by agarose gel electrophoresis (Figure 3.9). 
 
U
ive
rsi
ty 
of 
Ca
pe
 To
wn
67 
 
 
Figure 3.9. Agarose gel electrophoresis of assay PS2 dNTP titration using 1mM MgCl2 on H37Rv and W-Beijing 
templates. Lane 1: H37Rv  0.1mM, Lane 2: H37Rv 0.2mM ; Lane 3: H37Rv 0.3mM, Lane 4: H37Rv 0.4mM; Lane 
5: W-Beijing (1) 0.1mM, Lane 6: W-Beijing (1) 0.2mM ; Lane 7: W-Beijing (1) 0.3mM, Lane 8: W-Beijing (1) 
0.4mM; Lane 9: W-Beijing (2) 0.1mM, Lane 10: W-Beijing (2) 0.2mM ; Lane 11: W-Beijing (2) 0.3mM, Lane 12: 
W-Beijing (2) 0.4mM; Lane 13: Hyperladder IV; Lane 14: negative water control. 
 
No signal was observed in the negative water control, indicating that the reagents used were 
not contaminated (Figure 3.9). Products corresponding to 239bp were amplified in both H37Rv 
and W-Beijing 1 and W-Beijing 2 control templates (Figure 3.9; Lanes 1 – 12). Reaction 
conditions including MgCl2 at 1mM and 0.4mM dNTPs yielded product with the lowest intensity 
(Figure 3.9; Lane 4) yet retains the amplicons from the W-Beijing controls (Figure 3.9; Lanes 8 
and 12). The dNTP concentration was further increased to 0.5mM and 0.6mM in order to 
reduce the non-specific amplification from the H37Rv template. Following amplification, the 
products were separated by agarose gel electrophoresis (Figure 3.10). 
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Figure 3.10. Agarose gel electrophoresis of products from assay PS2 with an increase in dNTP concentration 
using H37Rv and W-Beijing control templates. Lane 1: Negative water control (0.5mM dNTPs); Lane 2: Negative 
water control (0.6 mM dNTPs); Lane 3: Hyperladder IV; Lane 4: WB (1) – 0.3mM dNTPs; Lane 5: WB (1) – 
0.4mM dNTPs; Lane 6: WB (1) – 0.5mM dNTPs; Lane 7: WB (1) – 0.6mM dNTPs; Lane 8: WB (2) – 0.3mM 
dNTPs; Lane 9: WB (2) – 0.4mM dNTPs; Lane 10: WB (2) – 0.5mM dNTPs; Lane 11: WB (2) – 0.6mM dNTPs; 
Lane 12: Hyperladder IV; Lane 13: H37Rv – 0.3mM dNTPs; Lane 14: H37Rv – 0.4mM dNTPs; Lane 15: H37Rv – 
0.5mM dNTPs; Lane 16: H37Rv – 0.6mM dNTPs. 
 
No signal was observed in either of the negative controls, ruling out the possibility of 
contamination (Figure 3.10). The expected products of 239bp were observed for both W-
Beijing controls (1 and 2) (Figure 3.10; Lanes 4 – 11). The same size product was also 
observed from the non-W-Beijing control (Figure 3.10; Lanes 13 – 16). An increase in dNTP 
concentration to 0.6mM results in the absence of signal from all templates (Figure 3.10; Lanes 
7, 11 and 16). This is most likely due to the increase in demand of free MgCl2 from the 
increase in dNTPs resulting in inadequate amounts of MgCl2 for the polymerase to function. 
Thus it appears that 0.5mM dNTPs results in a decrease of the signal from H37Rv while still 
maintaining the W-Beijing-specific signals. 
 
Another critical parameter in the PCR is the annealing temperature. This is the temperature at 
which the primers anneal to the template.  Generally the optimum annealing temperature is 
5°C lower than the melting temperature of the primers (Atlas and Bej, 1994). Annealing 
temperatures that are too low can cause mis-priming of the primers and can result in the non-
specific amplification of undesirable products (Atlas and Bej, 1994). Temperatures too high will 
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prevent the primers from binding to the template and can result in no amplification of the target 
sequence (Atlas and Bej, 1994). The annealing temperature for the PS2 primers was 
increased from 62°C to 64°C in order to decrease the non-specific products. Additionally, the 
concentration of dNTPs was assessed at 0.4mM and 0.5mM at 64°C. The MgCl2 
concentration was maintained at 1mM. Following amplification, the products were separated 
using agarose gel electrophoresis (Figure 3.11). 
 
Figure 3.11. Agarose gel electrophoresis of products from PS2 with increased dNTPs an annealing temperature 
using H37Rv control template. Lane 1: Negative water control; Lane 2: Hyperladder IV; Lane 3: 0.4mM dNTPs 
and 64°C; Lane 4: 0.5mM dNTPs and 64°C. 
 
No signal was observed in the negative water control indicating that the reagents used were 
not contaminated (Figure 3.11). Products of 239bp were amplified using the H37Rv control 
DNA (Figure 3.11; Lanes 3 – 4). Amplification conditions using 1mM MgCl2 and 0.5mM dNTPs 
at 64°C decreased the intensity of the observed product (Figure 3.11; Lane 4).  
 
An additonal increase in MgCl2 and dNTP concentration at both 62°C and 64°C and whether 
or not these conditions could improve the amplification, was assessed. Following amplification 
the products were separated by agarose gel electrophoresis (Figure 3.12). 
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Figure 3.12. Agarose gel electrophoresis of products from PS2 MgCl2, dNTP and annealing temperature 
optimizations. Lane 1: Negative water control (1.5mM MgCl2, 0.6mM dNTPs and 62°C); Lane 2: Negative water 
control (1.5mM MgCl2, 0.6mM dNTPs and 64°C); Lane 3: Hyperladder IV; Lane 4: 1.5mM MgCl2, 0.4mM dNTPs 
and 62°C; Lane 5: 1.5mM MgCl2, 0.4mM dNTPs and 64°C; Lane 6: 1.5mM MgCl2, 0.5mM dNTPs and 62°C; 
Lane 7: 1.5mM MgCl2, 0.5mM dNTPs and 64°C; Lane 8: 1.5mM MgCl2, 0.6mM dNTPs and 62°C; Lane 9: 1.5mM 
MgCl2, 0.6mM dNTPs and 64°C. 
 
No signal was observed in either of the negative water controls, indicating the reagents used 
were not contaminated (Figure 3.12). Products corresponding to 239bp were observed for the 
non-W-Beijing H37Rv control (Figure 3.12; Lanes 4 – 9). Amplification conditions with 1.5mM 
MgCl2 at 64°C, regardless of the dNTP, concentration yielded products of lesser intensity 
(Figure 3.12; Lane 5; 7 and 9). The intensity, however, is still less at 1mM MgCl2 and 0.5mM 
dNTPs at 64°C (Figure 3.11).  However, additional increases in dNTPs cannot occur without 
additional MgCl2, as the signal observed from the W-Beijing control will also decrease. 
Therefore, final amplification conditions of 1mM MgCl2 and 0.5mM dNTPs at 64°C reduced 
the intensity of the 239bp from the H37Rv non-W-Beijing control significantly. However further 
optimizations are still clearly needed to ensure no amplification of these products, and could 
include the use of alternative DNA polymerase systems and corresponding buffers, using 
enhancers, such as those found in the HotStartTaq system (Solution Q; Qiagen, Germany), or 
to redesign the primers for amplification in a similar region.  
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Several optimizations were similarly carried out for PS1, PS3 and PS4 using the H37Rv and 
W-Beijing (1) control strains as template (data not shown). Firstly, both the forward and 
reverse primers were titrated by adding 1pmol, 5pmol, 10pmol, 15pmol, 20pmol or 25pmol of 
each. PCR amplification of the expected products was optimal at 15pmol. MgCl2 was titrated 
from 1mM to 1.5mM, 2.0mM, 2.5mM, 3.0mM and to the recommended 3.5mM; amplification at 
1.5mM yielded the more intense product. Using 15pmol of each primer and 1mM of MgCl2, 
dNTP titrations were carried out. The recommended conditions use 4mM dNTPs, which is 
unusually high for a PCR assay. Following titration, 0.4mM of dNTPs yielded the most intense 
product. Finally, the number of amplification cycles was reduced from 45 cycles to 35 cycles, 
in order to reduce the intensity of the non-specific amplification without compromising the 
intensity of the positive controls. Amplification using 30 cycles reduced the intensity of the 
non-specific products. PCR amplification for PS1, PS3 and PS4 were carried out using a 
reaction mixture consisting of 15pmol of each primer, 1mM MgCl2, 0.4mM dNTPs and 1U of 
GoTaq in the buffer supplied. Cycling conditions were as follows: an initial denaturation of 
15min at 95°C, followed by 35 cycles of 94°C for 1min, 62°C for 1min and 72°C for 1min. 
Finally an additional elongation of 10min at 72°C completed the amplification.  
 
These conditions were carried out using W-Beijing and non-W-Beijing controls. Following 
amplification, products were separated by agarose gel electrophoresis (Figure 3.13). 
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Figure 3.13. Agarose gel electrophoresis of A: PS1, B: PS3 and C: PS4, using W-Beijing 1 and non-W-Beijing 
control strains. A – M: Hyperladder IV; Lane 1: negative water control; Lane 2: Void; Lane 3:W-Beijing control; 
Lane 4: non-W-Beijing control. B – M: Hyperladder IV; Lane 1: negative water control; Lane 2: Void; Lane 3: W-
Beijing control; Lane 4: non-W-Beijing control. C – M: Hyperladder IV; Lane 1: negative water control; Lane 2: 
Void; Lane 3: W-Beijing control; Lane 4: non-W-Beijing control. 
 
No signal was observed in the negative water controls, indicating that the reagents used were 
not contaminated (Figure 3.13). Products corresponding to 393bp was observed for the W-
Beijing control (Figure 3.13; A: Lane 3) and was absent in the non-W-Beijing control (Figure 
3.13; A: Lane 4), as expected. Products of 570bp was observed in the non-W-Beijing control 
(Figure 3.12; B: Lane 4) and was absent in the W-Beijing control (Figure 3.13; B: Lane 3), as 
expected. Similarly, products corresponding to 309bp was observed in the non-W-Beijing 
control (Figure 3.13; C: Lane 4), while it was absent in the W-Beijing control (Figure 3.13; C: 
Lane 3), as expected.  
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3.5.1. Screening of isolates from patients confirmed by spoligotyping as harbouring  
          mixed infections 
 
Since conditions for PS1 and PS3 were optimized (3.5), these assays, which detect W-Beijing 
and non-W-Beijing, respectively, were carried out on all isolates from the 6 patients indicated 
as carrying mixed infections following spoligotyping. Genomic DNA from isolates obtained 
from each patient (2.2.1) was used as template in the PCR assays. Following amplification, 
products were separated by agarose gel electrophoresis for PS1 (Figure 3.14), and PS3 
(Figure 3.15). 
 
 
Figure 3.14. Agarose gel electrophoresis of products of assay PS1 from mixed samples. Lane 1: Hyperladder IV; 
Lane 2: negative water control; Lane 3: VOID; Lane 4: W-Beijing control; Lane 5: non-W-Beijing control; Lane 6: 
24NC week (W) 0; Lane 7: 24NC W1; Lane 8: 24NC W2; Lane 9: 24NC W4; Lane 10: 24NC W4; Lane 11: 24NC 
W5; Lane 12: 24NC W6; Lane 13: 46JP W0; Lane 14: 46JP W1; Lane 15: 46JP W2; Lane 16: 46JP W3; Lane 
17: 46JP W4; Lane 18: 46JP W5; Lane 19: 73NC W0; Lane 20: 73NC W1; Lane 21: 73NC W2; Lane 22: 73NC 
W3; Lane 23: 73NC W4; Lane 24: 73NC W5; Lane 25: 73NC W6; Lane 26: 73NC W7; Lane 27: 73NC W8; Lane 
28: Hyperladder IV; Lane 29: negative water control; Lane 30: VOID; Lane 31: W-Beijing control; Lane 32: non-
W-Beijing control; Lane 33: 73NC W9; Lane 34: 81SM W0; Lane 35: 81SM W1; Lane 36: 81SM W2; Lane 37: 
107MD W0; Lane 38: 107MD W1; Lane 39: 107MD W2; Lane 40: 107MD W3; Lane 41: 107MD W4; Lane 42: 
107MD W5; Lane 43: 118AG W0; Lane 44: W1; Lane 45: W2. 
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No signal was observed in the negative water control, indicating that the reagents used were 
not contaminated (Figure 3.14). Products corresponding to 393bp were observed for the W-
Beijing control (Figure 3.14; Lanes 4 and 31). These products were not observed in the non-
W-Beijing control (Figure 3.14; Lanes 5 and 32). Isolates from week (W) 0 – 5 from patient 
24NC were indicated as being from the T4 lineage following spoligotyping, with the isolate 
from W6 being indicated as belonging to the S lineage. The absence of products 
corresponding to 393bp confirms the results that all isolates from this patient belong to the 
non-W-Beijing group of strains (Figure 3.14; Lanes 6 – 12). Similarly, isolates from W0 – 3 
from patient 46JP were indicated as being from the T1 lineage following spoligotyping, with 
isolates from W4 – 5 belonging to the S lineage. The absence of products corresponding to 
393bp confirms the result that all isolates from this patient belong to the non-W-Beijing group 
of strains (Figure 3.14; Lanes 13 – 18).  
 
Isolates from W0 – 2 from patient 73NC were indicated as being from the W-Beijing lineage, 
with the isolate from W3 belonging to the T4 lineage, and isolates from W4 – 9 belonging to 
the W-Beijing lineage. Products corresponding to 393bp in all isolates confirm the result that 
these isolates belong to the W-Beijing lineage, and that the W-Beijing isolate is still present at 
W2 (Figure 3.14; Lanes 19 – 27, and 33). Isolates from W0 – 3 from patient 81SM were 
identified as belonging to the W-Beijing lineage by spoligotyping, with the emergence of an 
additional X3 isolate in W3. Products for 393bp for all isolates confirm the result that these 
isolates belong to the W-Beijing lineage (Figure 3.14; Lanes 34 – 36). Similarly isolates from 
W0 – 5 from patient 107MD, were identified as belonging to the W-Beijing lineage by 
spoligotyping, with the emergence of an additional X3 isolate in W4 – 5. Products of 393bp in 
all isolates confirm the result that these isolates belong to the W-Beijing lineage (Figure 3.14; 
Lanes 37 – 42). Isolates from W0 – 1 from patient 118AG were identified as belonging to the 
LAM3 lineage by spoligotyping, and from the T4 lineage in W2. The absence of products 
corresponding to 393bp in all isolates confirms the result that these isolates belong to the non-
W-Beijing group of strains (Figure 3.14; Lanes 43 – 45). 
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Figure 3.15. Agarose gel electrophoresis of products of assay PS3 from mixed samples. Lane 1: Hyperladder IV; 
Lane 2: negative water control; Lane 3: VOID; Lane 4: W-Beijing control; Lane 5: non-W-Beijing control; Lane 6: 
24NC week (W) 0; Lane 7: 24NC W1; Lane 8: 24NC W2; Lane 9: 24NC W4; Lane 10: 24NC W4; Lane 11: 24NC 
W5; Lane 12: 24NC W6; Lane 13: 46JP W0; Lane 14: 46JP W1; Lane 15: 46JP W2; Lane 16: 46JP W3; Lane 
17: 46JP W4; Lane 18: 46JP W5; Lane 19: 73NC W0; Lane 20: 73NC W1; Lane 21: 73NC W2; Lane 22: 73NC 
W3; Lane 23: 73NC W4; Lane 24: 73NC W5; Lane 25: 73NC W6; Lane 26: 73NC W7; Lane 27: 73NC W8; Lane 
28: 73NC W9; Lane 29: Hyperladder IV; Lane 30: negative water control; Lane 31: VOID; Lane 32: W-Beijing 
control; Lane 33: non-W-Beijing control; Lane 34: 81SM W0; Lane 35: 81SM W1; Lane 36: 81SM W2; Lane 37: 
107MD W0; Lane 38: 107MD W1; Lane 39: 107MD W2; Lane 40: 107MD W3; Lane 41: 107MD W4; Lane 42: 
107MD W5; Lane 43: 118AG W0; Lane 44: W1; Lane 45: W2. 
 
No signal was observed in the negative water controls indicating that the reagents used were 
not contaminated (Figure 3.15). Products corresponding to 570bp were observed in the non-
W-Beijing control (Figure 3.15; Lanes 5 and 33), while were absent in the W-Beijing control 
(Figure 3.15; Lanes 4 and 32). Isolates from week (W) 0 – 5 from patient 24NC were indicated 
as being from the T4 lineage following spoligotyping, with the isolate from W6 being indicated 
as belonging to the S lineage. The presence of products corresponding to 570bp confirms the 
results that all isolates from this patient belong to the non-W-Beijing group of strains (Figure 
3.15; Lanes 6 – 12). Similarly, isolates from W0 – 3 from patient 46JP were indicated as being 
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from the T1 lineage following spoligotyping, with isolates from W4 – 5 belonging to the S 
lineage. The presence of products corresponding to 570bp confirms the result that all isolates 
from this patient belong to the non-W-Beijing group of strains (Figure 3.15; Lanes 13 – 18). 
Isolates from W0 – 2 from patient 73NC were indicated as being from the W-Beijing lineage, 
with the isolate from W3 belonging to the T4 lineage, and isolates from W4 – 9 belonging to 
the W-Beijing lineage. Products corresponding to 570bp in isolates from W2 – W9 confirm the 
result that these isolates harbour the T4 lineage, with the products in W3 being the most 
intense. The absence of products corresponding to 570bp in isolates from W0 – 1 indicates 
that the emergence of the T4 isolate did not occur until W2 (Figure 3.15; Lanes 19 – 28).  
 
Isolates from W0 – 3 from patient 81SM were identified as belonging to the W-Beijing lineage 
by spoligotyping, with the emergence of an additional X3 isolate in W3. Products 
corresponding to 570bp the isolate on W2 confirm the result that that isolate belongs to the 
non-W-Beijing lineage. The absence of the product in W0 – 1, indicates that the emergence of 
the X3 did not occur until W2 (Figure 3.15; Lanes 34 – 36). Similarly isolates from W0 – 5 from 
patient 107MD, were identified as belonging to the W-Beijing lineage by spoligotyping, with the 
emergence of an additional X3 isolate in W4 – 5. Products of 570bp in isolates from W4 - 5 
confirms the result that these isolates belong to the non-W-Beijing lineage. The absence of 
products in W0 – 3 indicates that the emergence of the X3 isolate did not occur until W4 
(Figure 3.15; Lanes 37 – 42). Isolates from W0 – 1 from patient 118AG were identified as 
belonging to the LAM3 lineage by spoligotyping, and from the T4 lineage in W2. The presence 
of products corresponding to 570bp in all isolates confirms the result that these isolates 
belong to the non-W-Beijing group of strains (Figure 3.15; Lanes 43 – 45). Therefore both 
assays PS1 and PS3 confirms the results from spoligotyping. 
 
3.5.2. Screening for additional mixed isolates in the study population 
To determine whether any additional patients harbour mixed isolates, the first and last isolate 
from each of the 129 patients included in this study, were screened with PS1 and PS3. The 
first and last isolates were screened as was previously noticed, the majority of mixed isolates 
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occurred in the final samples. Following amplification products were separated by agarose gel 
electrophoresis for PS1 (Figure 3.16) and PS3 (Figure 3.17). 
 
Figure 3.16. Agarose gel electrophoresis of products from PS1 on first and last isolate of 129 patients included in 
the study. Lane 1: Hyperladder IV; Lane 2: negative water control; Lane 3: VOID; Lane 4: W-Beijing control; Lane 
5: non-W-Beijing control; Lane 6: 20TM W0; Lane 7: 20TM W6; Lane 8: 54ER W0; Lane 9: 54 W4; Lane 10: 
61WM W0; Lane 11: 61WM W7; Lane 12: 79RC W0; Lane 13: 79RC W6; Lane 14: 80GI W0; Lane 15: 80GI W6; 
Lane 16: 85SA W0; Lane 17: 85SA W3; Lane 18: 86AF W0; Lane 19: 86AF W7; Lane 20: 87GK W0; Lane 21: 
87GK W8; Lane 22: 95AM W0; Lane 23: 95AM W8; Lane 24: 101GP W0; Lane 25: 101GP W7; Lane 26: 
Hyperladder IV; Lane 27: negative water control; Lane 28: VOID; Lane 29: W-Beijing control; Lane 30: non-W-
Beijing control; Lane 31: 104MM W0; Lane 32: 104MM W6; Lane 33: 105AD W0; Lane 34: 105AD W8; Lane 35: 
114VJ W0; Lane 36: 114VJ W1; Lane 37: 117TS W0; Lane 38: 117TS W7; Lane 39: 121VS W0; Lane 40: 121VS 
W2. 
 
No signal was observed in the negative water control indicating that the reagents used were 
not contaminated (Figure 3.16). Products corresponding to 393bp were observed for the W-
Beijing control (Figure 3.16; Lanes 4 and 29), and were absent in the non-W-Beijing control 
(Figure 3.16; Lanes 5 and 30). All additional patients screened were identified as harbouring 
W-Beijing isolates as determined by spoligotyping. Products corresponding to 393bp were 
observed for both the first and last isolate for each patient, confirming the result that these 
isolates belong to the W-Beijing lineage (Figure 3.16; Lanes 6 – 25, and 31 – 40).  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
78 
 
 
Figure 3.17. Agarose gel electrophoresis of products from PS3 on first and last isolate of 129 patients included in 
the study. Lane 1: Hyperladder IV; Lane 2: negative water control; Lane 3: VOID; Lane 4: W-Beijing control; Lane 
5: non-W-Beijing control; Lane 6: 20TM W0; Lane 7: 20TM W6; Lane 8: 54ER W0; Lane 9: 54 W4; Lane 10: 
61WM W0; Lane 11: 61WM W7; Lane 12: 79RC W0; Lane 13: 79RC W6; Lane 14: 80GI W0; Lane 15: 80GI W6; 
Lane 16: 85SA W0; Lane 17: 85SA W3; Lane 18: 86AF W0; Lane 19: 86AF W7; Lane 20: 87GK W0; Lane 21: 
87GK W8; Lane 22: 95AM W0; Lane 23: 95AM W8; Lane 24: 101GP W0; Lane 25: 101GP W7; Lane 26: 
Hyperladder IV; Lane 27: negative water control; Lane 28: VOID; Lane 29: W-Beijing control; Lane 30: non-W-
Beijing control; Lane 31: 104MM W0; Lane 32: 104MM W6; Lane 33: 105AD W0; Lane 34: 105AD W8; Lane 35: 
114VJ W0; Lane 36: 114VJ W1; Lane 37: 117TS W0; Lane 38: 117TS W7; Lane 39: 121VS W0; Lane 40: 121VS 
W2. 
 
No signal was observed in the negative water control indicating that the reagents used were 
not contaminated (Figure 3.17). Products corresponding to 570bp were observed in the non-
W-Beijing control (Figure 3.17; Lanes 5 and 30), while were absent in the W-Beijing control 
(Figure 3.17; Lanes 4 and 29). Products of 570bp were observed in all of the last isolates in 
each patient screened, indicating the emergence of a non-W-Beijing isolate (Figure 3.17; 
Lanes 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 31, 33, 36, 38, and 40). Products of 570bp were 
additionally observed in the W0 isolate in patients 79RC, 80GI, 87GK, 104MM, 105AD, and 
121VS, indicating that the presence of the non-W-Beijing isolate was part of the initial infection 
at the start of the study period (Figure 3.17; Lanes 12, 14, 20, 31, 33, and 39). 
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A total of 15 patients (20TM, 54GR, 61WM, 79RC, 80GI, 85SA, 86AF, 87GK, 95AM, 101GP, 
104MM, 105AD, 114VJ, and 121VS) were indicated as carrying mixed isolates from the 
screening with PS1 and PS3. This increases the number of mixed infections detected to 21 
patients (16.3%). 
 
3.6. Differentiation of mixed non-W-Beijing M. tuberculosis isolates     
       identified from clinical samples by spoligotyping. 
 
A PCR algorithm, consisting of 3 sequential PCRs, was developed to delineate the major non-
W-Beijing isolates circulating in the Western Cape, by the amplification or the lack of 
amplification of regions of difference (RoD) associated with each of the LAM, X, T and H 
strains (2.9). Sequentially, the algorithm will delineate the sample to each of the major 
circulating strain families. Genomic DNA, extracted from colonies grown from the suspected 
mixed MGIT cultures on LJ slopes (2.2.1), was used as template in the subsequent PCR 
assays. 
 
The control isolates of the LAM (LAM 1, LAM 2, and LAM 3), T (T 1, T 2 and T 3), X (X 1, X 2 
and X 3) and H (H 1, H 2 and H 3) families (kindly provided by J. Evans) as detected by 
spoligotyping, were used to optimize the RoD1, RoD2 and RoD3 assays (data not shown). 
Additionally, W-Beijing control 1 was included as a negative control as the regions amplified in 
RoD1, RoD2 and RoD3, are deleted in all W-Beijing isolates. 
 
For the optimization of RoD1, a MgCl2 titration was performed by adding 1mM, 1.5mM, 
2.0mM, 2.5mM, 3.0mM, 3.5mM, 4.0mM, and 4.5mM MgCl2 to the reaction. Amplification at a 
MgCl2 concentration of 3.5mM yielded products of the greatest intensity. Both the forward and 
reverse primers of RoD1 were titrated, both individually and together, by adding 25pmol, 
20pmol, 15pmol, 10pmol, 5pmol or 1pmol of each to the reaction mixture. Amplification at 
10pmol for the forward primer and 5pmol for the reverse primer yielded expected products and 
decreased the intensity of the non-specific amplicons. Further experiments were carried out 
and the annealing temperature was increased from 56°C to 58°C, in order to decrease the 
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intensity of the non-specific amplification further. Amplification of the expected product size 
occurred at an annealing temperature of 58°C, while decreasing the non-specific 
amplification. Lastly, the number of amplification cycles was reduced from 35 cycles to 30 
cycles, to reduce amplification of non-specific products. The RoD1 PCR assay was carried out 
using a reaction mixture containing 3.5mM MgCl2, 10pmol forward primer, 5pmol of the 
reverse primer and 1U of GoTaq DNA polymerase. The cycling conditions were 5min at 95°C, 
followed by 30 cycles of 95°C for 1min, 58°C for 1min and 72°C for 2min. Finally, an 
elongation at 72°C for 5min completed the amplification. Following amplification, the products 
were separated by agarose gel electrophoresis (Figure 3.18). 
 
 
Figure 3.18. Agarose gel electrophoresis of assay RoD1 using control strains as template. HI: Hyperladder I; 
Lane 1: Negative water control; Lane 2: VOID; Lane 3: W-beijing control 1; Lane 4: LAM 1; Lane 5: LAM 2; Lane 
6: T 1; Lane 7: T 2; Lane 8: X 1; Lane 9: X 2; Lane 10: H 1; Lane 11: H 2. 
 
No signal was observed in the negative water control, indicating that the reagents used were 
not contaminated (Figure 3.18). Products corresponding to 1529bp were observed, as 
expected, for the LAM control strains (Figure 3.18; Lanes 4 – 5), while the larger 1890bp 
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product was observed, as expected, for the T, X and H control strains (Figure 3.18; Lanes 6 – 
11). No product was observed for the W-Beijing isolate (Lane 3), as the target sequence is 
deleted in all W-Beijing isolates. 
 
Following RoD1 PCR, the RoD2 assay was carried out to further delineate non-W-Beijing 
isolates into T, X or H strains. Following amplification, the products were separated by 
agarose gel electrophoresis (Figure 3.19).  
 
Figure 3.19. Agarose gel electrophoresis of assay RoD2 using control strains as template. Lane 1: Hyperladder 
IV; Lane 2: Negative water control; Lane 3: VOID; Lane 4: LAM 1; Lane 5: LAM 2; Lane 6: LAM 3; Lane 7: T 1; 
Lane 8: T 2; Lane 9: T 3; Lane 10: X 1; Lane 11: X 2; Lane 12: X 3; Lane 13: H 1; Lane 14: H 2; Lane 15: H 3. 
 
No signal was observed in the water control, indicating that the reagents used were not 
contaminated (Figure 3.19). No products were obtained for the X control strains (Figure 3.19; 
Lanes 10 – 12).  Products corresponding to 240bp were observed as expected in the T control 
strains (Figure 3.19; Lanes 7 – 9) and the H control strains (Figure 3.19; Lanes 13 - 15). No 
amplification was observed using the LAM control strains (Figure 3.19; Lanes 4 – 6). This 
served as a confirmation of the LAM result obtained in the RoD1 assay (Figure 3.18). 
       
The presence of the 240bp product following assay RoD2 is indicative of either a T or an H 
strain. The RoD3 assay was then carried out to differentiate between these 2 strain families. 
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Amplification was carried out as described (2.9.3) except the number of cycles was decreased 
from 35 cycles to 30 cycles, to eliminate non-specific amplification. Following amplification, the 
products were separated by agarose gel electrophoresis (Figure 3.20). 
 
 
Figure 3.20. Agarose gel electrophoresis of assay RoD3 using control strains as template. Lane 1: Hyperladder 
IV; Lane 2: Negative water control; Lane 3: VOID; Lane 4: LAM 1; Lane 5: W-Beijing 1; Lane 6: LAM 2; Lane 7: T 
1; Lane 8: T 2; Lane 9: T 3; Lane 10: X 1; Lane 11: X 2; Lane 12: H 1; Lane 13: H 2; Lane 14: H 3. 
 
No signal is observed in the water control, indicating that the reagents used were not 
contaminated (Figure 3.20). Products corresponding to 395bp were observed as expected in 
the T and X control strains (Figure 3.20; Lanes 7 - 11). As RoD2 detects isolates of the X 
family RoD3 serves to confirm the RoD2 result. Similarly, a product observed with the LAM 
control (Figure 3.20; Lanes 4 and 6) confirms the result obtained using assay RoD1 (Figure 
3.18). No PCR amplification was detected for the H control strains (Figure 3.20; Lanes 12 – 
14) as well as the W-Beijing control (Figure 3.20; Lane 5), indicating that these isolates are 
neither T nor X strains.  
 
3.6.1. Screening of isolates from patients identified by spoligotyping as harbouring  
          mixed infections 
 
Assay RoD1 was carried out on all isolates for patients indicated as harbouring mixed 
infections following spoligotyping. Following amplification, the products were separated by 
agarose gel electrophoresis (Figure 3.21). 
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Figure 3.21. Agarose gel electrophoresis of assay RoD1 from mixed patient samples. Lane 1: Hyperladder I; 
Lane 2: negative water control; Lane 3: VOID; Lane 4: LAM 1; Lane 5: T 1; Lane 6: X 1; Lane 7: H 1; Lane 8: 
24NC Week (W) 0; Lane 9: 24NC W 1; Lane 10: 24NC W 2; Lane 11: 24NC W 3; Lane 12: 24NC W 4; Lane 13: 
24NC W 5; Lane 14: 24NC W 6; Lane 15: 46JP W 0; Lane 16: 46JP W 1; Lane 17: 46JP W 2; Lane 18: 46JP W 
3: Lane 19: 46JP W 4; Lane 20: 46JP W 5; Lane 21: 73NC W 0; Lane 22: 73NC W 1; Lane 23: 73NC W 2; Lane 
24: 73NC W 3; Lane 25: 73NC W 4; Lane 26: 73NC W 5; Lane 27: 73NC W 6; Lane 28: 73NC W 7; Lane 29: 
Hyperladder I; Lane 30: negative water control; Lane 31: VOID; Lane 32: LAM 1; Lane 33: T 1; Lane 34: X 1; 
Lane 35: H 1; Lane 36: 73NC W 8; Lane 37: 73NC W 9; Lane 38: 81SM W 0; Lane 39: 81SM W 1; Lane 40: 
81SM W 2; Lane 41: 107MD W 0; Lane 42: 107MD W 1; Lane 43: 107MD W 2; Lane 44: 107MD W 3; Lane 45: 
107MD W 4; Lane 46: 107MD W 5; Lane 47: 118AG W 0; Lane 48: 118AG W 1; Lane 49: 118AG W 2. 
 
No signal is observed in the either of the negative water controls, indicating that the reagents 
used were not contaminated (Figure 3.21). Products corresponding to 1529bp were observed 
for the LAM control strains, as expected (Figure 3.21; Lanes 4 and 32), as were products 
corresponding to 1890bp for the non-LAM control strains, T, X and H (Figure 3.21; Lanes 5 – 
7, and 33 – 35, respectively). Patient 24NC, which was identified using spoligotyping, as 
harbouring T4 strains in the samples isolated in W0 – 5 and an S strain in the sample isolated 
in W6, displays the expected 1890bp product for the samples isolated in W0 - 5 (Figure 3.21; 
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Lanes 8 – 13) and a product corresponding to 1529bp for the sample isolated in W6 (Figure 
3.21; Lane 14). Products corresponding to 1890bp are observed for the samples isolated in 
W0 - 3 of patient 46JP (Figure 3.21; Lanes 15 – 18), identified by spoligotyping as harbouring 
T1 strains in those isolates. Products of 1529bp were observed in the samples isolated in     
W4 - 5 of patient 46JP, identified by spoligotyping as harbouring S strains in these samples 
(Figure 3.21; Lanes 19 – 20). No products were observed in the samples isolated in W0 - 2 of 
patient 73NC, identified by spoligotyping as harbouring W-Beijing isolates (Figure 3.21; Lanes 
21 – 23), while a product corresponding to 1890bp was observed, as expected for the 
emerged T4 strain, in the sample isolated in W3 (Figure 3.21; Lane 24), while the samples 
isolated in W4 – 9 failed to yield products, due to the W-Beijing strains re-emerging in those 
samples (Figure 3.21; Lanes 25 – 28, and 36 – 37).  
 
Similarly no products were observed for the samples isolated in W0 - 1 of patient 81SM 
(Figure 3.21; Lanes 38 – 39), due to the identified W-Beijing isolates, while a low intensity 
product of 1890bp is observed in the sample isolated in W2 (Figure 3.21; Lane 40). This is 
most likely due to the low amount of X3 DNA in the mixed sample. Additionally, no products 
are observed in the samples isolated in W0 - 3 of patient 107MD, identified as harbouring W-
Beijing isolates (Figure 3.21; Lanes 41 – 44), and an additional X3 strain in the samples 
isolated in W4 - 5, where products of 1890bp were observed (Figure 3.21; Lanes 45 – 46). 
Finally, products of 1529bp are observed in the samples isolated in W0 – 1 of patient 118AG, 
identified as harbouring LAM3 strains (Figure 3.21; Lanes 47 – 48), while a 1890bp product 
was observed in the sample isolated in W2, identified as an emerged T4 strain (Figure 3.21; 
Lane 49). RoD1 confirmed the identification of strains detected by spoligotyping as either LAM 
or non-LAM. 
 
The RoD2 assay was subsequently used to further delineate non-LAM isolates as either T, X 
or H strains. RoD2 separates out T and H strains from X strains based on the presence or 
absence of a product corresponding to 240bp. Positive amplification is indicative of either T or 
H strains, while the absence of amplification indicates the presence of X or LAM strains. 
Following RoD2 amplification, products were separated by agarose gel electrophoresis 
(Figure 3.22). 
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Figure 3.22. Agarose gel electrophoresis of assay RoD2 from mixed patient samples. Lane 1: Hyperladder IV; 
Lane 2: negative water control; Lane 3: VOID; Lane 4: LAM 1; Lane 5: T 1; Lane 6: X 1; Lane 7: H 1; Lane 8: 
24NC W 0; Lane 9: 24NC W 1; Lane 10: 24NC W 2; Lane 11: 24NC W 3; Lane 12: 24NC W 4; Lane 13: 24NC W 
5; Lane 14: 24NC W 6; Lane 15: 46JP W 0; Lane 16: 46JP W 1; Lane 17: 46JP W 2; Lane 18: 46JP W 3: Lane 
19: 46JP W 4; Lane 20: 46JP W 5; Lane 21: Hyperladder IV; Lane 22: negative water control; Lane 23: VOID; 
Lane 24 LAM 1; Lane 25: T 1; Lane 26: X 1; Lane 27: H 1;  Lane 28: 73NC W 0; Lane 29: 73NC W 1; Lane 30: 
73NC W 2; Lane 31: 73NC W 3; Lane 32: 73NC W 4; Lane 33: 73NC W 5; Lane 34: 73NC W 6; Lane 35: 73NC 
W 7; Lane 36: 73NC W 8; Lane 37: 73NC W 9; Lane 38: 81SM W 0; Lane 39: 81SM W 1; Lane 40: 81SM W 2; 
Lane 41: 107MD W 0; Lane 42: 107MD W 1; Lane 43: 107MD W 2; Lane 44:  Hyperladder IV; Lane 45:  negative 
water control; Lane 46: VOID; Lane 47: LAM 1; Lane 48: T 1; Lane 49: X 1; Lane 50: H 1;Lane 51: 107MD W 3; 
Lane 52: 107MD W 4; Lane 53: 107MD W 5; Lane 54: 118AG W 0; Lane 55: 118AG W 1; Lane 56: 118AG W 2 
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No signal was observed in any of the negative water controls indicating that the reagents used 
were not contaminated (Figure 3.22). Products corresponding to 240bp were observed for the 
T control strains (Figure 3.22; Lanes 5, 25, and 48) and H control strains (Figure 3.22; Lanes 
7, 27, and 50), while no signal was observed in the LAM control strains (Figure 3.22; Lanes 4, 
24, and 47) and X control strains (Figure 3.22; Lanes 6, 26, and 49), as expected. Products of 
240bp were observed for samples isolated in W0 - 5 from patient 24NC, including the sample 
isolated in W6. This was expected, having previously been identified by spoligotyping to be of 
the T4 lineage (W0-5) and the S lineage (W6) (Figure 3.22; Lanes 8 – 14). The lack of product 
amplification in lanes 8 and 9 is most likely due to template concentration in these samples 
being too low for detection using this assay. It is not likely that it was an inability of the PCR to 
amplify T4 strains as the other samples were successfully amplified.  
 
Similarly, products of 240bp were observed, as expected, for samples isolated in W0 - 3 from 
patient 46JP, including the samples isolated in W4 – 5, having previously been identified as 
belonging to the T1 lineage (W0 – 3) and the S lineage (W4-5) (Figure 3.22; Lanes 15 – 20). 
Products of 240bp were observed in the samples isolated in W0 - 5, and again in the sample 
isolated in W7 (Figure 3.22; Lanes 28 – 33, and 35), of patient 73NC, which is unexpected, as 
these samples are known to be of the W-Beijing lineage, except for the sample isolated in W3, 
which belongs to the T4 lineage (Figure 3.22; Lane 32). However, this indicates that the T4 
strain was present, albeit in fractional amounts, from the initial infection. However, subsequent 
samples isolated in W6, and W8 to W9, failed to detect T4 DNA, and no amplification signals 
were observed, indicative of W-Beijing isolates (Figure 3.22; Lanes 34, and 36 - 37).  
 
No signals were observed in samples isolated in W0 – 2 from patient 81SM, indicative of the 
W-Beijing and X3 strains, both yielding no amplification (Figure 3.22; Lanes 38 – 40). 
Similarly, no signals were observed, as expected from the  samples isolated in W0 - 5 from 
patient 107MD, as these isolates were identified to be of the W-Beijing lineage in the samples 
W0 – 3 (Figure 3.22; Lanes 41 – 43), while an additional X3 isolate emerged in samples W4 
and W5 (Figure 3.22; Lanes 51 – 53). Products corresponding to 240bp were observed for 
samples isolated in W0 - 2 from patient 118AG, indicative of the underlying T4 strain that 
emerges in sample W2. Signals in samples W0 and W1 are less intense than in sample W2, 
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due most likely to the low numbers of T4 isolates present in the first 2 samples (Figure 3.22; 
Lanes 54 – 56). Assay RoD2 correctly identified and differentiated the T isolates from the X 
isolates and corresponded with the spoligotyping data. Furthermore, the assay was able to 
detect the underlying strains, present in low quantities, before they were detectable in 
subsequent samples by spoligotyping, thus indicating that the assay is more sensitive than 
spoligotyping in detecting mixed isolates earlier. 
 
Assay RoD3 differentiates T strains from H strains based on the presence or absence of a 
395bp product. The presence of the product is indicative of T strains present in the sample, as 
well as LAM or X strains, whiles the absence of amplification suggests the presence of H 
strains. As RoD1 and RoD2 assays detect LAM and X strains prior to RoD3, the presence of a 
signal here serves to confirm results obtained in the previous two assays. Following RoD3 
amplification, products were separated by agarose gel electrophoresis (Figure 3.23). 
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Figure 3.23. Agarose gel electrophoresis of assay RoD3 from mixed patient samples. Lane 1: Hyperladder IV; 
Lane 2: negative water control; Lane 3: VOID; Lane 4: LAM 1; Lane 5: T 1; Lane 6: X 1; Lane 7: H 1; Lane 8: 
24NC W 0; Lane 9: 24NC W 1; Lane 10: 24NC W 2; Lane 11: 24NC W 3; Lane 12: 24NC W 4; Lane 13: 24NC W 
5; Lane 14: 24NC W 6; Lane 15: 46JP W 0; Lane 16: 46JP W 1; Lane 17: 46JP W 2; Lane 18: 46JP W 3: Lane 
19: 46JP W 4; Lane 20: 46JP W 5; Lane 21: Hyperladder IV; Lane 22: negative water control; Lane 23: VOID; 
Lane 24 LAM 1; Lane 25: T 1; Lane 26: X 1; Lane 27: H 1 Lane 28: 73NC W 0; Lane 29: 73NC W 1; Lane 30: 
73NC W 2; Lane 31: 73NC W 3; Lane 32: 73NC W 4; Lane 33: 73NC W 5; Lane 34: 73NC W 6; Lane 35: 73NC 
W 7; Lane 36: 73NC W 8; Lane 37: 73NC W 9; Lane 38: 81SM W 0; Lane 39: 81SM W 1; Lane 40: 81SM W 2; 
Lane 41: 107MD W 0; Lane 42: 107MD W 1; Lane 43: 107MD W 2; Lane 44: VOID; Lane 45: Hyperladder IV; 
Lane 46: Hyperladder IV; Lane 47: negative water control; Lane 48: VOID; Lane 49: LAM 1; Lane 50: T 1; Lane 
51: X 1; Lane 52: H 1; Lane 53: 107MD W 3; Lane 54: 107MD W 4; Lane 55: 107MD W 5; Lane 56: 118AG W 0; 
Lane 57: 118AG W 1; Lane 58: 118AG W 2; Lane 59: Hyperladder IV. 
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No signal was observed in any of the negative water controls indicating that the reagents used 
were not contaminated (Figure 3.23). Products corresponding to 395bp were observed for the 
LAM control strains (Figure 3.23; Lanes 4, 24 and 49), T control strains (Figure 3.23; Lanes 5, 
25, and 50) and X control strains, as expected (Figure 3.23; Lanes 6, 26, and 51) and were 
absent using the H control strains (Figure 3.23; Lanes 7, 27, and 52). Products corresponding 
to 395bp were observed for the samples isolated in W0 - 6 of patient 24NC (Figure 3.23; 
Lanes   8 – 14). The products were also observed in the samples isolated in W0 - 5 for patient 
46JP (Figure 3.23; Lanes 15 – 20). This confirms the presence of the T and S strains in each 
patient.  
 
Products corresponding to 395bp were observed, at a low intensity, for samples isolated in 
W0 – 2 (Figure 3.23; Lanes 28 – 30) of patient 73NC, and samples isolated in W4 – 9 (Figure 
3.23; Lanes 32 – 37), indicative of the underlying T4 strain which emerges in the sample 
isolated in W3, showing a stronger intensity (Figure 3.23; Lane 31). No products were 
observed in the samples isolated in W0 – 1 from patient 81SM, corresponding to the W-Beijing 
strains isolated (Figure 3.23; Lanes 38 – 39). Product corresponding to 395bp was observed 
in the sample isolated in W2 (Figure 3.23; Lane 40) of patient 81SM. This indicates that X3, 
which emerged in the sample isolated in W2, was present in small quantities, too low to be 
detected in the first two samples. Similarly, no amplification was observed in samples isolated 
in W0 - 5 from patient 107MD (Figure 3.23; Lanes 41 – 43, and 53 – 55), despite the 
emergence of X3 in samples isolated in W4 – 5 (Figure 3.23; Lanes 54 – 55). Amplification of 
expected size was observed in samples isolated in W0 - 2 from patient 118AG, confirming the 
emergence of the T4 strain in sample W2 (Figure 3.23; Lanes 56 – 58). As there were no H 
strains detected by spoligotyping, assay RoD3, therefore confirmed the results obtained from 
the other two assays. 
  
3.6.2. Screening for additional mixed infections in the study population. 
Assays RoD1, RoD2 and RoD3 were carried out on the first and last isolates of the 129 l 
patients included in the study including the 15 patients identified as having mixed isolates by 
PCR. The RoD assays did not identify any additional patients that harboured mixed non-W-
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Beijing isolates, and confirmed the spoligotyping results of those patients. The RoD assays 
were used to screen the first and last isolate of the additional 15 patients. Following 
amplification with RoD1 products were separated by agarose gel electrophoresis (Figure 
3.24). 
 
 
Figure 3.24. Agarose gel electrophoresis of assay RoD1 of additional mixed isolates. Lane 1: Hyperladder I; 
Lane 2: negative water control; Lane 3: VOID; Lane 4: LAM 1; Lane 5: T 1; Lane 6: X 1; Lane 7: H 1; Lane 8: 
20TM W0; Lane 9: 20TM W6; Lane 10: 54ER W0; Lane 11: 54 W4; Lane 12: 61WM W0; Lane 13: 61WM W7; 
Lane 14: 79RC W0; Lane 15: 79RC W6; Lane 16: 80GI W0; Lane 17: 80GI W6; Lane 18: 85SA W0; Lane 19: 
85SA W3; Lane 20: 86AF W0; Lane 21: 86AF W7; Lane 22: 87GK W0; Lane 23: 87GK W8; Lane 24: 95AM W0; 
Lane 25: 95AM W8; Lane 26: 101GP W0; Lane 27: 101GP W7; Lane 28: Hyperladder I; Lane 29: negative water 
control; Lane 30: VOID; Lane 31: LAM 1; Lane 32: T 1; Lane 33: X 1; Lane 34: H 1; Lane 35: 104MM W0; Lane 
36: 104MM W6; Lane 37: 105AD W0; Lane 38: 105AD W8; Lane 39: 114VJ W0; Lane 40: 114VJ W1; Lane 41: 
117TS W0; Lane 42: 117TS W7; Lane 43: 121VS W0; Lane 44: 121VS W2. 
 
No signal was observed in the negative water control indicating that the reagents used were 
not contaminated (Figure 3.24). Products corresponding to 1529bp were observed for the 
LAM control strain (Figure 3.24; Lanes 4 and 31) while products of 1890bp were observed for 
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the T, X and H control strains (Figure 3.24; Lanes 5 – 7, and 32 – 34). No product is observed 
in the W0 isolate of patient 20TM, indicative of the W-Beijing isolate confirmed present by 
spoligotyping, while product corresponding to 1529bp in the W6 isolate indicates that this 
isolate is either a LAM or S strain (Figure 3.24; Lanes 8 – 9). Similarly, no product is observed 
in the W0 isolate of patient 54GR, while the 1529bp product in the W4 isolate is indicative of 
either a LAM or S strain (Figure 3.24; Lanes 10 – 11).  
 
No product is observed in the W0 isolate of patient 61WM indicative of the W-Beijing isolate in 
that sample, while the 1890bp product observed in the W7 isolate, indicative of either a T, X or 
H strain (Figure 3.24; Lane 12 – 13). Products corresponding to 1890bp were observed in 
both isolates of patient 79RC indicative of the non-W-Beijing isolate present in both samples, 
and may correspond to either a T, X, or H strain (Figure 3.24; Lanes 14 – 15).  Similarly 
products of 1890bp were observed in both isolates of patient 80GI, indicative of the non-W-
Beijing isolate present in both samples and may belong to either the T, X or H lineages (Figure 
3.24; Lanes 16 – 17). No product was observed in the W0 isolate of patient 85SA indicative of 
the W-Beijing isolate confirmed in that sample, while product corresponding to 1890bp 
observed in the W3 isolate is indicative of either a T, X or H isolate (Figure 3.24; Lanes 18 – 
19). Similarly, no product was observed in the W0 isolate from patient 86AF, indicative of the 
W-Beijing isolate confirmed in that sample, while product of 1890bp in the W7 isolate 
corresponds to either a T, X or H strain (Figure 3.24; Lanes 20 – 21).   
 
Product of 1529bp observed in both isolates of patient 87GK is indicative of the non-W-Beijing 
strains found in both samples and is indicative of either a LAM or S strain (Figure 3.24; Lanes 
22 – 23). No product was observed in the W0 isolate of patient 95AM, indicative of the W-
Beijing isolate confirmed in that sample, while product corresponding to 1529bp in the W8 
isolate indicates the presence of either a LAM or S strain (Figure 3.24; Lanes 24 – 25). No 
product was observed in the W0 isolate of patient 101GP, confirming the presence of the W-
Beijing isolate present in that sample, while product corresponding to 1890bp in the W7 isolate 
indicates the presence of either a T, X or H strain (Figure 3.24; Lanes 26 – 27). Products 
corresponding to 1890bp were observed in both isolates of patient 104MM, indicative of the 
non-W-Beijing strain present in both samples and corresponds to the presence of either a T, X 
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or H strain (Figure 3.24; Lanes 35 – 36). Similarly products corresponding to 1890bp were 
observed in both isolates of patient 105AD, indicative of the non-W-Beijing isolate present in 
both samples and corresponds to the presence of either a T, X or H strain (Figure 3.24; Lanes 
37 – 38).  
 
No product was observed in the W0 isolate of patient 114VJ, confirming the presence of the 
W-Beijing strain present in that sample, while product corresponding to 1529bp in the W1 
isolate indicates the presence of either a LAM or S strain (Figure 3,24; Lanes 39 – 40). No 
product was observed in the W0 isolate of patient 117VS, confirming the presence of the w-
Beijing strain present in that sample, while product corresponding to 1890bp was observed in 
the W7 isolate, which corresponds to the presence of either a T, X or H strain (Figure 3.24; 
Lanes 41 – 42). Products corresponding to 1890bp were observed in both isolates from 
patient 121VS, indicative of the non-W-Beijing isolate present on both samples, and 
corresponds to the presence of either a T, X or H strain (Figure 3.24; Lanes 43 – 44).  
 
The RoD2 assay was carried out subsequent to amplification of RoD1, to further discriminate 
between the T, X and H strains. Following amplification of RoD2 the products were separated 
by agarose gel electrophoresis (Figure 3.25). 
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Figure 3.25. Agarose gel electrophoresis of assay RoD2 of additional mixed isolates. Lane 1: Hyperladder I; 
Lane 2: negative water control; Lane 3: VOID; Lane 4: LAM 1; Lane 5: T 1; Lane 6: X 1; Lane 7: H 1; Lane 8: 
20TM W0; Lane 9: 20TM W6; Lane 10: 54ER W0; Lane 11: 54 W4; Lane 12: 61WM W0; Lane 13: 61WM W7; 
Lane 14: 79RC W0; Lane 15: 79RC W6; Lane 16: 80GI W0; Lane 17: 80GI W6; Lane 18: 85SA W0; Lane 19: 
85SA W3; Lane 20: 86AF W0; Lane 21: 86AF W7; Lane 22: 87GK W0; Lane 23: 87GK W8; Lane 24: 95AM W0; 
Lane 25: 95AM W8; Lane 26: 101GP W0; Lane 27: 101GP W7; Lane 28: Hyperladder I; Lane 29: negative water 
control; Lane 30: VOID; Lane 31: LAM 1; Lane 32: T 1; Lane 33: X 1; Lane 34: H 1; Lane 35: 104MM W0; Lane 
36: 104MM W6; Lane 37: 105AD W0; Lane 38: 105AD W8; Lane 39: 114VJ W0; Lane 40: 114VJ W1; Lane 41: 
117TS W0; Lane 42: 117TS W7; Lane 43: 121VS W0; Lane 44: 121VS W2. 
 
No signal was observed in the negative water control indicating that the reagents used were 
not contaminated (Figure 3.25). Products corresponding to 240bp were observed for the T and 
H control strains (Figure 3.25; Lanes 5 and 7, 32 and 35) while no products were observed for 
the LAM and X control strains (Figure 3.25; Lanes 4 and 6, and 31 – 33). No products are 
observed in both isolates of patient 20TM, indicative of the W-Beijing isolate confirmed 
present by spoligotyping in the W0 isolate, while the absence of product in the W6 isolate 
confirms the presence of a LAM strain, rather than an S strain, as these strains yield products 
in all 3 RoD assays (Figure 3.25; Lanes 8 – 9). Similarly, no products were observed in both 
isolates of patient 54GR, indicating the W-Beijing strain in the W0 isolate and a LAM strain in 
the W4 isolate (Figure 3.25; Lanes 10 – 11).  
 
No products are observed in both isolates of patient 61WM indicative of the W-Beijing isolate 
in the W0 sample, while the absence of product observed in the W7 isolate, confirms the 
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presence of an X strain due to the larger product being amplified in RoD1 (Figure 3.25; Lane 
12 – 13). Products corresponding to 240bp were observed in both isolates of patient 79RC 
indicative of the non-W-Beijing isolate present in both samples, and may correspond to either 
a T or an H strain (Figure 3.25; Lanes 14 – 15).  No products were observed in either of the 
isolates from patient 80GI, confirming the presence of an X strain in both samples (Figure 
3.25; Lanes 16 – 17). No products were observed in the both isolates of patient 85SA 
indicative of the W-Beijing isolate confirmed in the W0 sample, while absence of product 
observed in the W3 isolate is indicative of an X isolate (Figure 3.25; Lanes 18 – 19). No 
product was observed in the W0 isolate from patient 86AF, indicative of the W-Beijing isolate 
confirmed in that sample, while product of 240bp in the W7 isolate corresponds to either a T or 
H strain (Figure 3.25; Lanes 20 – 21).  
 
No products were observed in both isolates of patient 87GK and are indicative of a LAM strain 
found in both samples (Figure 3.25; Lanes 22 – 23). No product was observed in both isolates 
of patient 95AM, indicative of the W-Beijing isolate confirmed in the W0 isolate, while the 
absence of product in the W8 isolate indicates the presence of a LAM strain (Figure 3.25; 
Lanes 24 – 25). No product was observed in the either isolate of patient 101GP, confirming 
the presence of the W-Beijing isolate present in the W0 sample, while the absence of product 
in the W7 isolate indicates the presence of an X strain (Figure 3.25; Lanes 26 – 27). Products 
corresponding to 240bp were observed in both isolates of patient 104MM, indicative of the 
non-W-Beijing strain present in both samples and corresponds to the presence of either a T or 
H strain (Figure 3.25; Lanes 35 – 36).  
 
No products were observed in both isolates of patient 105AD, indicative of the non-W-Beijing 
isolate present in both samples and corresponds to the presence of an X strain in both 
samples (Figure 3.25; Lanes 37 – 38). No product was observed in either of the isolates of 
patient 114VJ, confirming the presence of the W-Beijing strain present in the W0 sample, 
while the absence of product in the W1 isolate indicates the presence of a LAM strain (Figure 
3.25; Lanes 39 – 40). No product was observed in either of the isolates of patient 117VS, 
confirming the presence of the W-Beijing strain present in the W0 sample, while the absence 
of product in the W7 isolate corresponds to the presence of an X strain (Figure 3.25; Lanes 41 
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– 42). Products corresponding to 240bp were observed in both isolates from patient 121VS, 
indicative of the non-W-Beijing isolate present on both samples, and corresponds to the 
presence of either a T or H strain in those samples (Figure 3.25; Lanes 43 – 44).  
 
RoD3 was carried out, subsequent to amplification by RoD2, to further discriminate between T 
and H strains. Following amplification the products were separated by agarose gel 
electrophoresis (Figure 3.26). 
 
 
Figure 3.26. Agarose gel electrophoresis of assay RoD3 of additional mixed isolates. Lane 1: Hyperladder I; 
Lane 2: negative water control; Lane 3: VOID; Lane 4: LAM 1; Lane 5: T 1; Lane 6: X 1; Lane 7: H 1; Lane 8: 
20TM W0; Lane 9: 20TM W6; Lane 10: 54ER W0; Lane 11: 54 W4; Lane 12: 61WM W0; Lane 13: 61WM W7; 
Lane 14: 79RC W0; Lane 15: 79RC W6; Lane 16: 80GI W0; Lane 17: 80GI W6; Lane 18: 85SA W0; Lane 19: 
85SA W3; Lane 20: 86AF W0; Lane 21: 86AF W7; Lane 22: 87GK W0; Lane 23: 87GK W8; Lane 24: 95AM W0; 
Lane 25: 95AM W8; Lane 26: 101GP W0; Lane 27: 101GP W7; Lane 28: Hyperladder I; Lane 29: negative water 
control; Lane 30: VOID; Lane 31: LAM 1; Lane 32: T 1; Lane 33: X 1; Lane 34: H 1; Lane 35: 104MM W0; Lane 
36: 104MM W6; Lane 37: 105AD W0; Lane 38: 105AD W8; Lane 39: 114VJ W0; Lane 40: 114VJ W1; Lane 41: 
117TS W0; Lane 42: 117TS W7; Lane 43: 121VS W0; Lane 44: 121VS W2. 
 
No signal was observed in the negative water control indicating that the reagents used were 
not contaminated (Figure 3.26). Products corresponding to 395bp were observed for the LAM, 
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T and X control strains (Figure 3.26; Lanes 4 – 6 and 31 – 33) while no products were 
observed for the H control strain (Figure 3.26; Lanes 7 and 34). No product was observed in 
the W0 isolate of patient 20TM, indicative of the W-Beijing isolate confirmed present by 
spoligotyping in that sample, while the presence of product corresponding to 395bp in the W6 
isolate confirms the presence of a LAM strain in that sample (Figure 3.26; Lanes 8 – 9). 
Similarly, no product was observed in the W0 isolates of patient 54GR, indicating the W-
Beijing strain, while product corresponding to 395bp in the W4 isolate confirms the presence 
of a LAM strain in that sample (Figure 3.26; Lanes 10 – 11).  
 
No product was observed in the W0 isolate of patient 61WM indicative of the W-Beijing strain, 
while the presence of product corresponding to 395bp observed in the W7 isolate, confirms 
the presence of an X strain in that sample (Figure 3.6 Lane 12 – 13). A product corresponding 
to 395bp was observed in both isolates of patient 79RC indicative of the non-W-Beijing isolate 
present in both samples, and thus corresponds to a T strain in both samples (Figure 3.26; 
Lanes 14 – 15).  Similarly products of 395bp were observed in both isolates of patient 80GI, 
confirming the X strain identified from RoD2 (Figure 3.26; Lanes 16 – 17). No product was 
observed in the W0 isolate of patient 85SA, confirming the presence of the W-Beijing isolate in 
that sample, while the presence of product corresponding to 395bp confirms the presence of 
an X isolate in that sample (Figure 3.26; Lanes 18 – 19).  
 
No product was observed in the W0 isolate from patient 86AF, indicative of the W-Beijing 
isolate confirmed in that sample, while product of 395bp in the W7 isolate corresponds to a T 
strain (Figure 3.26; Lanes 20 – 21).  Products corresponding to 395bp were observed in both 
isolates of patient 87GK and are indicative of a LAM strain found in both samples (Figure 3.26; 
Lanes 22 – 23). No product was observed in the W0 isolate of patient 95AM, indicative of the 
W-Beijing isolate confirmed in that sample, while the presence of product corresponding to 
395bp  in the W8 isolate confirms the presence of a LAM strain (Figure 3.26; Lanes 24 – 25). 
No product was observed in the W0 isolate of patient 101GP, confirming the presence of the 
W-Beijing isolate present in that sample, while the presence of product in the W7 isolate 
confirms the presence of an X strain (Figure 3.26; Lanes 26 – 27). Products corresponding to 
395bp were observed in both isolates of patient 104MM, indicative of the non-W-Beijing strain 
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present in both samples and corresponds to the presence of a T strain in both samples 
(Figure 3.26; Lanes 35 – 36).  
 
Products of 395bp were observed in both isolates of patient 105AD, confirming the presence 
of an X strain present in both samples (Figure 3.26; Lanes 37 – 38). No product was observed 
in the W0 isolate of patient 114VJ, confirming the presence of the W-Beijing strain present in 
that sample, while the presence of product corresponding to 395bp in the W1 isolate confirms 
the presence of a LAM strain (Figure 3,26; Lanes 39 – 40). No product was observed in the 
W0 isolate of patient 117VS, confirming the presence of the W-Beijing strain present in that 
sample, while the presence of product corresponding to 395bp in the W7 isolate confirms to 
the presence of an X strain (Figure 3.26; Lanes 41 – 42). Products corresponding to 395bp 
were observed in both isolates from patient 121VS, indicative of the non-W-Beijing isolate 
present on both samples, and corresponds to the presence of a T strain in those samples 
(Figure 3.26; Lanes 43 – 44). A summary of the lineages as confirmed by both PCR systems 
is reported in Table 3.3. 
 
              Table 3.3. Genotype of additional isolates from patients identified as harbouring mixed isolates    
                   following PS1 and PS3 PCR assays and RoD1, RoD2, and RoD3 PCR assays  
Patient Code Sample† Lineage 
20TM W0 W-Beijing 
 W6 W-Beijing + LAM 
54GR W0 W-Beijing 
 W4 W-Beijing + LAM 
61WM W0 W-Beijing 
 W7 W-Beijing + X 
79RC W0 W-Beijing + T 
 W6 W-Beijing + T 
80GI W0 W-Beijing + X 
 W6 W-Beijing + X 
85SA W0 W-Beijing 
 W3 W-Beijing + X 
86AF W0 W-Beijing 
 W7 W-Beijing + T 
87GK W0 W-Beijing + LAM 
 W8 W-Beijing + LAM 
95AM W0 W-Beijing 
 W8 W-Beijing + LAM 
101GP W0 W-Beijing 
 W7 W-Beijing + X 
104MM W0 W-Beijing + T 
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 W6 W-Beijing + T 
105AD W0 W-Beijing + X 
 W8 W-Beijing + X 
114VJ W0 W-Beijing 
 W1 W-Beijing + LAM 
117TS W0 W-Beijing 
 W7 W-Beijing + X 
121VS W0 W-Beijing + T 
 W2 W-Beijing + T 
                    †W: Week 
 
No H strains were identified in the patient samples as described earlier. The results indicate 
clearly the need for additional genotyping assays to be performed in conjunction with 
spoligotyping, as this increases the rate of isolating mixed infections in the study setting. 
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Chapter 4 
Discussion 
 
Previously, it was widely accepted that TB disease is the result of one infecting M. 
tuberculosis strain, and that that strain led to immunity from other infecting strains (Shamputa 
et al, 2004). The widely used M. bovis BCG vaccine is based on this theory (Kremer et al, 
2009). The attenuated strain is intended to prime the host immune system, allowing for the 
heightened detection and protection against future infecting strains (Kremer et al, 2009). 
Through advances in molecular genotyping, this theory has recently been revised to include 
that; firstly, disease progression can be due to multiple infecting strains. In addition, little to no 
immunity is conferred as a result of such infection and infections could result from exogenous 
reactivation from prior dormant strains or reinfection with a new superinfection (de Viedma et 
al, 2004; Shamputa et al, 2004; Shamputa et al, 2006; Palomino et al, 2007). Thus the 
efficacy of the protection afforded by BCG in this setting becomes unknown, as BCG alone 
may not be sufficient for protection later on (Kremer et al, 2009). Despite advances in strain 
genotyping, little is known about the scope of mixed infections, or clonal heterogeneity, which 
could greatly impact interpretation of epidemiological data and subsequent treatment of 
patients (Shamputa et al, 2004, 2006; Warren et al, 2004). This study investigated the 
detection of mixed infections in weekly sputum samples collected from newly diagnosed TB 
patients using a number of molecular typing tools. The patients were recruited in the Delft 
region of the Western Cape as part of a larger study conducted to look at the effects of 
micronutrient supplementation, in conjunction with standard therapy, on sputum conversion 
(M. Visser, personal communication). 
 
At the end of the 8-week study period, samples from 154 enrolled adults had been collected. A 
number of patients and samples had to be excluded from analysis. Samples from 8 patients 
were excluded due to the lack of positive cultures, most likely due to early sputum conversion 
as a result of treatment (M. Visser, personal communication). Samples from a further 6 
patients were excluded as they were misplaced or discarded erroneously during storage. 
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Additionally, many individual samples were excluded due to contamination. Of the samples 
collected 12.8% of the total collection of samples was contaminated, with the majority 
containing heavy fungal growth. Reports suggest that the general contamination rate for liquid 
media is between 8 and 10% (Burman and Reves, 2000). Increases in this rate of 
contamination may be due to laboratory contamination, incorrect handling and storage of 
samples, inadequate sputum decontamination and technician error (Burman and Reves, 
2000), which could account for the slightly elevated contamination rate in this study. As a 
result of this contamination, many patients had less than the anticipated 9 samples available 
for analysis. A final total of 686 samples, collected from 140 patients, were included in this 
study. 
 
To assess the epidemiology of the circulating M. tuberculosis strains in Delft, as well as an 
initial screen for mixed infections, spoligotyping was carried out on all patient isolates 
collected. Based on the differences in the DR of each isolate, spoligotyping detected 6 
different strain families infecting the 140 patients enrolled. A large proportion of patients 
(48.7%) harboured W-Beijing strains. This is highly elevated compared to previous data 
obtained in similar settings, but lends credence to the claim that the rate of isolation of W-
Beijing strains is increasing in the Western Cape (Hillemann et al, 2006). In 2004, 16.5% of 
isolates were of the W-Beijing lineage (Victor et al, 2004), while 25% of strains were W-Beijing 
in a 2005 study (Nicol et al, 2005); this increased to 36% in 2006 (Marais et al, 2006).  
 
Other M. tuberculosis strain families detected in this study included LAM (17.1%), T (14.3%), 
X (6.4%), Haarlem (7.9%), S (4.3%), and Family 33 (2.1%). The isolation of LAM strains 
(17.1%) is much lower than the 30% previously reported (Nicol et al, 2005; Marais et al, 2006) 
with the prevalence of T strains (14.3%) twice that indicated earlier (7%) (Nicol et al, 2005). 
These discordant results may reflect the different populations of M. tuberculosis circulating in 
adults versus children as both previous studies were conducted using isolates obtained from 
children, whereas only adults were included in the Delft study. Furthermore, the differences 
observed could be uniquely attributed to the community of Delft. However, it may, too, 
represent a shift in M. tuberculosis populations circulating in the Western Cape. 
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Of the 140 patients examined by spoligotyping, 11 had only 1 viable isolate, and were thus 
excluded from the analysis for mixed infections. Of the 129 patients with multiple sequential 
isolates, 123 patients (95.3%) displayed homogenous genotypes for all isolates tested and 6 
patients (4.7%) displayed evidence of mixed infections, as determined by spoligotyping. This 
is concordant with the previous report of 4.8% detection of mixed infection using spoligotyping 
(Warren et al, 2004). Of the 6 patients indicated as containing mixed infections, 4 patients 
(66.6%) (24NC, 46JP, 73NC, and 118AG) were first infected by one strain which was then 
replaced by a second strain. The mixed infection in the remaining 2 patients (33.3%) (81SM 
and 107MD) are a result of a dual infection, suggesting that these two patients harboured two 
strains each. 
 
Of the 7 isolates obtained from patient 24NC, the first 6 isolates were of the T4 lineage while 
the 7th isolate was of the S lineage. In patient 46JP the first 4 isolates of the total 6 isolates 
collected were of the T1 lineage, with the last 2 isolates from the S lineage. Similarly, in 
patient 118AG, the first 3 strains collected were of the LAM3 lineage while the last isolate was 
of the T4 lineage. Of the 10 isolates obtained from patient 73NC, however, the first 4 strains 
were of the W-Beijing lineage, then in week 5 a T4 strain emerged, thereafter from weeks 4 
through to 8 W-Beijing strains re-emerged. With patients 24NC and 118AG, the change in 
genotype occurred in the last isolates, with no additional samples to confirm the change. One 
can argue therefore that these may not represent true mixed infections, and could point to 
clerical error, or laboratory cross-contamination, both of which have been reported as 
confounders in sample genotyping studies (Warren et al, 2004). The 2 sequential isolates 
obtained from patient 46JP in the last 2 weeks suggest that this is a true mixed infection in this 
patient. Due to the infrequent isolation of S isolates (4.3%) and the fact that 2 sequential 
isolates both indicate the change, the likelihood of this patient harbouring a mixed infection is 
strengthened. In patient 73NC, the change in genotype from W-Beijing to T4 occurred mid-
way through the study period. The fact that the next isolate was once again a W-Beijing could 
also indicate possible clerical error, in this case, the mislabelling of a sample tube. 
Considering the frequency of isolating a strain from the T4 lineage (1.4%) is a rare event 
however, could aid in confirming the mixed nature of these samples. The isolation of 1 mixed 
sample, or a sample that displays a change in genotype, out of a collection of several 
homogeneous sequential isolates, particularly at the end of the study period, places doubt 
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onto the validity of that patient harbouring mixed infections. One would ideally need to follow 
up after the change is noticed, in order to confirm the presence of that additional isolate, 
otherwise one could argue that laboratory cross contamination, or a clerical error, could more 
likely account for the change, and would not in fact, represent a true mixed infection. 
 
Patients 81SM and 107MD both displayed a mixed spoligotype signal indicating that W-Beijing 
strains were isolated and that the patients then acquired M. tuberculosis of the X3 lineage. 
Since the change in strain lineage was only detected with the last isolates in both patients, the 
true mixed nature of the sample could not be confirmed.  However, up to 57% of patients 
infected with W-Beijing strains were repeatedly infected with an additional non-W-Beijing 
strain (Warren et al, 2004). This along with the fact that X lineage strains were identified at a 
very low frequency, suggests that these patients are dually infected with a W-Beijing strain 
and an X isolate. 
 
The 4.7% reported here in terms of the frequency of mixed infections is clearly an 
underestimate, due mainly to the problems associated with spoligotyping to detect mixed non-
W-Beijing infections. As W-Beijing isolates display such a distinct spoligotyping pattern, and 
due to the sensitivity of the PCR assay used (Kamberbeek et al, 1997), one can clearly 
observe mixed infections of W-Beijing and non-W-Beijing samples. Unfortunately, one cannot 
so easily distinguish between mixed non-W-Beijing isolates as the spoligotyping patterns are 
so similar in appearance, and any underlying strains will not be detected. Thus a need for 
differentiating these possible mixed non-W-Beijing isolates is evident. 
 
It has been reported that a change in genotype can be associated with a change in drug 
susceptibility profiles (Kruuner et al, 2002). To this end phenotypic and genotypic DST was 
performed on a selection of isolates, to ascertain whether the changes in genotype observed 
in these 6 patients corresponded to a change in drug susceptibility. Phenotypic DST was 
performed routinely on the baseline and week 8 samples from each patient, at C18, GSH. As 
the isolation of drug resistant strains is more frequently observed in retreatment cases rather 
than new cases (Warren et al, 2004) one can expect that the frequency of drug resistance was 
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low. Of the 140 patients analysed in this study, 6 (4.3%) patients had isolates that were 
resistant to either RIF or INH in week 8. Of these 6 patients, 1 patient (105AD) had an isolate 
that is resistant to both RIF and INH in week 8, 4 patients (20TM, 48ML, 52SM and 95AM), 
had RIF mono-resistant strains isolated in week 8, and 1 patient (22JE), had an INH mono-
resistant strain isolated in week 8. Of the 5 patients with RIF resistant isolates, 3 patients 
(60%) were harbouring isolates of the W-Beijing lineage, supporting the association of drug 
resistance with W-Beijing strains (Bifani et al, 2001; Hillemann et al,  2006; Evans et al, 2009). 
 
Recently, an association between INH mono resistance and X3 strains in the Western Cape 
was reported (Evans et al, 2009). It is therefore interesting to note the association of X3 
strains with W-Beijing isolates in patient samples isolated towards the end of the study period. 
Although these X3 isolates are neither resistant to RIF nor INH, these may represent isolates 
with a greater potential to becoming resistant to INH. It would therefore be worth following up 
with these patients to monitor when drug resistant strains emerge and to detect the strain 
lineages of these isolates. Several hypotheses to why certain strains become drug resistant, 
or their ability to remain virulent, have been postulated in recent years (Gagneux et al, 2006 (1 
and 2)). W-Beijing strains are widely known to illicit powerful immune responses in patients 
and it has been hypothesised that the W-Beijing isolates are hypervirulent, despite their 
propensity to become drug resistant and MDR (Lopez et al, 2003, Gagneux et al, 2006 (1)). It 
has also been reported that the phenolic glycolipids associated with W-Beijing strains allow 
them to evade the immune response (Reed et al, 2007). Also it has been seen in mouse 
models and hypothesised to occur in humans that the immune protection afforded by BCG is 
circumvented by W-Beijing isolates, and that W-Beijing strains might represent “escape 
variants” of M. bovis BCG vaccination. This might highlight a possible route to the global 
circulation of these strains, owing to the wide-use of the vaccine (Kremer et al, 2009). Either or 
a combination of these factors may contribute to the emergence of these X3 clones, with their 
associated drug resistance, in the Western Cape. 
 
Of the 6 patients with mixed infections, all isolates from each patient were fully susceptible to 
both RIF and INH by genotypic DST with the GenoType MTBDRplus assay. However, this 
neither confirms nor disproves the mixed nature of these isolates, as this could represent the 
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isolation of mixed drug susceptible strains, which seems probable due to the fact that these 
patients have newly diagnosed TB and have therefore not been treated prior to this study. 
 
Further discrimination of all the mixed isolates identified by spoligotyping was carried out by 
12-locus MIRU-VNTR analysis (Supply et al, 2000, 2001). To determine whether the 
sequential isolates were clonal in nature or if over the study period several different clones of 
the same lineage had been isolated. Isolates from each patient showed clonal homogeneity 
using MIRU-VNTR up until the change in spoligotype, where a corresponding change in the 
MIRU profile was observed. Interestingly, the MIRU-VNTR profiles of the initial isolates from 
patients 73NC and 107MD were identical, suggesting that these patients may be have been 
infected with a clonally related strain. Furthermore, MIRU-VNTR analysis revealed a 2 allele 
difference between the W-Beijing strains from patients 73NC and 107MD as compared to 
81SM. This suggests that even in a close community such as Delft, several different clonal 
sub-populations of the same lineage may be circulating and causing disease. Using the MIRU-
VNTRplus algorithm (www.miru-vntrplus.org/miru), employing a maximum difference of 2 
alleles between clonal complexes, the T1, T4, W-Beijing and W-Beijing + X3 strains were 
found to form a clonal complex, which indicates that these isolates are related.  
 
This confirms the need for genotyping assays to be carried out in combination with each other. 
Although the MIRU data identifies that the clonal complex isolates are related, in terms of the 
spoligotyping data, they are unrelated to each other, representing discreet lineages. Thus the 
discriminatory power of just a single genotyping assay is not sufficiently high enough, and 
requires additional assays to be carried out to increase the total discriminatory power when 
detecting for mixed infections. Isolates obtained from patients 81SM and 107MD that had 
different spoligotypes from the initial isolates produced discordant MIRU data. The profiles 
obtained following the change in spoligotyped pattern from W-Beijing to X3 were of an 
amalgamation of the W-Beijing strain observed in the initial isolates and that of a different 
strain, which is suggestive of a mixed infection (Shamputa et al, 2006; Stavrum et al, 2009). It 
should be noted that the initial W-Beijing isolate and the W-Beijing isolate in the mixed 
infection may not be the same strain. These patients may have acquired a subsequent 
infection with a different W-Beijing strain as well as with an X3 isolate. However, that the 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
105 
 
MIRU profiles of the initial W-Beijing isolate and the mixed sample differed at only 2 loci 
suggests that this is not the case. It is interesting to note that the MIRU-VNTR profiles of all of 
the W-Beijing + X3 isolates are identical, which suggests that these patients may have 
become co-infected with the same X3 strain. 
 
To obtain a more accurate estimation of the rate of mixed M. tuberculosis infections in 
patients, it is worth investigating inter-lineage differences associated with specific strains. 
Using a PCR assay, the prevalence of mixed infections was estimated at 19% in the Western 
Cape (Warren et al, 2004). This PCR assay consists of four separate primer sets for the 
differentiation of W-Beijing and non-W-Beijing isolates. Amplification products obtained using 
assays PS1 and PS3 confirmed the spoligotyping results obtained for the 6 patients (24NC, 
46JP, 73NC, 81SM, 107MD, and 118AG) indicated as containing mixed infections. It is 
interesting to note that the majority of the 6 patients harbouring mixed infections were infected 
with W-Beijing isolates, which formed the basis of the infection. This could suggest that 
infection with a W-Beijing strain may predispose a patient to subsequent infections with other 
strains. However it cannot be assumed that infection with W-Beijing isolates occurred first with 
subsequent infections occurring later; as the methods employed in this and other studies are 
limited in terms of identifying a time-line of infection (Warren et al, 2004).  
 
To identify additional mixed infections in the population, the first and last isolate of the 129 
patients were screened and an additional 15 patients were indicated as harbouring mixed W-
Beijing and non-W-Beijing isolates. These patients include 20TM, 54GR, 61WM, 79RC, 80GI, 
85SA, 86AF, 87GK, 95AM, 101GP, 104MM, 105AD, 114VJ, and 121VS. This increases the 
estimation of recovering mixed infections in the population to 16.3%, which approximates the 
previous study conducted in this setting (Warren et al, 2004). 
 
The limiting factor with this PCR assay is that in certain patients with mixed isolates, such as 
patients 24NC, 46JP and 118AG, the assay does not delineate the non-W-Beijing isolates 
(Warren et al, 2004). A PCR algorithm, consisting of 3 separate PCR assays (RoD1, RoD2, 
and RoD3), was designed to differentiate potential mixed non-W-Beijing isolates. Primers 
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were designed to detect lineage-specific regions of difference in the DRs of M. tuberculosis 
strain families. RoD1, RoD2 and RoD3 all correctly amplified the targeted regions of the DR in 
the mixed samples, and confirmed the results obtained by spoligotyping. No undetected non-
W-Beijing strains were observed in patients with mixed non-W-Beijing isolates (patients 24NC, 
46JP and 118AG).  
 
The RoD assays were then used to screen the first and last isolate of 129 patients included in 
this study. Of the 15 patients, 6 (61WM, 80GI, 85SA, 101GP, 105AD, and 117TS) harboured 
dual infections with X isolates, 5 patients (20TM, 54GR, 87GK, 95AM, and 114VJ) harboured 
dual infections with LAM isolates, and 4 patients (79RC, 86AF, 104MM, and 121VS) 
harboured dual infections with T isolates. However, the RoD assays do not discriminate the 
specific sub-family of the lineages detected, and thus additional genotyping tools will be 
required. As such, it would be of interest if the X isolates harboured by the additional 6 
patients belong to the X3 subgroup, and furthermore if they are drug resistant. Again the 
association of X strains with W-Beijing strains in a relatively large proportion (38%) of the 
patients harbouring mixed infections is noteworthy. No additional patients harbouring mixed 
non-W-Beijing isolates were detected in the first and last isolate from the 129 patients tested, 
and confirmed the spoligotyping data obtained for each patient. This suggests that the 
proportion of patients harbouring a mixed infection of only non-W-Beijing isolates is very small. 
 
Following the screen of the first and last isolate of all patients included in this study, it is worth 
screening the rest of the samples from the additional 15 patients, with both PCR assays, to 
observe when the change in spoligotype pattern occurred, especially in those patient samples 
where the non-W-Beijing isolate was not detected in the first isolate. Additionally, it would be 
of interest to perform DST on the same isolates to observe if a change in spoligotype 
coincides with a change in drug susceptibility. This is especially important in terms of the X3 
dual infections detected in the additional 15 patients. Similarly, as mentioned previously, it 
would be valuable to follow up on these patients to ascertain whether drug resistance 
emerges and when, and also to determine whether changes in the infecting population had 
also occurred. 
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The RoD assays, in some instances, such as with patients 73NC, 81SM, and 107MD, did not 
readily detect the additional isolates early in the first few samples. This may be due to the W-
Beijing DNA being over-represented in the sample and masking what little T4 or X3 DNA 
present, suggesting a low population of the latter strains.  However it may be that these 
assays are not optimized to adequately detect mixed isolates early on in the infection when 
numbers of isolates is low. To this end, it would be valuable to titrate various template 
concentrations, thereby simulating a mixed infection, in order to detect the lowest 
concentration of DNA detected in a mixed sample using this assay. However, the assays did 
detect the underlying infecting strain early on in patients 24NC, 46JP, and 118AG, as well as 
patients 79RC, 80GI, 87GK, 104MM, 105AD, and 121VS, suggesting that spoligotyping was 
not as sensitive as the RoD assays in these instances. 
 
In the initial screening of the mixed samples it was discovered that S strains also amplify a 
1529bp product, which is a shortfall of the assay, as both strains yield products of 1529bp in 
RoD1, they both yield products from all 3 assays. Thus the RoD assay requires further design 
to include an S-specific region of difference that will allow the identification of S strains. 
Furthermore, the RoD assays have only been designed to differentiate out a limited but major 
group of non-W-Beijing isolates, and therefore the possibility exists of strains not being 
detected and differentiated. Additionally, it is worth noting, the potential difficulties in using the 
DR region of M. tuberculosis as means of differentiating non-W-Beijing isolates. Although a 
generalized consensus spoligotype pattern for each non-W-Beijing lineage can be determined, 
there exists isolates within that lineage that deviates slightly from that consensus, and as such 
may not be detected, or more importantly may be identified as belonging to another lineage 
erroneously.  
 
Perhaps, a more specific and reliable method of differentiating non-W-Beijing isolates is to 
utilize lineage-specific polymorphisms, such as the Rv1519 deletion defining EAI strains 
(Newton et al, 2006), or the mgtC codon 182 SNP that defines the Haarlem genotype (Alix et 
al, 2006). However the benefit of the RoD assay described here is that the majority of non-W-
Beijing strains circulating in the Western Cape are identified in an algorithm format, making 
interpretation of the results simpler. Thus the clinical implications of such an assay are highly 
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beneficial. Once fully tested on a larger group of isolates, and the specificity and sensitivity of 
the assay are optimized, then this assay could be used in the clinical setting, at point of care. 
The materials and reagents needed for PCR are minimal and cost effective, and many 
samples can be tested at one time, ideal for resource-limited clinics and laboratories.  
 
This data confirms that the rate of mixed infections in the Western Cape is of a relatively high 
proportion. This has great implications on the epidemiology of M. tuberculosis studied in this 
region. Of greater importance are the subsequent implications that such data has on the way 
one treats TB patients in this country. Accordingly 17% of newly diagnosed patients are 
infected or will acquire a mixed infection during treatment (Warren et al, 2004), and the 
presence of a drug resistant isolate within the mixed population could go unnoticed, resulting 
in a greater chance of the spread of drug resistant strains in the communities. As South Africa 
has one of the highest incidences of TB in the world (WHO, 2007), the importance of 
considering mixed infections in treatment regimes and vaccine trails is vital.   
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Conclusion 
 
This study investigated the frequency of mixed M. tuberculosis infections in the Delft 
community of the Western Cape.  
 
The sequential samples collected from each patient during the study period allowed for the 
identification of a relatively high proportion (16.3%) of mixed infections in the population. 
Spoligotyping was shown to underestimate the frequency (4.3%) of isolating mixed infections. 
This was thought to be due to the similarities observed in the non-W-Beijing spoligotyping 
profiles. Spoligotyping, therefore, needs to be carried out in conjunction with a PCR assay to 
allow for a more accurate representation of the frequency of mixed infections in the 
population. 
 
Although at the time of DST these isolates were susceptible to both RIF and INH, the 
association of W-Beijing and X3 isolates in dual infections, strains previously identified to be 
associated with MDR and INH mono-resistance, respectively, suggests a high predisposition 
of these isolates to become drug resistant in the future. The need for further follow up to 
confirm this, was highlighted. 
 
Analysis of the genetic relatedness of the strains identified mostly clonal homogeneity within 
patients, and between patients, but that inter-patient strain differences can and did occur. A 
clonal complex was formed by the T lineage strains and W-Beijing lineage strains. Although 
MIRU-VNTR analysis identified these strains to be related, spoligotyping separates these 
strains out into distinct lineages. Thus, even within a relatively close community, different 
subpopulations of strain families are circulating and causing disease.  
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The PCR assay developed to detect mixed infections caused by W-Beijing and non-W-Beijing 
isolates in the same sample, offers a reliable and modest estimation of the rate of mixed 
infections in the Western Cape, but was limited in the differentiation of mixed non-W-Beijing 
isolates. 
 
The RoD assay was developed for the purposes of differentiating the non-W-Beijing isolates 
present in mixed infections. It was able to confirm the results obtained from spoligotyping, but 
detected no mixed non-W-Beijing infections in the study population, without the presence of 
an infecting W-Beijing isolate. Thus it was concluded that the proportion of patients harbouring 
a mixed infection of non-W-Beijing isolates alone, is very small. This assay represents a novel 
means of differentiating the major circulating non-W-Beijing isolates in the Western Cape, in 
an easy to follow format that allows for the rapid interpretation of results. Further optimizations 
are required, however, before it can be used routinely at the point of care facilities.  
 
This data has great implications into how one interprets clinical and epidemiological data. Of 
concern is the growing proportion of drug resistant isolates particularly MDR M. tuberculosis 
isolates. Thus the field of mixed infections requires further study to identify reliable methods in 
distinguishing between mixed isolates, particularly those samples that have mixed drug 
susceptibilities, as this has considerable consequences in the manner in which patients are 
treated.  Furthermore, from this and other studies, it can be clearly established that no 
immune protection is afforded by the initial infecting strains towards subsequent infecting 
strains. Therefore further studies into protective immunity, and particularly into vaccine design, 
need to be mindful of this eventuality.  
 
TB is one of mankind’s oldest diseases, and still is considered an emerging disease, with 
thousands of people becoming infected or dying as a result of this affliction. Apart from HIV 
infections, TB is one of Africa’s most pressing concerns. Our understanding into the various 
aspects of TB disease progression, the vaccines designed to protect against the pathogen, as 
well as our antibiotics utilised in treating patients, should be revised in terms of the frequency 
of mixed infections, if we are to have any chance in combating this disease.  
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Appendix A 
 
Solutions and Reagents 
 
1% Agarose 
2g Agarose (Whitehead Scientific) 
200ml 1X TAE Buffer 
2μl EtBr 
Boil agarose and 1X TAE in microwave on high power for 3 – 4 minutes. Add EtBr when agarose has 
cooled slightly. 
 
1.5% Agarose 
3g Agarose (Whitehead Scientific) 
200ml 1X TAE Buffer 
2μl EtBr 
Boil agarose and 1X TAE in microwave on high power for 3 – 4 minutes. Add EtBr when agarose has 
cooled slightly. 
 
24:1 Chloroform / Isoamyl Alcohol (50ml) 
48ml chloroform (Saarchem, Merck) 
2ml isoamyl alcohol (Saarchem, Merck) 
Add 48 parts chloroform with 2 parts isoamyl alcohol. Store at room temperature. 
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10% CTAB (100ml) 
10g CTAB (Sigma) 
80ml distilled water 
Add CTAB slowly while heating to 60°C. Make up to 100ml with distilled water. 
 
20mM EDTA (100ml) pH 8 
0.74g EDTA (Saarchem, Merck) 
70ml distilled water 
Dissolve EDTA in water and adjust the pH with concentrated NaOH. Make up to 100ml with distilled 
water. 
 
80% Ethanol  
80ml 100% Ethanol (Saarchem, Merck) 
20ml distilled water 
 
5M NaCl (100ml) 
29.22g NaCl (Saarchem, Merck) 
100ml distilled water 
Dissolve NaCl in distilled water. 
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10% SDS (100ml) 
10g SDS (Sigma) 
80ml distilled water 
Dissolve SDS in water while heating to 60°C. Make up to 100ml with distilled water. 
 
 
20X SSPE (1000ml) pH 7.4 
35.6g Na2HPO4*2H2O (0.2M) (Saarchem, Merck) 
210.24g NaCl (3.6M) (Saarchem, Merck) 
7.4g EDTA (20mM) (Saarchem, Merck) 
700ml distilled water 
Dissolve all components in distilled water. Adjust pH to 7.4. Make up to 1 litre with distilled water. 
 
2X SSPE (500ml) 
50ml 20X SSPE 
450ml distilled water 
 
2X SSPE / 0.5% SDS (1000ml) 
100ml 20X SSPE 
50ml 10% SDS (Sigma) 
850ml distilled water 
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2X SSPE / 0.1% SDS (1000ml) 
100ml 20X SSPE 
10ml 10%SDS (Sigma) 
890ml distilled water 
 
 
50X TAE Buffer 
242g Tris (Trizma) 
57.1ml Glacial acetic acid (ProAnalyst, Merck) 
100ml EDTA (Saarchem, Merck) 
Make up to 1000ml with distilled water 
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Appendix B 
 
Molecular Weight Markers 
 
(i) Hyperladder I (Bioline) 
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(ii) Hyperladder IV (Bioline) 
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Appendix C 
 
List of patients and samples included in this study 
 
 
Patient Number Patient Name Sample Number Date of Isolation 
2 FA 1234421 2005/06/17 
4 UO 1223737 2005/06/09 
  1260616 2005/06/30 
  1269351 2005/07/07 
5 GS 1255768 2005/06/29 
6 RB 1246392 2005/06/23 
7 XT 1281542 2005/07/14 
  1293114 2005/07/21 
8 RJ 1265215 2005/07/05 
  1277144 2005/07/12 
9 OA 1265212 2005/07/05 
  1289163 2005/07/19 
  1307762 2005/07/26 
  1312157 2005/08/02 
10 MO 1251338 2005/06/27 
  1262949 2005/07/04 
11 DP 1251339 2005/06/27 
  1262971 2005/07/04 
  1277114 2005/07/11 
  1329408 2005/08/01 
  1343923 2005/08/23 
12 TM 1267623 2005/07/06 
  1279425 2005/07/13 
  1314276 2005/08/03 
13 BB 1265207 2005/07/05 
  1277147 2005/07/12 
  1307768 2005/07/26 
  1312165 2005/08/02 
  1329397 2005/08/11 
  1359908 2005/08/31 
14 MM 1307754 2005/07/29 
  1312146 2005/08/02 
  1324741 2005/08/10 
  1334015 2005/08/16 
15 JS 1307737 2005/07/28 
  1316335 2005/08/03 
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  1329383 2005/08/11 
  1349874 2005/08/25 
  1373431 2005/09/08 
16 DM 1349872 2005/08/25 
  1367291 2005/09/01 
  1373444 2005/09/08 
  1400869 2005/09/22 
  1412610 2005/09/30 
17 MM 1334036 2005/08/16 
18 WJ 1359916 2005/08/31 
  1383382 2005/09/15 
  1395446 2005/09/21 
  1407244 2005/09/28 
  1432842 2005/10/12 
  1458241 2005/10/27 
19 BB 1367311 2005/09/01 
  1373435 2005/09/08 
  1385616 2005/09/15 
  1400856 2005/09/22 
  1408412 2005/09/29 
20 TM 1367330 2005/09/05 
  1383361 2005/09/13 
  1395430 2005/09/20 
  1405193 2005/09/27 
  1415619 2005/10/03 
  1453396 2005/10/25 
  1465991 2005/10/31 
21 CJ 1367317 2005/09/05 
  1379060 2005/09/12 
  1390854 2005/09/19 
  1415616 2005/10/03 
22 JE 1367303 2005/09/05 
  1383342 2005/09/13 
  1390857 2005/09/19 
  1403194 2005/09/26 
  1415602 2005/10/03 
  1428216 2005/10/10 
  1440829 2005/10/17 
  1453398 2005/10/24 
  1465977 2005/10/31 
23 FM 1383351 2005/09/14 
  1408414 2005/09/29 
  1420420 2005/10/05 
  1432846 2005/10/12 
  1445748 2005/10/20 
24 NC 1371553 2005/09/07 
  1383366 2005/09/14 
  1395436 2005/09/21 
  1408416 2005/09/29 
Un
ive
rsi
ty
of 
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pe
 To
wn
119 
 
  1420396 2005/10/05 
  1432832 2005/10/13 
  1470151 2005/11/03 
 1408411 2005/09/29 
  1420409 2005/10/06 
  1470138 2005/11/03 
26 YK 1415610 2005/10/03 
  1465961 2005/10/31 
28 JJ 1420405 2005/10/06 
  1470119 2005/11/03 
29 FJ 1420418 2005/10/06 
  1445737 2005/10/20 
  1458226 2005/10/26 
  1482453 2005/11/10 
  1507276 2005/11/24 
  1519359 2005/11/30 
30 AV 1494783 2005/11/17 
  1539261 2005/12/13 
32 WC 1470273 2005/11/02 
  1494798 2005/11/17 
33 WH 1470135 2005/11/02 
  1494790 2005/11/16 
  1507295 2005/11/23 
  1543475 2005/12/14 
34 CI 1494793 2005/11/17 
  1507273 2005/11/24 
  1568275 2006/01/04 
35 NN 1482475 2005/11/10 
  1507264 2005/11/23 
  1543473 2005/12/15 
36 BQ 1494784 2005/11/17 
  1507268 2005/11/24 
37 KM 1568273 2005/01/05 
38 TP 1579214 2006/01/12 
  1641282 2006/02/15 
  1653902 2006/02/22 
39 JD 1579217 2006/01/12 
  1603044 2006/01/26 
  1615749 2006/02/02 
  1661615 2006/02/27 
40 SD 1588560 2006/01/16 
  1598645 2006/01/22 
  1623700 2006/02/07 
  1649304 2006/02/20 
  1661614 2006/02/27 
  1673416 2006/03/06 
41 SM 1588562 2006/01/16 
  1610958 2006/01/31 
42 MM 1610936 2006/01/30 
Un
ive
rsi
ty
of 
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pe
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  1628716 2006/02/06 
  1661618 2006/02/27 
  1673381 2006/03/06 
43 XM 1623695 2006/02/07 
  1636638 2006/02/13 
  1661611 2006/02/28 
  1685858 2006/03/13 
  1710042 2006/03/28 
  1610954 2006/01/31 
44 DL 1623688 2006/02/07 
  1649308 2006/02/21 
  1685846 2006/03/13 
45 LG 1641334 2006/02/16 
  1653910 2006/02/23 
  1664849 2006/03/02 
  1678125 2006/03/09 
  1695690 2006/03/17 
  1702154 2006/03/23 
  1715014 2006/03/30 
46 JP 1641320 2006/02/16 
  1653908 2006/02/23 
  1678107 2006/03/09 
  1690893 2006/03/15 
47 ZM 1636639 2006/02/13 
  1649274 2006/02/20 
  1661608 2006/02/27 
  1678080 2006/03/06 
  1696795 2006/03/20 
  1710014 2006/03/27 
48 ML 1636635 2006/02/14 
  1649265 2006/02/21 
  1661620 2006/02/28 
  1673413 2006/03/07 
  1685832 2006/03/13 
  1702184 2006/03/22 
  1710019 2006/03/28 
  1722731 2006/04/04 
49 DN 1623691 2006/02/07 
  1641298 2006/02/15 
  1661616 2006/02/28 
  1685850 2006/03/14 
  1702161 2006/03/22 
50 SD 1628703 2006/02/09 
  1641293 2006/02/16 
  1653906 2006/02/23 
  1664836 2006/03/02 
  1678129 2006/03/09 
  1690895 2006/03/16 
  1702164 2006/03/22 
Un
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  1715023 2006/03/30 
51 SM 1653904 2006/02/22 
  1664832 2006/03/02 
  1678086 2006/03/09 
  1690881 2006/03/16 
  1727539 2006/04/06 
52 SM 1664845 2006/03/02 
  1678067 2006/03/08 
  1690897 2006/03/16 
  1702159 2006/03/23 
  1715026 2006/03/30 
  1727541 2006/04/06 
  1740707 2006/04/13 
  1750132 2006/04/20 
  1760497 2006/04/26 
53 TN 1678117 2006/03/09 
  1690888 2006/03/15 
  1702182 2006/03/22 
54 ER 1690891 2006/03/16 
  1715028 2006/03/30 
  1740711 2006/04/13 
  1760498 2006/04/25 
  1772240 2006/05/04 
55 BM 1702179 2006/03/23 
  1715015 2006/03/30 
  1735554 2006/04/10 
  1750127 2006/04/20 
  1760502 2006/04/26 
  1780684 2006/05/08 
  1785629 2006/05/11 
56 TZ 1745403 2006/04/18 
  1767931 2006/05/02 
57 SM 1785633 2006/05/11 
  1798432 2006/05/18 
  1810230 2006/05/25 
  1822840 2006/05/31 
  1836616 2006/06/08 
  1849019 2006/06/15 
  1860258 2006/06/22 
  1885012 2006/07/06 
58 NM 1794023 2006/05/15 
  1810235 2006/05/25 
  1818053 2006/05/29 
  1831075 2006/06/06 
  1844175 2006/06/13 
  1855694 2006/06/20 
  1872720 2006/06/28 
  1880528 2006/07/04 
59 AM 1798436 2006/05/16 
Un
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ty 
of 
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pe
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wn
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  1810237 2006/05/25 
  1822851 2006/05/31 
  1836623 2006/06/08 
  1849023 2006/06/14 
  1860266 2006/06/21 
  1885016 2006/07/05 
  1897788 2006/07/12 
60 JS 1805913 2006/05/22 
  1818059 2006/05/29 
  1831073 2006/06/05 
  1844174 2006/06/12 
  1855683 2006/06/19 
  1867927 2006/06/26 
61 WM 1805900 2006/05/23 
  1831081 2006/06/06 
  1844176 2006/06/13 
  1855688 2006/06/20 
  1867952 2006/06/27 
  1885028 2006/07/05 
  1893056 2006/07/11 
  1905871 2006/07/18 
62 CG 1818055 2006/05/29 
63 MC 1836612 2006/06/07 
  1860254 2006/06/21 
  1885026 2006/07/05 
  1910319 2006/07/19 
64 BV 1855692 2006/06/20 
  1867961 2006/06/27 
  1885032 2006/07/05 
  1923227 2006/07/26 
65 RR 1867947 2006/06/21 
  1880519 2006/07/03 
  1893049 2006/07/10 
  1905870 2006/07/17 
  1931626 2006/08/01 
66 RP 1880507 2006/07/04 
  1893053 2006/07/11 
  1905867 2006/07/18 
  1931651 2006/08/01 
  1955253 2006/08/15 
  1967936 2006/08/22 
  1980993 2006/08/29 
67 CE 1905875 2006/07/17 
  1931637 2006/08/01 
  1943975 2006/08/08 
  1980998 2006/08/29 
  1993557 2006/09/04 
68 NM 1905886 2006/07/17 
  1918533 2006/07/24 
Un
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  1931656 2006/08/01 
  1967887 2006/08/21 
  1980985 2006/08/29 
69 BD 1936392 2006/08/03 
  1985554 2006/08/30 
  1998477 2006/09/07 
70 JB 1931645 2006/08/01 
  1959613 2006/08/17 
71 NV 1936389 2006/08/02 
  1959624 2006/08/16 
  1985556 2006/08/30 
  1998472 2006/09/06 
  2013120 2006/09/13 
72 VF 1980989 2006/08/29 
  1993553 2006/09/04 
73 NC 1993545 2006/09/05 
  2006928 2006/09/11 
  2025035 2006/09/21 
  2031330 2006/09/20 
  2031350 2006/09/26 
  2044964 2006/10/03 
  2057353 2006/10/09 
  2072165 2006/10/16 
  2084284 2006/10/24 
  2096927 2006/10/31 
74 SE 1998486 2006/09/06 
  2025032 2006/09/20 
  2036235 2006/09/27 
  2049406 2006/10/04 
75 CK 2011461 2006/09/14 
  2025027 2006/09/20 
  2036254 2006/09/27 
76 BD 2011453 2006/09/14 
  2036242 2006/09/28 
78 NM 2011445 2006/09/14 
  2062425 2006/10/12 
  2077181 2006/10/18 
  2101420 2006/11/02 
79 RC 2021372 2006/09/19 
  2031347 2006/09/26 
  2044990 2006/10/03 
  2062433 2006/10/11 
  2072176 2006/10/17 
  2084281 2006/10/24 
  2096885 2006/10/31 
80 GI 2044977 2006/10/02 
  2057348 2006/10/09 
  2072169 2006/10/16 
  2084278 2006/10/23 
Un
ive
rsi
ty 
of 
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  2111418 2006/11/06 
  2122853 2006/11/13 
  2154757 2006/11/30 
81 SM 2049397 2006/10/04 
  2062417 2006/10/11 
  2077185 2006/10/19 
85 SA 2072182 2006/10/17 
  2084286 2006/10/24 
  2111422 2006/11/07 
  2163978 2006/12/05 
86 AF 2101416 2006/11/01 
  2117175 2006/11/10 
  2127756 2006/11/15 
  2140904 2006/11/23 
  2154760 2006/11/30 
  2168826 2006/12/06 
  2182012 2006/12/14 
  2189515 2006/12/19 
87 GK 2243402 2007/01/23 
  2257049 2007/01/30 
  2271521 2007/02/06 
  2292224 2007/02/15 
  2300164 2007/02/20 
  2321659 2007/02/28 
  2334688 2007/03/08 
  2343213 2007/03/13 
  2357158 2007/03/19 
88 NG 2248487 2007/01/24 
  2262600 2007/02/01 
  2277221 2007/02/08 
  2292226 2007/02/15 
  2305514 2007/02/21 
  2321650 2007/02/28 
  2334686 2007/03/08 
  2348573 2007/03/14 
89 ZB 2257053 2007/01/29 
  2271502 2007/02/05 
  2300173 2007/02/20 
  2314753 2007/02/27 
  2329135 2007/03/06 
  2357132 2007/03/20 
90 CD 2287598 2007/02/13 
  2300161 2007/02/19 
  2314762 2007/02/27 
91 IF 2271511 2007/02/06 
  2287584 2007/02/13 
  2300162 2007/02/20 
  2314766 2007/02/27 
  2334682 2007/03/08 
Un
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  2368422 2007/03/27 
92 DS 2381952 2007/04/03 
93 SB 2287575 2007/02/13 
  2300169 2007/02/20 
  2314763 2007/02/27 
  2329148 2007/03/06 
  2343236 2007/03/13 
  2357125 2007/03/20 
  2368435 2007/03/27 
  2381942 2007/04/03 
94 CJ 2300166 2007/02/20 
  2314760 2007/02/27 
  2329139 2007/03/06 
  2343225 2007/03/13 
  2360664 2007/03/22 
  2368436 2007/03/27 
  2381944 2007/04/03 
95 AM 2305489 2007/02/21 
  2321661 2007/02/28 
  2334690 2007/03/08 
  2348564 2007/03/14 
  2360659 2007/03/22 
  2373570 2007/03/29 
  2387479 2007/04/03 
  2397609 2007/04/10 
  2412926 2007/04/18 
96 PJ 2305484 2007/02/21 
  2321655 2007/02/28 
  2334695 2007/03/08 
  2348568 2007/03/14 
  2387480 2007/04/04 
  2397573 2007/04/10 
98 HV 2329142 2007/03/06 
  2348570 2007/03/13 
  2368429 2007/03/27 
  2397586 2007/04/11 
99 TN 2343232 2007/03/13 
  2357140 2007/03/19 
  2373572 2007/03/29 
  2381947 2007/04/03 
  2412934 2007/04/18 
  2420723 2007/04/24 
100 CW 2343210 2007/03/13 
  2360661 2007/03/22 
  2368431 2007/03/27 
  2381954 2007/04/03 
101 GP 2368418 2007/03/27 
  2381960 2007/04/03 
  2392943 2007/04/10 
Un
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  2406395 2007/04/16 
  2420705 2007/04/23 
  2436048 2007/05/03 
  2444764 2007/05/08 
  2463464 2007/05/16 
103 RP 2368426 2007/03/27 
  2381946 2007/04/03 
  2392946 2007/04/10 
  2406399 2007/04/17 
  2436021 2007/05/02 
  2444760 2007/05/08 
  2458557 2007/05/15 
104 MM 2381956 2007/04/03 
  2397580 2007/04/11 
  2406407 2007/04/17 
  2420730 2007/04/24 
  2436017 2007/05/02 
  2444761 2007/05/08 
  2470980 2007/05/22 
105 AD 2381949 2007/04/03 
  2392953 2007/04/10 
  2406398 2007/04/17 
  2420727 2007/04/24 
  2436040 2007/05/02 
  2444763 2007/05/08 
  2458556 2007/05/15 
  2470977 2007/05/22 
  2487860 2007/05/30 
107 MD 2420713 2007/04/24 
  2450525 2007/05/10 
  2463471 2007/05/16 
  2475803 2007/05/23 
  2499983 2007/06/06 
  2522521 2007/06/20 
108 NM 2450518 2007/05/10 
109 NB 2458564 2007/05/15 
  2470986 2007/05/22 
  2483448 2007/05/25 
  2499986 2007/06/06 
  2507075 2007/06/12 
  2518177 2007/06/19 
  2534771 2007/06/28 
  2554536 2007/07/10 
111 AL 2470987 2007/05/21 
  2483451 2007/05/28 
  2495358 2007/06/04 
  2507079 2007/06/11 
  2530167 2007/06/25 
  2542114 2007/07/02 
Un
ive
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  2554540 2007/07/09 
112 AP 2483446 2007/05/28 
  2495346 2007/06/04 
  2507077 2007/06/11 
  2518170 2007/06/18 
  2542117 2007/07/02 
  2554538 2007/07/09 
  2566085 2007/07/16 
113 DM 2554545 2007/07/10 
114 VJ 2580200 2007/07/26 
  2605935 2007/08/08 
115 JM 2570047 2007/07/19 
  2580204 2007/07/26 
  2590099 2007/08/02 
  2611332 2007/08/16 
116 NS 2576272 2007/07/24 
  2586523 2007/07/31 
  2596842 2007/08/07 
  2611330 2007/08/15 
117 TS 2580203 2007/07/25 
  2586526 2007/07/31 
  2596844 2007/08/07 
  2611356 2007/08/16 
  2620257 2007/08/22 
  2630473 2007/08/29 
  2641863 2007/09/05 
  2651137 2007/09/12 
118 AG 2621209 2007/08/23 
  2630475 2007/08/30 
  2672229 2007/09/27 
119 FK 2620251 2007/08/23 
  2630470 2007/08/30 
  2641871 2007/09/06 
  2651143 2007/09/13 
  2662051 2007/09/20 
  2672224 2007/09/27 
  2681777 2007/10/04 
  2692219 2007/10/11 
  2713829 2007/10/24 
120 IB 2626509 2007/08/27 
  2636811 2007/09/03 
  2648503 2007/09/10 
  2667046 2007/09/25 
  2677821 2007/10/02 
  2688588 2007/10/08 
121 VS 2630468 2007/08/30 
  2641866 2007/09/06 
  2651135 2007/09/13 
122 HC 2648510 2007/09/11 
Un
ive
rsi
ty
of 
Ca
pe
 To
wn
128 
 
  2657823 2007/09/18 
  2671040 2007/09/26 
123 EJ 2657824 2007/09/17 
  2671044 2007/09/27 
  2688594 2007/10/09 
  2699020 2007/10/15 
  2711521 2007/10/22 
124 TJ 2657825 2007/09/18 
  2677814 2007/10/02 
  2688584 2007/10/09 
126 NS 2681771 2007/10/03 
  2692216 2007/10/10 
  2703218 2007/10/17 
  2757094 2007/11/21 
127 ZC 2847783 2008/01/29 
  2859718 2008/02/05 
128 SK 2864062 2008/02/07 
  2883247 2008/02/19 
  2895166 2008/02/26 
  2911046 2008/03/06 
  2922789 2008/03/13 
  2934605 2008/03/20 
129 MN 2841309 2008/01/24 
  2852598 2008/01/30 
  2864066 2008/02/06 
  2887637 2008/02/20 
  2899269 2008/02/27 
130 MJ 2847789 2008/01/29 
  2883248 2008/02/19 
  2896432 2008/02/27 
  2938789 2008/03/25 
131 DD 2847787 2008/01/29 
  2859716 2008/02/05 
  2870913 2008/02/12 
  2895161 2008/02/26 
  2930404 2008/03/18 
133 SM 2859720 2008/02/05 
  2883246 2008/02/18 
  2895164 2008/02/26 
  2930398 2008/03/18 
  2950237 2008/04/01 
134 DG 2875963 2008/02/13 
  2899266 2008/02/27 
  2934608 2008/03/19 
135 SS 2895165 2008/02/26 
  2962092 2008/04/08 
136 JI 2930402 2008/03/17 
  2938800 2008/03/25 
  2950230 2008/04/01 
Un
ive
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ty
of 
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  2966131 2008/04/10 
  2973611 2008/04/15 
137 BJ 2883244 2008/02/19 
  2938788 2008/03/25 
  2962089 2008/04/08 
  2973626 2008/04/15 
138 PD 2934606 2008/03/20 
  2954632 2008/04/03 
  2966136 2008/04/10 
  2979186 2008/04/18 
  2989396 2008/04/24 
  2995249 2008/04/29 
139 DG 2954633 2008/04/03 
  2989399 2008/04/24 
  2995247 2008/04/29 
  3020751 2008/05/15 
  3045041 2008/05/29 
140 PW 2954629 2008/04/03 
  2986159 2008/04/23 
  2995251 2008/04/29 
  3008635 2008/05/08 
  3020749 2008/05/15 
141 NE 2966138 2008/04/10 
  2979184 2008/04/18 
  2989397 2008/04/24 
  3008638 2008/05/08 
  3020746 2008/05/15 
  3032468 2008/05/22 
  3045047 2008/05/29 
142 WV 2986162 2008/04/23 
  2995248 2008/04/29 
  3003779 2008/05/06 
  3015892 2008/05/13 
  3032470 2008/05/22 
143 JB 3003781 2008/05/11 
144 EJ 3008641 2008/05/08 
  3020750 2008/05/15 
  3032447 2008/05/22 
  3059731 2008/06/06 
  3073051 2008/06/13 
  3083399 2008/06/19 
  3096602 2008/06/26 
  3109322 2008/07/03 
145 NN 3015891 2008/05/13 
  3027689 2008/05/20 
  3040100 2008/05/27 
  3053349 2008/06/03 
  3066628 2008/06/10 
  3078400 2008/06/17 
Un
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  3092804 2008/06/25 
  3117074 2008/07/08 
146 GM 3032464 2008/05/22 
  3045039 2008/05/29 
  3059733 2008/06/06 
  3073049 2008/06/13 
  3083396 2008/06/19 
  3104303 2008/07/01 
  3109317 2008/07/03 
  3117053 2008/07/08 
147 SD 3032466 2008/05/22 
  3045075 2008/05/29 
  3059734 2008/06/06 
  3073048 2008/06/13 
  3083401 2008/06/19 
  3096604 2008/06/26 
  3122437 2008/07/10 
148 DJ 3053363 2008/06/03 
  3066626 2008/06/10 
  3078404 2008/06/17 
  3092805 2008/06/25 
  3104294 2008/07/01 
  3117067 2008/07/08 
  3131665 2008/07/16 
  3145083 2008/07/23 
149 WM 3066621 2008/06/10 
  3078406 2008/06/17 
  3092806 2008/06/25 
  3104296 2008/07/01 
  3117063 2008/07/08 
  3131675 2008/07/16 
  3157452 2008/07/29 
150 ME 3073050 2008/06/13 
  3083395 2008/06/19 
  3096599 2008/06/26 
  3109319 2008/07/03 
  3122440 2008/07/10 
  3150579 2008/07/25 
  3175941 2008/08/07 
151 BH 3104298 2008/07/25 
152 CB 3117060 2008/07/08 
  3131672 2008/07/16 
  3145091 2008/07/23 
  3157457 2008/07/29 
  3185468 2008/08/12 
  3199257 2008/08/19 
  3213595 2008/08/26 
153 WI 3145095 2008/07/23 
  3157463 2008/07/29 
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  3185469 2008/08/05 
  3199250 2008/08/15 
  3213591 2008/08/26 
  3226446 2008/09/02 
154 MM 3145080 2008/09/23 
  3157465 2008/07/29 
  3175940 2008/08/07 
  3185466 2008/08/12 
  3199252 2008/08/19 
  3213594 2008/08/26 
  3226443 2008/09/02 
  3244991 2008/09/11 
 3254518 2008/09/16 
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Appendix D 
 
MIRU-VNTR Allele Tables 
 
Table D1. Main MIRU-VNTR allele table 
 
Allele MIRU 02 MIRU 04 MIRU 10 MIRU 16 MIRU 20 MIRU 232 MIRU 24 MIRU 262 MIRU 27 MIRU 31 MIRU 39 MIRU 40 
0 402 175 482 565 437 150 395 285 498 492 540 354 
1 455 252 537 618 514 200 447 336 551 545 593 408 
2 508 329 590 671 591 253 501 387 604 598 646 462 
3 561 406 643 724 668 306 555 438 657 651 699 516 
4 614 483 696 777 745 359 609 489 710 704 752 570 
5 667 560 749 830 822 412 663 540 763 757 805 624 
6 720 637 802 883 899 465 717 591 816 810 858 678 
7 773 714 855 936 976 518 771 642 869 863 911 732 
8 826 791 908 989 1053 571 825 693 922 916 964 786 
9 879 868 961 1042 1130 624 879 744 975 969 1017 840 
10 932 945 1014 1095 1207 677 933 795 1028 1022 1070 894 
11 985 1022 1067 1148 1284 730 987 846 1081 1075 1123 948 
12 1038 1099 1120 1201 1361 783 1041 897 1134 1128 1176 1002 
13 1091 1176 1173 1254 1438 836 1095 948 1187 1181 1229 1056 
14 1144 1253 1226 1307 1515 889 1149 999 1240 1234 1282 1110 
15 1197 1330 1279 1360 1592 942 1203 1050 1293 1287 1335 1164 
The numbers represented in this table correspond to the sizes of the amplified MIRU loci and the equivalent VNTR alleles. (Adapted from Supply et al, 2000) 
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Table D2. MIRU-VNTR alleles of isolates obtained from patients identified by spoligotyping as harbouring mixed infections 
†WB: W-Beijing 
Cluster Lineage† MIRU02 MIRU04 MIRU10 MIRU16 MIRU20 MIRU23 MIRU24 MIRU26 MIRU27 MIRU31 MIRU39 MIRU40 
Cluster 1 T4 2 2 4 3 2 5 1 5 3 3 2 3 
Cluster 2 S 2 2 3 3 2 3 1 5 3 3 3 2 
Cluster 3 WB 2 3 4 3 2 5 1 7 3 5 3 3 
Cluster 4 LAM 3 2 3 4 3 2 6 1 5 3 5 4 3 
Cluster 5 WB + X3 2 3 4 3 2 5 1 7 3 3 2 3 
Cluster 6 WB 2 2 3 3 2 5 1 7 3 5 3 3 
Cluster 7 T1 2 2 3 4 2 5 1 5 3 3 2 3 
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